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ABSTRACT 
Corey Andrew Kalbaugh:  Burden estimates, post-diagnosis care and outcomes associated with 
peripheral artery disease in the Atherosclerosis Risk in Communities Study 
(Under the direction of Laura Loehr and Gerardo Heiss) 
 
 Peripheral artery disease (PAD) is a progressive atherosclerotic disorder of the lower 
extremities that causes adverse individual- and health care system-level consequences as 
populations age. This doctoral dissertation research estimated the annual period prevalence and 
incidence of PAD as well as the frequency of care and mortality following diagnosis in the 
outpatient or inpatient setting.  
 The majority (>70%) of all PAD encounters occurred in the outpatient setting. The 
weighted mean age-standardized prevalence and incidence of outpatient PAD was 11.8% (95% 
CI: 11.5, 12.1) and 22.4 (95% CI: 20.8, 24.0) per 1000 person-years, respectively. Blacks had a 
higher mean weighted mean age-standardized prevalence (15.6%; 95% CI: 14.6, 16.4) as 
compared to whites (11.4%; 95% CI: 11.1, 11.7). Blacks also had a higher incidence rate of PAD 
(31.3 per 1000 person-years; 95% CI: 27.3, 35.4) as compared to whites (25.4 per 1000 person-
years; 95% CI: 23.5, 27.3). PAD prevalence and incidence did not differ by gender alone. 
    One-thousand eighty six incident cases of PAD were identified from 2002-2010. PAD-
related post-diagnosis encounters were 2.15 (95% CI: 2.10, 2.21) and 1.02 (95% CI: 0.94, 1.10) 
among those with an incident PAD diagnosis in the outpatient and inpatient setting, respectively. 
Participants with PAD had an average of 6-8 primary care encounters per person-year over the 
course of our study. PAD-related and all-cause hospitalization was 6.4% (95% CI: 4.8, 8.1) and 
32.2% (95% CI: 29.0, 35.2) at one year among those with incident outpatient PAD. 
iv 
Approximately 14% (95% CI: 9.3, 18.7) of participants diagnosed with inpatient PAD had a 
PAD-related rehospitalization at one year while 43.4% (95% CI: 36.3, 49.7) had an all-cause 
rehospitalization at one year. One year age-standardized case fatality was 7.1% (95% CI: 5.4, 
8.7) and 16.0% (95% CI: 11.0, 21.1) among those diagnosed in the outpatient and inpatient 
setting, respectively. 
   Peripheral artery disease and utilization of outpatient health care services was common 
among men and women 65 years of age and older with enrollment in a Medicare fee-for-service 
program sampled of four US communities. 
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CHAPTER 1: INTRODUCTION 
 Peripheral artery disease (PAD) is a prevalent atherosclerotic disorder characterized by 
plaque build-up in the lower extremities.  Functional limitations resulting from PAD lead to poor 
quality of life, high health care utilization and costs of care, and an increase in mortality risk.  A 
diagnosis of PAD suggests presence of atherosclerosis in other vascular beds, and PAD 
significantly increases the risk of coronary and cerebrovascular disease events.  The direct and 
indirect contribution of this disease to the morbidity associated with other chronic disease 
conditions is important yet health professional and public awareness of PAD is low in 
comparison with awareness of other chronic cardiovascular diseases; up to 50% of those with 
PAD are unaware they have the disease and physicians often do not evaluate for the presence of 
PAD.  Disease awareness is critical as the burden of PAD is expected to increase as our 
population ages.   
 Most estimates of the population burden of PAD evaluate hospitalized events, while 
excluding PAD diagnosed and treated in the outpatient setting [1]. Missing information on 
outpatient PAD is important because the evolution of endovascular technologies and wound care 
therapies, including angiogenesis, is changing the clinical location where PAD is managed [2, 3]. 
Disease manifestations which formerly required hospitalization can now be treated in an 
outpatient setting. Furthermore, initial diagnoses of PAD currently frequently occur in the 
outpatient setting. Since prior research has focused on PAD in the inpatient setting, the practice 
shift to the diagnosis and treatment of previously unmanaged PAD in the outpatient setting has 
resulted in a high, yet undocumented, burden of PAD [4-7]. The proposed work operates under 
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the hypothesis that the burden of PAD is underreported and that quantifying both inpatient and 
outpatient events is critical to a more accurate representation of PAD burden and to the 
assessment of post-diagnosis care. 
 Proposed analyses will provide an assessment of the frequency of care and outcomes 
associated with a PAD diagnosis. Administrative claims allow characterization of the care 
following a PAD diagnosis from the health care setting of the first diagnosis to the subsequent 
processes of PAD-related care at the outpatient and inpatient levels. Proposed research will 
address possible patient-level factors that affect a patient’s transition from outpatient 
management to hospitalization, an area of research that is currently underreported in the 
literature.  
 The proposed research will take advantage of the Center for Medicare and Medicaid 
Services (CMS) Medicare claims available for residents of the Atherosclerosis Risk in 
Communities (ARIC) Study. By placing the assessment of PAD in four diverse geographic 
regions, for which there are available data on the prevalence and incidence of atherosclerotic 
conditions other than PAD, a unique opportunity exists for future research to evaluate the burden 
of PAD in relation to those conditions. Proposed assessment of potential disparities in the burden 
and post-diagnosis care of PAD across age, gender, and race subgroups, along with contextual 
information, will lead to an improved understanding of groups with high atherosclerotic burden. 
Information from the proposed research will provide a foundation for further work that examines 
co-occurrence of PAD and other cardiovascular diseases.  
3 
CHAPTER 2: STUDY OBJECTIVES AND SPECIFIC AIMS 
 The proposed study aims to estimate the prevalence and incidence of PAD and to 
estimate the frequency of care and outcomes following an incident PAD diagnosis among 
Medicare fee-for-service beneficiaries ages 65 years and older in the biracial ARIC study cohort 
[8].  
 Specific Aim 1: Estimate the annual period prevalence (2003-2012) and incidence (2005-
2012) of PAD in the outpatient and inpatient setting among Black and White CMS Medicare fee-
for-service beneficiaries in the ARIC study cohort (Manuscript 1; Chapter 5).  Estimates will be 
stratified by age, gender and race to inform prevention efforts. Direct standardization methods 
will be used to estimate burden.   
 Specific Aim 2: Estimate the frequency of care and mortality following an initial 
diagnosis in the outpatient or inpatient or outpatient setting among Black and White CMS 
Medicare fee-for-service beneficiaries in the ARIC study cohort (Manuscript 2; Chapter 6). 
Direct standardization will be used to estimate age-standardized rates of encounters. Time-to-
event analysis will be used to estimate the time to (re)hospitalization and case fatality. Race and 
gender differences in the rates of- and time-intervals between- outpatient and inpatient 
encounters will be examined.  
 This study will address an important gap in the PAD literature by providing 
methodologically replicable estimates of PAD burden and health care utilization using an 
administrative claims data source. The claims data will be linked with an ongoing cohort study 
and will provide a rich level of detail regarding covariates that is not possible in using claims 
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alone. Limitations that will affect the interpretation of findings include exclusion of participants 
with MA enrollment, misclassification of prevalent as incident events, and survivor bias 
associated with the cohort. Findings from the study will address issues of health care utilization 
and outcomes among elderly individuals with PAD that will improve the evidence base 
regarding the assessment of disease and disparities in care for PAD. This study will highlight the 
significance of PAD in an elderly population and could aid in identifying high burden groups, 
which could inform secondary prevention efforts. 
5 
CHAPTER 3: BACKGROUND AND SIGNIFICANCE 
 Peripheral artery disease is a prevalent atherosclerotic disorder characterized by plaque 
build-up in arteries distal to the abdominal aorta [9].  Current estimates suggest that more than 8 
million individuals in the United States have PAD with increasing prevalence expected as the 
population ages [10].  Health professional and public awareness of PAD remains low in 
comparison with awareness of other cardiovascular diseases; up to 50% of those with PAD are 
unaware they have the disease and physicians often fail to evaluate for the presence of PAD [11].  
PAD presents clinically as intermittent claudication (pain with exercise), or as critical limb 
ischemia (a PAD subtype that can be limb and life threatening) [12].  Functional limitations 
resulting from PAD lead to poor quality of life [13], high health care utilization [14], high costs 
of care [15], and an increase in mortality risk [16].  PAD is frequently associated with coexisting 
atherosclerosis in the coronary and cerebral arterial beds, and the direct and indirect contribution 
of this disease to the morbidity associated with other chronic disease conditions is significant 
[17].  PAD is largely managed in the outpatient setting with risk factor modification [18], 
exercise therapy [19], and pharmacologic therapy [20, 21].  Once the disease is severe enough to 
warrant invasive management, therapeutic choices include endovascular procedures [22], open 
surgical revascularization [23, 24], and limb amputation [25].  
  
6 
3.1 Anatomy and Pathophysiology of Peripheral 
Atherosclerosis 
Processes involved in the development of 
peripheral atherosclerosis are similar to the pathogenesis 
of coronary, cerebral, and renal atherosclerosis [26].  
Figure 1 provides an example of peripheral atherosclerosis 
in the posterior tibial artery.  The current understanding of 
this process has been described by Libby (2000) as a three 
stage presentation: lesion initiation, lesion progression, 
and plaque complications [27].  Atherogenesis begins 
when blood leucocytes (white blood cells) attach to 
endothelial cells lining the intima layer of an artery [28].  
Adhesion molecules on vascular endothelial cells facilitate leukocyte adhesion.  Chemokines 
direct leucocytes to enter into the arterial wall.  A fibrous cap forms, 
signaling the end of the atherogenesis initiation process [29].  
Atherogenesis progression takes place when proteins create a net 
positive balance of growth stimuli, such that smooth muscle cells 
proliferate and eventually migrate if platelets are activated [29].  The 
migration causes a thickening of the fibrous cap, which leads to 
thrombus formation.  Clinically important atheroma complications are 
commonly the result of thrombus formation and disruption [27].   
A plug containing platelets and fibrinogen molecules 
forms [30].  The plug can either remain attached to the 
arterial wall while it grows until it completely obstructs the vessel lumen or it can dislodge from 
Figure 2: Lower extremity 
atherosclerosis; adapted from 
NIH.gov 
Figure 1: Lower extremity arterial 
system; adapted from 
qualityvascular.com 
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the vessel wall because of rapid arterial flow.  If the plug dislodges, platelet rich emboli are 
released into the arterial tree.  These obstructions deprive the tissues of crucial oxygenated blood 
necessary to meet the metabolic requirements of ambulation (claudication) or wound healing 
(critical limb ischemia) [30].   
 Changes in and disruption of the fibrous cap can cause blood flow-related conditions in 
the vessels of the lower extremities, including the descending abdominal aorta and the iliac, 
femoral, popliteal, and tibial arteries, as shown in Figure 2 [26].  Disease can be bilateral or 
unilateral, depending on anatomic location; disease tends to be bilateral in the iliac arteries and is 
more often unilateral in femoral/popliteal/tibial arteries [31]. 
3.2 Relationship of PAD to other Cardiovascular Diseases  
 
 The presence of PAD is indicative of increased atherosclerotic burden throughout the 
cardiovascular system [32, 33].  Aronow et al (1994) identified the coexistence of symptomatic 
peripheral, coronary, and cerebrovascular disease among 1886 patients 62 years of age and older 
in a long-term health care facility [34].  These investigators found that among those with 
symptomatic PAD, 58% also had coronary artery disease and 34% had cerebrovascular disease 
[34].  The Reduction of Atherothrombosis for Continued Health (REACH) registry, an 
international study of general physician practices comprising more than 65,000 individuals ages 
45 and older, also measured coexisting vascular diseases. The REACH registry found that, of 
those with PAD, 65% had clinical evidence of either coronary or cerebrovascular disease [17].
 Early detection of PAD and interventions aimed at preventing PAD progression can 
therefore be beneficial  in delaying myocardial infarction, stroke, and other major circulatory 
system disorders [10, 25, 35].  Although potentially modifiable risk factors make PAD largely 
preventable, the disease is commonly under-diagnosed and remains an understudied public 
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health problem as compared to other cardiovascular conditions for which awareness is greater 
[11].   
3.3 Clinical Manifestations of PAD 
 
 Natural history studies estimate that 20%-50% of individuals with detectable PAD are 
asymptomatic [12].  The most common PAD manifestation is intermittent claudication (IC), a 
condition producing leg cramping and pain during exercise that causes functional limitations and 
decreases quality of life [13].  Critical limb ischemia (CLI) is a more severe presentation of 
PAD, with symptoms that include ischemic rest pain and tissue loss due to non-healing wounds, 
ulcerations, and gangrene [36].  Figure 3 
is a depiction of the most commonly seen 
clinical progression of PAD, from 
asymptomatic disease to gangrene 
presentation. 
 Disease severity is frequently 
measured in a clinical setting using one of two classification schemes, as shown below in Table 1 
[31, 37].  Briefly, the Rutherford classification system assigns grades and category scores for 
clinical presentations ranging from asymptomatic disease (Grade 0, Category 0) to major tissue 
loss (Grade III, Category 6) [31].  The Fontaine classification system classifies PAD according to 
stages, ranging from I (asymptomatic disease) to IV (ulceration or gangrene) [37].   
  
Figure 3: Clinical progression of 
PAD 
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Table 1. PAD classification schemes by severity 
 Rutherford Criteria Fontaine Criteria 
Clinical Presentation Grade Category Stage 
Asymptomatic 0 0 I 
Mild claudication I 1 IIa 
Moderate claudication I 2 IIb 
Severe claudication I 3 IIb 
Ischemic rest pain II 4 III 
Ulceration III 5 IV 
Gangrene III 6 IV 
Adapted from Norgren et al (2007) 
3.3.1 Claudication 
 Claudication (Rutherford I, Fontaine II), or pain with exercise, is the most common form 
of symptomatic PAD [38].  Claudication-induced pain can present as a cramping, aching, or 
general discomfort in the lower extremities [18].  Although this pain typically occurs in the 
calves, claudication can also occur in the thighs, buttocks, hips, and feet depending on the 
location of the underlying arterial blockage.  Claudication in the upper two-thirds of the calf is 
indicative of superficial femoral artery (SFA) disease while disease in the lower third of the calf 
is indicative of popliteal disease [39].  In vascular-related claudication, the limb pain continues 
during exercise but subsides with rest, generally within five to ten minutes.  Individuals affected 
by claudication may experience significant functional limitations and have a significantly lower 
quality of life compared to the general population [40].  A study of 201 claudicants who were 
administered the SF-36 quality of life questionnaire found statistically significant (p<0.05) health 
decrements compared to population norms at all measures of physical, emotional, mental, and 
general health [40]. 
 Prevalence estimates of claudication in general populations vary significantly by country 
and increase with age [13].  For example, in the US-based, ARIC study, only one percent of 
participants 45-64 years of age had claudication, defined as a positive Rose questionnaire 
10 
(discussed in section 1.4) at baseline [41].  However, He et al (2006) used the Rose questionnaire 
and found a much higher prevalence of 11.3% in a population-based study of individuals 60 
years of age and older in a small Chinese province [42].  Generally, population-based studies 
measuring claudication found increasingly higher prevalence the higher the mean age of 
participants.  These studies will be reviewed in more detail in section 1.6 of this proposal.    
 Despite the progressive nature of atherosclerosis, approximately 75% of those with 
clinically diagnosed claudication will stabilize or improve over time [12].  The remaining 25% 
experience worsening claudication (10-20%) or progression to critical limb ischemia (5-10%).  
Of those with deteriorating symptoms, approximately 5% will require surgical intervention and 
2% will require lower extremity amputation [12].   
3.3.2 Critical Limb Ischemia 
 Critical limb ischemia (CLI) is the “end stage” of PAD resulting from a chronic lack of 
oxygen that is needed for limb vitality [43].  Clinically, CLI is defined by an international 
consensus as presence of any one of the following: 1) chronic ischemic rest pain or pain in the 
extremities while at rest, 2) ulceration of the lower extremity, or 3) gangrene due to occlusive 
PAD [44].  Although a small proportion of patients with diagnosed claudication will eventually 
deteriorate to CLI, CLI can manifest with no prior PAD history [45, 46].   
 Ischemic rest pain (Rutherford II, Fontaine III) is a chronic condition characterized by 
pain, numbness, or tingling at rest in the toes, metatarsal heads, or proximal foot.  Once an 
individual has rest pain, the pain is characterized by three severity-based stages.  Initially the 
pain starts and ends quickly and the person can remain supine for pain relief.  The second stage 
requires the person to dangle their leg in order to relieve the pain.  In the final stage, the person 
must remain seated for pain relief.  Rest pain can be difficult to measure because of pain 
perception, as is the case in those with diabetic neuropathy [47]. 
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 The end stages of PAD involve tissue loss (Rutherford III, Fontaine IV) to an extremity 
and include ischemic ulceration or gangrene.  Clinically these end-stage processes present as 
non-healing wounds on the toes, foot, shin, or heel.  An ischemic lesion can result from minor 
trauma because of arterial insufficiency, although compromised arterial flow can preclude any 
size lesion from healing [47].   
 CLI is a rare outcome and is infrequently quantified in studies.  A study among 5800 
randomly selected participants in four regions of Sweden found a prevalence of CLI of 1.6% 
using a low ankle blood pressure measurement (<70 mm Hg) as the indicator of CLI presence 
[48].  A Norwegian study that quantified CLI by self-reported ulcers or rest pain, found an age-
adjusted prevalence of 0.24% [49].  Ulcers were not categorized by cause and, thus, could be 
misclassified as CLI when the cause might be neuropathic or traumatic.  One study estimated 
CLI incidence by examining a sample of CLI hospitalizations from 27 Northern Italy hospitals 
[50].  They found the annual incidence of CLI to be 260 per 1,000,000 person years.  Incidence 
of CLI was 652 per 1,000,000 person-years among those 45 years of age and older [50].  Many 
studies have assumed a percentage of amputations are related specifically to CLI to quantify CLI 
incidence [25, 50, 51].  Information derived from this methodology is subject to substantial 
misclassification bias and true CLI incidence remains unknown. 
 Approximately one-half of individuals with CLI have arterial reconstruction and one-
fourth is managed non-surgically.  About 25% of individuals presenting with CLI will 
immediately undergo limb amputation surgery [25].  Non-healing ulcerations caused by lower 
extremity arterial disease are the leading cause of lower limb amputation in men and women in 
the US [52].  Only approximately one-fourth of CLI patients experience symptom resolution and 
amputation-free survival at one year following diagnosis [12].    
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3.4 Methods to Detect PAD 
 Prior to discussing the prevalence and incidence of PAD, I will introduce the various 
methods to identify and diagnose PAD in research and clinical settings. 
3.4.1 Questionnaires 
 Leg pain can be multi-factorial and appropriate diagnoses are often difficult to determine 
with precision and reproducibility.  Causes of leg pain can include IC, as well as sciatica or 
osteoarthritis.  As a result of the challenges associated with appropriately diagnosing the cause of 
leg pain, a series of questionnaires have been created to better delineate PAD from other 
potential causes [53-55].  Commonly used questionnaires are discussed below. 
3.4.1.1 WHO/Rose Intermittent Claudication Questionnaire  
 The Rose Questionnaire  (1962) was created to target the diagnosis of IC in 
epidemiologic research and to facilitate international comparisons of prevalence estimates [53].  
Initially, the Rose Questionnaire (RQ) was administered to thirty-seven individuals with IC and a 
control group of eighteen individuals with other types of diagnosed walking-induced leg pain 
(control group).  Thirty-four (92%) of the 37 patients with IC met all six criteria outlined to 
delineate IC from other leg pain syndromes while none of the control group met the criteria [53].   
 The RQ was adopted by the World Health Organization (WHO/RQ, herein) in 1968 to 
determine PAD prevalence rates [56].  The WHO/RQ was modified in 1977 to enable self-
administration [57].  Studies have found sensitivity values that range from 9%-92% and 
specificity values that range from 95%-100% [58].   
 Despite its ease of use and the various adaptations, there are limitations to using the 
WHO/RQ in population-based research.  First, while false positives are exceedingly rare, false 
negatives are common which is consistent with the lower sensitivity reported above.  Second, it 
is not possible to detect CLI using this instrument.  Even with the surveys limitations, the 
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WHO/RQ is commonly used to screen for PAD and is the primary survey tool used to identify 
claudication in population-based research [42, 48, 59, 60].   
3.4.1.2 Edinburgh Claudication Questionnaire  
 While the WHO/RQ is highly specific, the moderate sensitivity results shown across 
several population-based studies led scientists at the London School of Tropical Medicine and 
Hygiene to create a new questionnaire, the Edinburgh Claudication Questionnaire (ECQ) [54].  
Leng et al (1992) found more than 50% of the false negatives generated by the WHO/RQ 
resulted from one question: Does your pain disappear on walking?[54] These investigators also 
found that the specificity was upheld by asking only three particular questions: 1) Do you have 
pain when standing/sitting? 2) Do you have pain in the calf? and 3) Is your pain gone in 10 
minutes of stopping? [54].  The investigators pre-tested new questions and piloted their new 
survey in 300 subjects.  The ECQ had a sensitivity of 91.4% and a specificity of 99.3%, and 
repeatability was excellent at six months (kappa=0.76) [54].  The ECQ is only moderately 
sensitive (~50%) in detecting PAD in high risk patients [61, 62]    
3.4.1.3 San Diego Claudication Questionnaire  
 Neither the WHO/RQ nor the ECQ allow for leg-specific (right versus left) assessment of 
claudication symptoms.  While calf pain is the most typical location of pain in those with 
claudication, the WHO/RQ and ECQ surveys also do not allow for assessment of non-calf 
claudication.  With these limitations in mind, the San Diego Claudication Questionnaire (SDCQ) 
was created and tested among 508 patients [63].  The SDCQ contains questions about anatomic 
location of pain and the extremity (left, right, both) affected.  In the study by Criqui et al (1996), 
the SDCQ identified 40% more claudication than the Rose in the same participants [55].     
 Each of these questionnaires has benefits and drawbacks, and each has been used 
extensively in population-based studies of PAD.  A recent review article by Schorr and Treat-
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Jacobson (2013) reported inconsistency across studies in how these questionnaires were utilized 
causing biased prevalence estimates [58].  Table 2 describes the questions contained within each 
of these three questionnaires and shows the differences between the questions used to assess 
claudication in each questionnaire.  Estimate comparisons across studies are, therefore, difficult 
and fluctuate depending on the methodology and survey used.   
Table 2. Claudication assessment questionnaire comparison 
 Questionnaire 
Question WHO/RQ* ECQ
†
 SDCQ
‡
 
Do you get a pain in either leg on walking? Y Y Y 
- or either buttock (Right or Left)   Y 
Does this pain ever begin when you are standing 
still? 
Y  Y 
- or sitting  Y Y 
Do you get this pain in your calf (or calves?) Y   
Where do you get this pain or discomfort?  Y  
In what part of the leg or buttock do you feel it?   Y 
Do you get it when you walk uphill or hurry? Y Y Y 
Do you get it when you walk at an ordinary pace 
on the level? 
Y  Y 
Does the pain ever disappear while you are still 
walking? 
Y  Y 
What do you do if you get it when you are 
walking? 
Y  Y 
What happens to it if you stand still? Y Y Y 
How soon?   Y 
* World Health Organization adaptation of the Rose Questionnaire;
 †
 Edinburgh Claudication 
Questionnaire; 
‡ 
San Diego Claudication Questionnaire 
3.4.2 Non-invasive Tests to Detect PAD 
 PAD is commonly diagnosed through non-invasive testing such as ankle-brachial index 
(ABI) measurement, which is discussed below.  PAD prevalence is also frequently quantified via 
these same measurements.  Most often, the prevalence of PAD in population-based studies is 
estimated by calculating ABI [11, 41, 42, 48, 59, 60, 64-80].  Infrequently, PAD is also measured 
using the reactive hyperemia test [81] . Each of these tests is described in more detail below. 
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3.4.2.1 Ankle-brachial Index Test 
 A physician or vascular laboratory technician can perform the ABI test, which requires a 
standard sphygmomanometer, a hand-held Doppler, and acoustic gel [36].  Systolic 
measurements are taken in the brachial artery in each of the upper arms and in both the posterior 
tibial and dorsalis pedis arteries of the legs.  As PAD can be a unilateral disease the ABI is 
calculated for each limb separately.  The value is determined as the ratio of the lowest systolic 
value obtained in the leg to the highest systolic value obtained in either arm.  An ABI value 
<0.90 is indicative of PAD and is a cut-point used to detect asymptomatic PAD.  The ABI test 
has a high sensitivity (>90%) and a high specificity (>90%) in detecting >50% occlusion in 
contrast angiography [26, 82].  However, inclusion criteria for studies, the number of times the 
measurement is repeated, and calculation methods, such as using the highest versus the lowest or 
median systolic values, vary widely resulting in low comparability across studies [83].   
3.4.2.2 Reactive Hyperemia Test  
 The reactive hyperemia test is infrequently used to identify asymptomatic PAD [26].  
According to the Edinburgh Artery Study protocol [81], the test is performed by occluding 
arterial flow above the knee for four minutes, following which ankle systolic pressure is then 
measured in both legs fifteen seconds after releasing the cuff.  A drop in blood pressure of at 
least 35% is considered indicative of PAD.  A hyperemic drop of 20-35% with an abnormal ABI 
is also indicative of PAD.  The sensitivity and specificity of the reactive hyperemia test at 
predicting abnormal ABI is 64% and 94%, respectively [84]. 
3.4.3 Imaging Techniques Used to Identify PAD 
 Individuals with PAD that possibly warrant invasive intervention often first undergo 
imaging prior to revascularization.  The gold standard is digital subtraction contrast angiography, 
although new technologies, such as duplex ultrasound, magnetic resonance angiography (MRA), 
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and computed tomography angiography (CTA) are less invasive ways to assess PAD [85].  Each 
of these techniques is described in the following section.    
3.4.3.1 Contrast angiography to Identify PAD 
 Contrast angiography (CA) is the gold standard in identifying and characterizing PAD 
lesions [86].  In this procedure a small puncture in the common femoral or brachial artery allows 
access to the vasculature, such that sheaths and guidewires are inserted into the arterial tree and 
directed toward the site of expected anatomical lesions; these lesions are first identified through 
non-invasive testing.  Radiopaque contrast is injected into the vessels in order to visualize 
stenotic or occluded arteries and determine appropriate invasive management.  CA is an 
expensive procedure accompanied by significant risk, including a 0.16% mortality risk, and is 
associated with contrast-induced nephropathy and renal failure, pseudoaneurysm, hematoma, and 
other complications associated with vascular access[25, 86].  Figure 4a, below, is an image from 
a contrast angiography procedure. 
3.4.3.2 Duplex Ultrasound to Identify PAD 
 Duplex ultrasound measures flow velocity using a Doppler instrument and provides real-
time, B-mode imaging of the arterial system via duplex scanners [87].  Peak systolic velocity 
(PSV) is measured across the lower extremity arteries and changes in the velocity signal indicate 
severity of disease.  A 50%-99% stenosis is detected by a doubling in the PSV when moving 
from a more proximal lesion (i.e. popliteal to tibial vessel) [36].  Arteries with no blood velocity 
are believed to be occluded [87].  Duplex ultrasound had a median sensitivity of 88% (range: 
80%-98%) and a specificity of 96% (range: 89%-99%) in a systematic review of non-invasive 
methods of detecting PAD as compared to contrast angiography [85].  Findings suggest higher 
sensitivity in detecting disease among the iliac and femoral arteries as compared to the popliteal 
and tibial arteries [88, 89].  
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3.4.3.2 Magnetic Resonance Angiography to Identify PAD 
 Magnetic resonance angiography  uses a super-conducting system and pulse sequencing 
to image blood flow and to measure the presence and size of atheroma [90, 91].  MRA eliminates 
exposure to ionizing radiation and recent advancements in non-iodine-based intravenous contrast 
agents allow a more accurate revascularization plan with MRA in comparison to duplex 
ultrasound [92].  In a systematic review where contrast angiography was the gold standard, MRA 
had a median sensitivity of 95% (range: 92%-99.5%) and a median specificity of 97% (range: 
64%-99%) in identifying significant stenosis (>50%) [85].  MRA can overestimate degree of 
stenosis due to turbulence, it is not safe for patients with pacemakers or defibrillators, and 
imaging of metal stents and calcified arteries is challenged [86].  Figure 4b, below, is an MRA 
image of the lower extremity arterial system.      
3.4.3.3 Computed Tomography Angiography to Identify PAD 
 Computed tomography angiography (CTA) is the most recently developed method 
used to identify PAD.  It provides up to 128 simultaneous cross-sectional images of the arterial 
system [86], and uses a peripheral intravenous cannula to deliver iodinated contrast media [92]. 
A recent systematic review found that CTA is 91% sensitive (range: 89%-99%) and 91% specific 
(range: 83%-97%) in detecting significant (> 50% stenosis or occlusion) disease [85].  CTA 
allows for more rapid and detailed image acquisition as compared to other imaging modalities 
[92].  Radiation dosage is significant, although it is less than what is received in contrast 
angiography procedures [86].  The risk of nephropathy and acute tabular necrosis is also 
significant because CTA requires a contrast agent [86, 92].  Figure 4c, below, is a CTA image of 
the lower extremity arterial system.  
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Figure 4: Evolution of imaging techniques 
3.5 Clinical Management of PAD 
 Peripheral artery disease is managed both non-invasively and invasively, and each of 
these management strategies is described in the section below.  
3.5.1 Non-invasive Management of PAD 
 Risk factor modification, exercise therapy, and pharmacologic intervention are often the 
first steps in management of PAD.  The main targets of risk factor modification in individuals 
with PAD are tobacco cessation and diabetes control [18].  Tobacco cessation has been shown to 
decrease the risk of PAD progression and reduces cardiovascular events among claudicants [20].  
Guidelines suggest that maintaining a glycated hemoglobin A1c  close to 6% or less is optimal in 
individuals with diabetes [25].  
a) Contrast angiography of popliteal and tibial vessels; b) Magnetic resonance 
angiography of lower extremity arterial system; c) Computed tomography angiography 
of lower extremity arterial system; Figure 4a provided by Greenville Hospital System, 
Greenville, SC; Figure 4b, c adapted from hearthealthywomen.org 
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 Risk factor modification is combined with exercise therapy and pharmacologic 
management in many claudicants.  Supervised exercise programs, including 30 minutes of total 
walking time per day, at least three times per week, increase walking distances (compared to 
usual care or placebo) in individuals with claudication [19].  Regarding pharmacologic 
management, only one PAD-specific drug, Cilostazol, has repeatedly shown positive impacts on 
walking ability in randomized clinical trials [20, 21].  Often, these non-invasive options do not 
result in symptom resolution for the patient and the next steps include consideration of 
modalities for invasively treating PAD.   
3.5.2 Invasive Management of PAD 
 There are three primary modalities for invasively treating PAD.  These include 
endovascular management, open surgical bypass or endarterectomy, and lower limb amputation.   
3.5.2.1 Endovascular Management 
 Endovascular management of PAD includes Percutaneous Transluminal Angioplasty 
(PTA) with or without a stent, first described in 1964 with the pioneering work of Dotter and 
Judkins [22].  Stents were not commonly used in the management of PAD until the 1980s [93].   
 Percutaneous treatments are minimally invasive and are associated with lower morbidity 
and mortality than open surgery or limb amputation.  The major weakness of endovascular 
management is the frequent failure of these procedures to maintain arterial patency (i.e. to keep a 
blockage open) [26].  Endovascular management is most common among individuals with 
claudication and those with short-segment disease in the aorto-iliac region [4]. As an example, in 
a study of 1000 consecutive interventions for claudication, 643 were performed using 
endovascular technology and 701 were for aorto-iliac disease [7].  A study by Taylor et al 
(2007), however, suggests that there are some patients with critical limb ischemia for whom 
minimally invasive management is an appropriate strategy [94].  
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3.5.2.2 Open surgical Management 
 Two primary open revascularization options exist for clinically diagnosed PAD.  Surgical 
endarterectomy, a procedure first described by Dos Santos (1947), involves removing thrombus 
from an arterial segment [23], and is commonly used for isolated common femoral artery disease 
[95].  An alternative to endarterectomy is the surgical bypass (bypass) procedure which first 
occurred in humans in 1906 [24].  Open surgical procedures cause higher morbidity and 
mortality than PTA, but have longer patency and require fewer repeat operations.  Open 
management is most common among individuals with critical limb ischemia and those with 
long-segment arterial disease [26].  A recent study reported, however, that open management can 
be appropriate in certain individuals with claudication [7]. 
3.5.2.3 Limb Amputation Management 
 The final invasive treatment option for the severe and treatment resistant PAD is lower 
extremity limb amputation, which was first performed for PAD-related gangrene around 400 BC 
[96].  Lower limb amputation is indicated for life-threatening wound infection, uncontrollable 
rest pain, unreconstructable arterial disease, non-ambulatory patients, and others in whom 
treatment has failed [25].  Amputation is defined as primary, implying no prior intervention has 
been attempted, or secondary, in which a prior attempt at arterial reconstruction has failed, and is 
categorized, based on location of the amputation, as below-, through-, or above- the knee.   
 Limb amputation procedures are associated with high morbidity and mortality rates, 
particularly among diabetics [97].  In several studies, approximately 50% of individuals with 
lower extremity amputation (LEA) were deceased at two years [98, 99].  However, research 
indicates that LEA could be the best treatment for severe PAD if the result is early prosthetic 
fitting and a return to functional living [2]. 
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3.5.3 Trends Associated with PAD Management 
 Recent evidence indicates increases in rates of endovascular management of PAD while 
the rates of limb amputation and bypass procedures are either stable or decreasing [100, 101].  
O’Brien-Irr et al (2012) found that endovascular management increased while limb amputation 
procedures decreased between 2003 and 2008 [1].  Goodney et al (2009) found similar increases 
in endovascular procedures with a decrease in the use of bypass procedures by 42%, and declines 
in amputation over a ten-year period [102].  Evidence specific to trends among the Medicare 
population have not been examined and are a gap in the literature.   
3.6 Epidemiology of PAD 
 Peripheral artery disease is inconsistently defined across studies, and source populations 
differ significantly to include a variety of population-based and clinical-based settings.  The 
following section is meant to serve as an extensive literature review of the seminal PAD 
prevalence and incidence studies reported to date, while acknowledging cross-study comparisons 
are difficult because of methodological and source population differences.  Appendix 2 contains 
tables that highlight the important features of these seminal studies and each table highlights a 
methodology used to define PAD.  In reviewing this literature, important gaps in this literature 
will be identified that the proposed research will address.  Prevalence studies will be discussed 
prior to studies that quantified PAD incidence.  A section detailing the seminal CVD cohort 
studies that measured PAD will be discussed within the section on incidence, as will risk factors 
identified from these studies.  The final topic of PAD epidemiology will be the use of 
administrative claims sources to quantify burden.  
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3.6.1 Prevalence of PAD 
3.6.1.1 PAD Prevalence Based on ABI Measurement 
 The most common method of quantifying PAD prevalence in research studies is through 
measurement of the ABI, a procedure described above in section 1.4 of this research proposal.  
Prevalence of PAD originating from population-based studies from the U.S. ranged from 3.0% 
among the middle aged (45-64 years of age) participants in the ARIC cohort to 13.4% among 
older participants (> 65 years of age) in the Cardiovascular Health Study (CHS) [41, 72].  Selvin 
et al (2004) observed a similar prevalence of PAD in the National Health and Nutrition 
Examination Survey (NHANES) (14.5%, 95% CI: 10.8%-18.2%) [64].   
 In studies identified through this review, prevalence estimates were uniformly higher 
among hospital-based or clinic-based cohorts compared to population-based studies.  For 
example, the German Epidemiological Trial on Ankle Brachial Index (getABI study) measured 
ABI on 6,880 patients (> 65 years) identified from 344 general practitioners across Germany.  
Using ABI <0.90 as the cut point, the age-adjusted prevalence of PAD was 19.8% [73].  A 
Houston-based study of primary care clinics and the DeBakey Veterans Administration hospital 
found an overall prevalence of 16.7% among 403 participants over the age of 50.  Results were 
stratified by race and gender with particularly high prevalence estimates seen among black 
women (20.3%) and white men (20.1%) as compared to other white, black and Hispanic 
participants [78].  Further studies that used ABI measurement as the sole identifier of PAD are 
shown in Appendix Table 1 and Appendix Table 2.   
 Studies using only ABI are likely to underestimate PAD prevalence.  While the ABI test 
may help identify asymptomatic PAD, studies that did not use a second measure, such as a 
questionnaire, are likely to underreport symptomatic disease. 
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3.6.1.2 PAD Prevalence Based on Questionnaires with or without ABI 
 Prevalence is commonly measured using only questionnaires although some studies use 
both a questionnaire and the ABI measurement to detect PAD. Estimates that use both methods 
are important because they can capture both asymptomatic and symptomatic disease.  Not 
unexpectedly, prevalence estimates based on this combined methodology are uniformly higher 
than estimates based on ABI alone.  As an example, the lowest prevalence identified in a search 
of the literature was from a population-based study of randomly selected individuals from four 
regions in Sweden.  This study had an “any PAD” category, defined by ABI <0.90 or a positive 
Rose/WHO Questionnaire [48].  Prevalence of this definition of PAD was 17.9% (95%CI, 16%-
20%); 11.1% had asymptomatic PAD identified by ABI and 6.8% had symptomatic disease.  The 
highest prevalence of PAD identified through combined ABI and questionnaire method was 
19.1% (95% CI: 18.1%-20%) in the Rotterdam Study, a population-based study in the 
Netherlands.  This study also used  ABI <0.90 to detect asymptomatic disease and the 
Rose/WHO Questionnaire to define symptomatic PAD [59].  Studies using this combined 
methodology had low response rates for enrollment.  Many studies reported poor response rates 
for completion of the questionnaire.  These studies also used different questionnaires to assess 
for claudication making cross study comparisons difficult [59, 80].  Results from other studies 
using this methodology are shown in Appendix Table 3.   
 As previously discussed, the WHO/RQ, one of the primary instruments used in studies of 
PAD prevalence, has a low sensitivity and likely underestimates disease burden, leading to 
misclassification bias.  Studies that used the SDQC as an alternative to the WHO/RQ or the EQC 
should better represent PAD burden because the SDQC allows identification of non-calf IC.  A 
study by Wang et al (2005), for example, identified an additional 1.7% of individuals who had 
either thigh or buttock claudication by using the SDQC [103].     
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3.6.1.3 PAD Prevalence Based on Self-report and ABI or Questionnaires 
 Several studies of PAD prevalence used a combination of self-report with or without one 
other assessment modality to quantify PAD burden.  The lowest estimate came from a 
population-based study in the industrialized urban regions of Western Germany that used ABI 
<0.90 or self-reported physician diagnosis to conclude an overall PAD prevalence of 6.8% [67].  
The highest prevalence was found in the PAD Awareness, Risk, and Treatment: New Resources 
for Survival (PARTNERS) program [11].  The PARTNERS program included 350 primary care 
practices in 27 sites (25 cities) across the US and enrolled individuals that were either 1) 50-69 
years of age with a history of diabetes or smoking or 2) 70 years of age and older.  Using ABI 
<0.90, or documented PAD in a medical record, PAD prevalence was 29% [11]. Studies 
quantifying PAD prevalence by a combination of self-report with one additional modality show 
inconsistent methodologies, causing a wide range of estimates.  Estimate comparisons across 
studies, therefore, are difficult.  Further information on studies using these criteria can be found 
in Appendix Table 4 and Appendix Table 5.   
3.6.1.4 Summary of PAD Prevalence Studies 
 PAD prevalence estimates vary widely and are dependent on the methodology used to 
assess PAD.  As would be expected, studies that used ABI in combination with a second 
detection method reported higher prevalence estimates than those that used a single assessment 
method.  Studies conducted in populations with a higher mean age or in high risk populations, 
such as the CHS study of people 65 years of age and older, had the highest prevalence estimates.  
Studies such as the study in Western Germany, described above, which included healthy 
workers, showed much lower prevalence estimates.  Existing estimates of PAD prevalence rarely 
reported on outpatient events or on CLI and, as such, the literature on these topics is sparse. 
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3.6.2 Incidence of PAD 
 Estimates of PAD incidence are exceedingly rare in population-based studies as PAD is 
an infrequently examined endpoint.  Many of the studies that do measure PAD have different 
population bases and detection methods to assess PAD, making cross-study comparisons 
difficult.  The following section details cohort studies that measured and have reported findings 
for incident PAD.  Incidence of PAD obtained from longitudinal studies ranged from 1 per 1000 
person years to 23.8 per 1000 person year.  Estimates for PAD incidence are comparable to 
estimates for stroke and myocardial infarction incidence.  Incidence of PAD is, however, lower 
than incidence of atrial fibrillation and heart failure [104].  Further information from a review of 
the literature presenting PAD incidence estimates is shown in Appendix Table 6.  
3.6.2.1 Cohort Studies Measuring Incident PAD 
 Several major cardiovascular cohort studies that measured incident PAD are described 
below.  These studies are highlighted because they are the seminal studies in the literature with 
well-defined methodologies and reported results.  They are also primarily US-based, providing a 
reference point for the proposed research. With the exception of a study by Murabito et al 
(2005), which found that the incidence of claudication is declining over time, all literature 
reviewed indicates that PAD incidence is expected to increase as the population ages [105].   
3.6.2.1.1 The Framingham Heart Study  
 The Framingham Heart Study (FHS) is a community-based cohort study from the 
community of Framingham, Massachusetts, an industrial and trading center of approximately 
30,000 individuals [106].  A sample of 5,209 participants (29 to 62 years of age at baseline), 
chosen based on a local census list and stratified by family size and precinct of residence, was 
enrolled in the study.  The investigators measured the presence of IC using criteria of cramping 
discomfort with exercise that was relieved with rest derived from a physician-administered 
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questionnaire.  All IC cases were reviewed and adjudicated by a panel of investigators [107].  
Over the first fourteen years of follow-up 125 cases of IC were identified with an average annual 
incidence of IC of 26 per 10,000 person-years among males and 12 per 10,000 person-years 
among women.  A follow-up study assessed temporal trends of IC incidence over a fifty-year 
period [105].  Incident cases increased through the 1970s with a peak rate of 34.5 per 10,000 
from 1970-1979.  The number of cases declined in the 1980s and 1990s and decreased to 22.5 
per 10,000 from 1990-1999 [105]. 
 While the FHS provided valuable insights into PAD etiology and trends associated with 
PAD burden over more than sixty years of follow-up, the Framingham Study has several 
limitations.  The FHS excludes all minority groups and is poorly generalizable to the broader US 
population.  Claudication was defined only by medical history documentation, which might 
result in misclassification bias.    
3.6.2.1.2 Edinburgh Artery Study  
 The Edinburgh Artery Study (EAS) examined the natural history of PAD among 1,592 
residents of Edinburgh, Scotland, 55 to 74 years of age [108].  EAS investigators used ABI 
measurements with hyperemic drop calculation and administration of the WHO/RQ to estimate 
asymptomatic and symptomatic PAD, respectively [108].  Follow-up for the EAS (Leng, 1996) 
identified 116 incident IC cases (15.5 per 1000 person-years) over five years of follow-up.  Men 
had a higher incidence proportion of IC than women (8.7% vs. 6.6%).  Over five years of follow-
up, 8.2% of those with IC had a myocardial infarction (MI), 9.6% developed new angina, and 
6.8% had a major cerebrovascular event.  Approximately 20% of those with IC were deceased at 
five years of follow-up and 13.7% had experienced a cardiovascular-related death.  Four percent 
of those with baseline IC had required a limb amputation at five years [81].   
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 The EAS was one of the first studies that monitored peripheral atherosclerosis endpoints, 
and is a rare study that reports incidence rates.  The study includes information on individuals 
across social class and educational attainment and uses several measures to delineate PAD 
prevalence.  Their inclusion of participants from poorer areas led to a lower response rate than 
they had expected.   
3.6.2.1.3 Atherosclerosis Risk in Communities (ARIC) Study  
 The ARIC study is a bi-ethnic longitudinal study of the natural history of atherosclerotic 
diseases among 15,792 residents of four US communities: Forsyth County, North Carolina, 
Washington County, Maryland, Jackson, Mississippi, and suburban Minneapolis, Minnesota [8].  
ARIC study participants were 45-64 years of age at baseline.   
 Zheng et al (2005) conducted a cross-sectional analysis using ABI <0.90 to identify PAD 
and found an age-adjusted PAD prevalence of 3.0% among ARIC study participants [70].  Age 
adjusted prevalence among gender and race subgroups was as follows: African American men, 
3.1%; African American women, 4.4%; white men, 2.3%; white women, 3.2% [70].  Selvin et al 
(2006) used the Rose Questionnaire, ABI <0.90, or a PAD-related hospitalization to quantify 
incident PAD among those with diabetes in the ARIC cohort [109].  Crude incident rates 
reported for IC, low ABI, and PAD-hospitalization were 2.1, 18.9, and 2.9 per 1000 person-
years, respectively, during 9.8 mean years of follow-up.  Wattanakit (2005) conducted a similar 
study among diabetic participants in ARIC and found a total PAD event rate of 13.9 per 1000 
person-years [110]. 
 The ARIC study is a geographically diverse, bi-ethnic cohort, providing distinct 
advantages over similar cohort studies, such as the FHS, that were from single centers or 
examined only one ethnicity.  There are some disadvantages to the ARIC cohort study.  ABI was 
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measured in only one leg at baseline and only in segments of the cohort at subsequent visits.  
Follow-up ABI testing was completed for 4,575 participants at the third clinic visit (1993-1995) 
and in 6,404 participants at the fourth clinic visit (1996-1998). Thus, estimates from this study 
likely underestimate PAD burden in this population.        
3.6.2.1.4 Women’s Health Initiative (WHI)  
 The Women’s Health Initiative (WHI) is a clinical trial (n=16,608) and observational 
study (n=69,000) designed to delineate causes of morbidity and mortality among 
postmenopausal women 50-79 years of age [111].  The study was initiated in 1992 and follow-up 
is ongoing.  The clinical trial component, the Women’s Health Initiative Estrogen Plus Progestin 
trial, randomized women to placebo or estrogen therapy.  Peripheral artery disease, measured by 
self-reported history of carotid or lower extremity surgery, was exceedingly rare (0.5%) at 
baseline exam. 
 Hsia et al (2003) reported on incident lower extremity events, defined as overnight 
hospitalization with either symptoms or intervention and confirmed by procedure, absence of 
pulses, or non-invasive vascular studies [112].  Over 5.6 years of follow-up, the incidence 
proportion of PAD was 0.14% per year.  Incident PAD events occurred more frequently among 
women with a history of coronary artery disease (CAD) or PAD (13 per 1000 person-years) than 
women with no history of arterial disease (1 per 1000 person-years).   
 The WHI is a large study that provides valuable data on PAD in women across the 
country at forty sites.  The sample was not, however, random, and the healthy volunteer effect 
may be leading to lower PAD event rates than would be expected in the general population.  The 
study is limited to women and estimates are not generalizable to men.     
29 
3.6.3 PAD Risk Factors Identified from Reviewed Literature 
 In the following section, traditional and sociodemographic risk factors for PAD will be 
discussed to further place PAD in the context of overall atherosclerotic disease burden.  As PAD 
has a shared risk factor profile with coronary and cerebral atherosclerosis, the implication of 
reducing the prevalence of PAD risk factors extends to benefits in delaying or preventing 
myocardial infarction, stroke, and other major circulatory system disorders [25, 35, 113]. 
3.6.3.1 Traditional Risk Factors 
 Risk factors for PAD are identical to traditional cardiovascular disease risk factors, with 
diabetes [109, 110, 114, 115] and smoking [116-118] particularly predictive of PAD.  Other 
important risk factors include hypertension [119-121], dyslipidemia [122-124], renal 
insufficiency [125, 126], poor diet [127-129], and lower levels of physical activity [130-132].  
Risk factor profiles are similar for all stages of PAD severity, although diabetes may have a 
stronger association with CLI as compared to claudication [133].  
 
3.6.3.1.1 Diabetes Mellitus/Impaired Glucose Tolerance as a PAD Risk Factor 
 Diabetes Mellitus (DM) causes an abnormal metabolic state which increases the 
susceptibility to atherosclerotic diseases in the three primary vascular beds: the coronary arteries, 
the lower extremity arteries and the extracranial arteries [134].  Diabetes is more predictive of 
PAD than of MI and stroke, and is considered one of the most prominent risk factors for PAD 
[120, 135].  The predictive ability of DM is so substantial that the American Diabetes 
Association has recommended ABI measurement, the most common test for PAD, every five 
years, for life, among diabetics [136].   
 In the CHS, the relative risk of PAD (ABI <0.90) among diabetics was 4.1 (95% CI: 2.8-
5.9) compared to non-diabetics [72].  Research suggests that hyperglycemia, glucose intolerance, 
and glycosuria are all associated with an increased risk of claudication [121].  The risk of 
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claudication among women with glycosuria was 8.6 times the risk of claudication among women 
without glycosuria [121].   
 Diabetic patients are more likely to have disease in their distal (below the knee) arterial 
tree where vessels are smaller [134].  Disease in the popliteal and tibial arteries is associated with 
the more severe PAD sequelae [137].  Diabetic patients are at an increased risk of foot ulcers 
because of neuropathic complications and poor infection response [134].  As a result of these 
complicating factors, DM is associated with an increased risk of CLI and limb amputation [25, 
138].  The risk of amputation is five-fold greater among diabetics as compared to non-diabetics, 
and DM is implicated in the majority of non-traumatic limb amputations [139, 140].  Diabetes 
represents a modifiable risk factor that, if appropriately managed, could reduce the overall 
burden of PAD.  
3.6.3.1.2 Smoking as a PAD Risk Factor 
 While diabetes is largely associated with small vessel PAD, smoking is associated with 
progression of large vessel PAD [137] and is considered a well-known and significant risk factor 
for intermittent claudication [141, 142].  The first prospective study that identified smoking as a 
risk factor for PAD was the Framingham Study, which reported on the association between 
baseline number of cigarettes smoked daily (none, <20, 20, or >20) and incidence of intermittent 
claudication over a sixteen year period [117].  All levels of smokers had a higher incidence of IC 
at all age groups, although heavy smokers (>20 per day) were three times as likely as never 
smokers to develop IC over 16 years [117].  Association of smoking with PAD observed in FHS 
is similar to the relationship seen in the Cardiovascular Health Study (CHS).  In CHS, the 
relative risk of PAD (defined as ankle-brachial index <0.90) among current smokers was 2.55 
(95% CI: 1.76-3.68) compared to never smokers [72].  Other studies confirm a similar dose-
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response relationship [116, 122, 143].  Smoking is associated with CLI [25] but does not 
confound the relationship of CLI to outcomes such as mortality and limb amputation [144, 145]. 
3.6.3.2 Sociodemographic Traits as PAD Risk Factors 
 Prior studies have shown that important sociodemographic traits such as age, gender, 
race, and socioeconomic status are associated with PAD [41, 64, 66, 67, 69].  Disease prevalence 
increases significantly with age and the American Heart Association recommends all individuals 
over the age of 65 be screened for PAD via the ABI test [60, 64, 86].  Selvin et al (2004) studied 
2,174 participants aged 40 and older with ABI measurements in the National Health and 
Nutrition Examination Survey (NHANES I), conducted from 1999-2000 to estimate PAD 
prevalence [64].  Overall prevalence (ABI <0.90) was 4.3% (95% CI: 3.1%, 5.5%) among those 
40-49 years of age, 2.5% (95% CI: 0.5%-4.5%) among those 50-59 years of age, 4.7% (95% CI: 
2.5%-6.9%) among those 60-69 years of age and 14.5% (95% CI: 10.8%, 18.2%) among those 
70 years of age and older.  Overall, the investigators estimated that during the period of 
observation more than 5 million individuals in the US had PAD, including at least 4 million 
among those over 70 years of age [64].   
 The majority of population-based studies stratify estimates by gender, although evidence 
concerning differences in PAD prevalence between men and women is conflicting.  The 
NHANES study identified no differences in PAD prevalence among men (4.5%, 95% CI: 2.9%-
6.1%) as compared to women (4.2%, 95% CI: 2.8%-5.6%) [64].  The ARIC study did find a 
slightly greater prevalence of PAD (ABI <0.90) among women as compared to men [41].  
Results from the FHS indicate a higher incidence rate of PAD among men (26 per 10,000 
person-years ) as compared to women (12 per 10,000 person-years ) while information from the 
Limburg Peripheral Artery Occlusive Disease Study found higher incidence rate of PAD among 
women (14.2 per 1000 person-years) as compared to men (8.2 per 1000 person-years) [107, 146].   
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 PAD burden estimates stratified by race in the US have consistently found that PAD 
prevalence is typically higher among blacks as compared with whites.  Blacks had a higher 
prevalence (7.9%, 5.2%-10.6%) than whites (4.4%, 95% CI: 2.8%-6.0%) in NHANES [64].  
Baseline PAD prevalence (ABI <0.90), among 2,343 participants of the San Diego Population 
Study (SDPS) of randomly selected population of former/current employees, was 7.8% in blacks 
and 4.9% in whites [69].  Prevalence is generally lower among Hispanics as compared to blacks 
and is sometimes lower than prevalence in whites.  Less than 2% of Hispanics in the SDPS had 
PAD at baseline [69].  Three percent (95% CI, 1.4%-4.6%) of Mexican Americans in NHANES 
had prevalent PAD [64].  Prevalence of PAD (ABI<0.90) among 6,653 participants in the Multi-
Ethnic Study of Atherosclerosis (MESA) was 7.2% in African Americans, 3.6% in whites, and 
2.4% in Hispanics [147].  Results for race and gender are summarized in Table 3, below.  Each 
of the studies described in Table 3 use homogeneous measurement methods (ABI < 0.90) to 
quantify PAD prevalence.  The ages of the population eligible for inclusion of the study, 
however, are significantly different.  The CHS Study enrolled only those 65 years of age and 
older.  Estimates were similar among ARIC, NHANES, MESA, and San Diego, studies that 
included predominantly middle-aged individuals.    
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Table 3. PAD prevalence estimates by gender and race 
 Gender Race 
Study Population Female 
(%) 
Male  
(%) 
Black 
(%) 
White 
(%) 
ARIC 3.5 2.5 3.7 2.8 
CHS 12.4 14.8 21.5 11.9 
NHANES 4.2 4.5 7.9 4.4  
MESA 3.7 3.7 7.1 2.7 
San Diego 3.6 6.1 7.8 4.9 
 
 Reports on the association between socioeconomic status (SES) and PAD are limited.   
In the population-based Heinz Nixdorf Recall Study in Germany, PAD prevalence (ABI<0.90) 
was inversely related to education and income among 4,738 individuals [67].  PAD prevalence 
among low (< 10 years), medium (11-13 years), and high education (> 14 years) was 8.1%, 
7.5%, and 5.3%, respectively.  Among 6,791 participants in the NHANES study, SES, defined 
by income, was inversely associated with prevalent PAD (ABI<0.90).  Individuals with low SES 
had the highest PAD prevalence (8.4%, 95% CI: 7.3%-9.5%), while individuals in the highest 
SES category had the lowest PAD prevalence (3.4%, 95% CI: 1.8%-3.6%) [148].  Other studies 
only found weak associations between SES and PAD [149, 150].   
 Sociodemographic disparities in PAD extend to variations in rates of procedures.  Several 
studies of revascularization procedures for PAD report lower procedure rates among blacks, 
women, and individuals of low SES in comparison with whites, men, and those of high SES, 
respectively [151, 152].  Numerous studies have reported disparities in surgery for lower 
extremity amputation [6, 153, 154].  Research relevant to sociodemographic procedure variations 
implicates poor access to care among these higher risk groups.     
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3.6.4 Literature Summary for PAD Epidemiology 
 PAD is an arterial disease that has significant consequences, both to the individual and to 
the health care system, if it is not identified and aggressively managed.  Total all-cause 
hospitalizations for PAD are in excess of $21 billion with 57% of those due to revascularization 
procedures and amputations [15].  PAD can cause life-altering physical limitations with limb- 
and life-threatening consequences.  More than 50% of individuals with critical limb ischemia, 
the most severe PAD, will be deceased or have experienced a limb amputation within one year of 
diagnosis.  As such, early detection and management is critical.  Furthermore, as PAD is 
associated with disease in other vascular beds, increasing awareness of PAD could have benefits 
in the prevention of myocardial infarction, stroke, and cardiovascular-related death. One of the 
primary hopes of the proposed research, therefore, is simply to raise awareness of PAD and to 
provide information that will allow PAD to be placed in context with other more well-known 
atherosclerotic conditions.   
 A thorough review of existing of PAD prevalence and incidence literature reveals widely 
varying estimates.  Population bases and detection methods to assess PAD differ, making cross-
study comparisons difficult.  Differences among characteristics of PAD incidence studies include 
single gender representation, race-specific population studies, population-based versus clinic-
based samples, differing questionnaires, and adjudicated versus non-adjudicated events among 
others.  In the majority of population-based studies where PAD is an endpoint, it is synonymous 
with intermittent claudication to the exclusion of more severe sequelae, such as critical limb 
ischemia.  Current estimates do not contain information on outpatient visits and procedures 
where the majority of encounters likely occur.    
 One method to address these methodological concerns is to use an administrative claims 
data source as a research study population.  Medicare claims data are limited to those ages 65 
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years and older which is a limitation of this data source. Other administrative sources, such as 
Medicaid and commercially available claims databases, include information on younger 
populations. These sources are, however, not linked with the ARIC study.  Further, the 
Medicare-eligible population is a reasonable population to study PAD because it is a disease of 
aging primarily found in the elderly.  The next section will detail the use of administrative claims 
as a research tool to quantify PAD.    
3.6.5 Identification of PAD Events from Administrative Claims Data 
 Administrative claims originating from federal and private insurers are increasingly used 
for research purposes.  Claims are created by health care providers for payers and indicate what 
services a provider billed for during a particular visit. The International Classification of 
Diseases, Clinical Modification, version 9 (ICD-9-CM), Current Procedural Terminology, 4
th
 
edition (CPT-4) codes, Healthcare Common Procedure Coding System (HCPCS) codes, and 
Federally Qualified Healthcare Center codes (FQHC) are used to identify clinical events and 
procedures in claims data. A description of these codes is found below in Table 4 (p.41).  
Administrative claims data frequently are examined in Medicare Fee-for-Service (FFS) and 
Managed Care Programs, which are discussed below. 
3.6.5.1 Medicare Fee-for-Service and Medicare Advantage Programs 
 Medicare FFS is the program that provides hospital and ambulatory care to persons 65 
years and older in the United States.  FFS includes Part A (hospital insurance) and Part B 
(supplemental insurance that covers physician and outpatient services).  Medicare beneficiaries, 
with the exception of those with end-stage renal disease and those on hospice care, also have the 
option to enroll in a MA program where individuals can attain supplemental insurance to cover 
the costs of their health care services [155].  Medicare Advantage receives capitated monthly 
payments to provide health services to their clients and are at an advantage to enroll low-risk 
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individuals who are likely to have low medical care costs [156].  Significantly, MA is not 
required to submit claims information to Medicare for their enrollees; therefore health care 
utilization is not quantifiable for beneficiaries enrolled in MA using Medicare claims and 
researchers must note this study design limitation.  The percentage of Medicare beneficiaries 
enrolled in MA varies significantly across states and geographic regions.  An example of this 
variation (and significant to the proposed research) is the ARIC study, where penetrance ranges 
from <10% (Washington County, Jackson from 2003-2005) to >40% (Forsyth County, 2005-
present).  Figure 5, below, is a representation of penetrance among the four ARIC regions from 
2001-2008.  
  
Figure 5. Percent managed care penetrance by ARIC community from 2001-2008; adapted from 
ARIC website 
3.6.5.2 Validation of Administrative Claims Data 
 Administrative data studies examining the validity of ICD-9 and CPT codes to identify 
PAD are rare and only three studies on the validation of PAD related codes from claims data 
were identified for review [157-159].   
 The Mayo Clinic has developed the Mayo Clinic algorithm (MCA), a billing code-based 
algorithm for identifying PAD patients from an electronic medical record (EMR). The MCA, 
originally used to identify the PAD phenotype in genomics research, contains an exhaustive list 
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of ICD-9-CM and CPT-4 codes relevant to PAD [160]. Recently published work examined the 
application of the MCA in a community-based sample of 4420 Olmstead County residents seen 
at the Mayo Clinic with a PAD-related billing code [161]. Of these patients, 225 patient records 
were randomly selected for manual record abstraction by an experienced cardiologist. Results 
included: sensitivity, 68.0% (95% CI: 56.2-78.3); specificity, 87.6% (95% CI: 80.9-92.6); 
positive predictive value (PPV), 75.0% (95% CI: 63.0-84.7), and negative predictive value 
(NPV), 83.3% (95% CI: 76.2, 89.0).  An additional study of 22,000 individuals at the Mayo 
clinic used billing codes and the ABI test to ascertain PAD.  Area under the operating-receiver 
was 0.86, indicating sufficient PAD identification ability of the algorithm [159].  Appendix 
Table 7 provides a detailed report of these studies. 
 The Women’s Health Initiative (WHI) study investigators validated ICD-9-CM codes in 
comparison with reviewer diagnosis and adjudication of 470 potential PAD events and found a 
sensitivity of 0.61 (95% CI: 0.54,0.68) and a positive predictive value of 0.31 (95% CI: 
0.26,0.36; ICD-9-CM codes 443.9, 440.2) [158].  A second study by Fisher et al (1992) 
examined 217 hospitalized PAD events abstracted from a hospital record to assess 
agreement/reliability as compared to reabstraction, completed by the Office of the Inspector 
General [157].  The sensitivity of ICD-9-CM codes (in any position) to identify PAD was 0.58 
(95% CI: 0.51, 0.64) with a PPV of 0.53.  This study also examined a PAD diagnosis based on 
ICD-9-CM codes in the primary or secondary position and found that sensitivity and PPV were 
much higher at 0.76 and 0.69, respectively [157].   
 To date, no published report has examined the validity of using claims to quantify 
outpatient events.  As such, a validation study of PAD ICD-9-CM codes, to include both 
inpatient and outpatient, would be a valuable contribution to the literature.   
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3.6.5.3 Estimates of PAD Burden Based on Administrative Claims 
 A small body of literature quantifies PAD prevalence and incidence using ICD-9-CM 
and/or CPT-4 codes obtained from administrative databases, with source populations originating 
from Medicare and managed care.  The majority of those studies were completed for the purpose 
of assessing PAD-related costs [1, 15, 102, 162-165].  Each of the salient studies is discussed 
below.  Appendix Table 8 lists the diagnostic codes used to define PAD in each study.   
 For the purposes of this review, the term PAD prevalence is used to describe the 
occurrence of PAD among individuals eligible for inclusion in administrative claims-based data 
sources.  Thus, estimates are representative of individuals who have had medical encounters (i.e. 
the source of a claim) and do not reflect a true population-based denominator.  PAD estimates 
from claims sources are unique in comparison to the previous literature discussed because 
asymptomatic disease, defined by ABI or questionnaire in the literature reviewed, cannot be 
quantified using administrative claims.  Further, administrative claims allow outpatient PAD, for 
which there is limited information available otherwise, to be quantified.  Estimates from 
administrative claims are, therefore, a reflection of the burden of clinically diagnosed PAD. 
3.6.5.3.1 Estimates of PAD Burden Based on CMS Medicare Claims  
 The 5% Surveillance, Epidemiology, and End Results (SEER) non-cancer data for 
calendar year 2001 was used to determine PAD-related national health care expenditures in the 
US [162].  The SEER registry is a population-based cancer registry that collects information on 
about 28% of the US population.  SEER includes information on Medicare enrollment and 
utilization.  Hospitalized PAD events were identified on the basis of a PAD-related ICD-9-CM 
code in the primary or secondary position as well as a PAD-specific diagnosis-related group 
(DRG), as shown in Appendix Table 8.  This study also included outpatient events, although the 
method of ascertainment was not described.  Approximately 7% of the more than 150,000 
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beneficiaries studied had a PAD-related claim.  PAD-related hospitalizations accounted for 
nearly 90% of expenditures among those with PAD, although only 6.4% (n=668) of those with 
PAD had an inpatient claim with a PAD-related diagnostic code.  This study indicates that 
majority of PAD events occur in the outpatient setting, although the study investigators only 
present outpatient costs and do not present detailed burden information for outpatient claims.  
This study underscores the need to further examine PAD events occurring in the outpatient 
setting.   
 A 5% random sample of Medicare beneficiaries from the Medicare Standard Analytic 
Files (Medicare Part A and Part B) was used to quantify PAD costs and to assess clinical 
outcomes following invasive management [163].  PAD was defined using pre-specified ICD-9-
CM and CPT code algorithms, as shown in Appendix Table 8.  A range of 2.1 to 2.4 million 
beneficiaries were enrolled in the data set, depending on the year.  Of these, 57,043 beneficiaries 
receiving PAD-related treatment were identified.  Inpatient PAD prevalence increased during the 
period of observation from 8.2% in 1999 to 9.5% in 2005.  Projected estimates for the full 
Medicare beneficiary population indicate prevalence of 4.3 million in 2005.  Prevalence 
increased incrementally with age with the highest rates (19.3%) seen among those > 85 years of 
age.  Prevalence was comparable among men (9.3%) and women (9.7%).  Among individuals 
treated for PAD less than 6% underwent limb amputation procedures and 27% died during the 
six years of follow-up.  This is an important study that provides useful information on inpatient 
PAD-related care.  The study, however, excludes outpatient data and does not provide 
information on PAD subtypes. 
 The PAD estimates above are presented to establish precedence for using Medicare 
claims to quantify clinically diagnosed PAD and to identify limitations in the existing literature.  
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The notable exclusion of outpatient data likely underreports PAD burden and, as such, is an 
important scientific need to be addressed by this proposal.  
3.6.5.3.2 Administrative Claims from Managed Care Database to Estimate PAD 
 Administrative claims from a managed care database of 6.67 million members of two 
health plans in the western and southeastern US were used to examine PAD-related costs [14].  
Those meeting inclusion criteria, 18 years of age and continuous plan eligibility from January 1
st
, 
1999 to August 31
st
, 2003, were enrolled in the study.  PAD was defined by ICD-9-CM codes 
(diagnosis and procedure) in the primary or secondary position, CPT codes, or by a pharmacy 
claim for PAD-specific medications, Cilostazol or Pentoxifylline.  Of the total population of 
managed care participants examined, 30,561 (1.2%) had a PAD-related claim.  PAD prevalence 
was 10.8 per 1000 plan members and increased significantly with age.   
 This study was limited to managed care participants, a traditionally healthier and younger 
group of individuals as compared to those with federally provided insurance [166].  Thus, while 
this study provides valuable information on those with private insurance, limited inferences can 
be made as to the prevalence and incidence of PAD among a more elderly population with 
greater prevalence of comorbidities.   
3.6.5.4 Summary of PAD Estimates Based on Administrative Claims 
 Administrative claims present an opportunity to estimate the burden of PAD in defined 
populations and have several strengths over other types of data sources.  Clinically diagnosed 
symptomatic PAD is an understudied problem and claims data are capable of assessing the 
magnitude of the disease in a particular population (65 years of age and older) that represents the 
most significant risk for this disease.  In addition, while burden estimates from the literature 
largely exclude outpatient events making it difficult to quantify the full spectrum of PAD-related 
care, claims data present the ability to quantify PAD events in the outpatient setting.   
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 Administrative data have several limitations and the limitations specific to CMS 
Medicare claims are discussed next.  CMS claims data do not provide detailed information on 
comorbidities or illness severity.  Coding inconsistencies and missing data, specifically missing 
information on self-reported race, are also problematic.  Additionally, enrollment of Medicare 
beneficiaries in the MA programs or with other private insurers (i.e. health maintenance 
organization (HMO) penetrance) effectively creates study populations with additional insurance 
which may differ on health status as compared to those with only Medicare fee-for-service [167].  
Information concerning health care encounters for those with MA plans and those with other 
private insurance is not available from Medicare claims, thus making it impossible to collect all 
relevant data for these individuals.  This selective loss in our population base impacts the 
generalizability of our findings, which will be specific only to those with continuous FFS 
Medicare coverage. The findings will not be generalizable to the broader Medicare population or 
to those enrolled in a managed care program.   
3.6.5.5 Relevance of Administrative Claims to Proposed Research  
 The previously discussed PAD estimates based on administrative claims are presented 
because this data source is relevant to the proposed study, which will use CMS Medicare claims 
linked to the population-based surveillance database for the ARIC study.  Claims are available as 
a 100% sample of health care claims among those that live in the four geographically defined 
areas of the ARIC study.  These claims are available over multiple consecutive years and are 
managed by the ARIC Study Coordinating Center here at UNC.  By placing the proposed study 
in the context of geographic regions we have the ability to examine clinically diagnosed PAD in 
relationship to other clinically diagnosed cardiovascular conditions, such as heart failure, stroke, 
and acute myocardial infarction, which have been the subject of other claims-based research in 
ARIC.  The ARIC study population is well-characterized in demographic and comorbid traits, 
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which will further help contextualize the importance of PAD in these particular communities.  
While the ARIC study regions were not chosen because they are nationally representative 
estimates, attained estimates could reflect PAD burden in communities with similar population 
traits.   
3.7 Public Health Significance 
 PAD remains an understudied problem of public health significance for which there is 
poor awareness compared to other cardiovascular diseases [11]. The proposed research addresses 
important gaps in the literature by contributing to: sparse information for PAD in the outpatient 
setting, the longitudinal evaluation of post-diagnosis care, limited information for incidence, and 
PAD data by sociodemographic traits. By attaining age-, race-, and gender-specific estimates of 
PAD burden and post-diagnosis care, and with the knowledge that atherosclerotic diseases share 
risk profiles, results of this study could be used to implement more targeted and effective 
prevention efforts. These prevention efforts could have significant downstream benefits at 
delaying myocardial infarction, stroke, and other circulatory system disorders. Results of the 
proposed research will create a foundation for future studies aimed at comparing, by 
demographics and comorbid conditions, the different trajectories associated with clinically 
manifest PAD diagnosed in the inpatient or outpatient setting. Future work could also include 
examination of the relationship between PAD and other cardiovascular diseases, such as heart 
failure, on which similar research is being conducted.  
43 
CHAPTER 4: RESEARCH METHODS 
4.1 Study Population 
 The study population for Specific Aims 1 and 2 will include Black and White ARIC 
cohort participants ages 65 years and older enrolled in the Center for Medicare and Medicaid 
Medicare fee-for-service program.  
4.1.1 The ARIC Study Cohort Data Linked to CMS Medicare Claims 
 The ARIC cohort includes 15,792 participants (ages 45-64 at baseline) selected by 
probability sampling from four US communities: Jackson, MS; Forsyth County, NC; 
Washington County, MD; and Minneapolis, MN (Figure 6). Participants from Forsyth County 
were selected from area sampling of households. Participants were also selected from drivers 
licenses (MS, MD, MN), identification cards (MS, MN), voter registration cards (MN), and 
individuals listed in a 1975 private county health census (MD). Of note, blacks were 
oversampled in Forsyth County (NC) and constitute 100% of individuals sampled from the 
Jackson (MS) site. 
 
 
Figure 6. Map of the four ARIC communities 
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 Potential cohort members were interviewed in their homes and then invited to a clinical 
examination. Overall, sixty percent of invitees chose to participate in the study including 49% of 
black females, 42% of black males, 68% of white females, and 67% of white males. Differences 
in comorbid conditions between respondents and non-respondents were more pronounced for 
men and women than for blacks and whites [168]. The ARIC cohort contains a limited number 
of Asian (n=44) and American Indian/Alaskan (n=14) persons who are traditionally excluded 
from analyses due to the lack of representation of these race groups. Twenty-seven percent 
(n=4266) of the baseline ARIC cohort population are black, 55% (n=8695) are female, and 24% 
(n=3754) have less than a high school education.  
 The cohort began enrollment in 1987 and recruited its final participant in 1989. There 
have been five clinic examinations with the fifth visit concluding in 2013. All hospitalizations 
associated with the ARIC Cohort are available through discharge data and from CMS claims. 
These inpatient data sources will be used estimate calibration factors associated with inpatient 
PAD.  
 Data from the ARIC cohort study does not include participants’ outpatient visits. Instead, 
each participant agreed to annual follow-up (AFU) questionnaires in the form of a telephone 
interviews conducted by ARIC-trained representatives. The AFU questionnaires are used to 
capture non-hospitalized medical encounters that occur between the clinical examinations. Data 
from AFU questionnaires will be used to estimate calibration factors relevant to outpatient PAD. 
Notably, response rates are excellent (>85%) throughout study follow-up at all centers. All 
participants will be >65 years of age during the years sample for this study. 
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 Our study will use FFS Medicare claims specifically linked to extant data for participants 
of the ARIC cohort study. The ARIC cohort participants are matched to CMS Medicare data on 
three factors: social security number, sex, and date of birth.  
 The CMS data are provided to the ARIC Study as part of the Interagency Agreement 
between the National Heart Lung and Blood Institute and the Centers for Medicare and Medicaid 
Services. The CMS data are curated and managed on an ongoing basis by the ARIC Study 
Coordinating Center. 
4.1.1.1 Centers for Medicare and Medicaid Services Medicare Fee-for-Service Claims Data 
 The study will use claims from the Medicare FFS program, which provides hospital 
insurance (Part A) and supplemental insurance that covers physician and outpatient services (Part 
B) to persons ages 65 years and older in the United States.  
4.1.1.2 Organization of Center for Medicare and Medicaid Services Data  
 The CMS data are organized into various files containing pertinent health care 
information including: the Master Beneficiary Summary File, Outpatient claim file, Carrier claim 
file, and the Medicare Provider Analysis and Review (MedPAR) file. Each of these CMS files is 
linked by a unique beneficiary identification number. A brief description of the contents of these 
files follows. The information is summarized in Table 4, which follows this section. 
4.1.1.3 The Master Beneficiary Summary File  
 The Master Beneficiary Summary File includes beneficiary demographic traits including 
age, race, gender, and date of birth. The file includes information about beneficiary enrollment 
in: Medicare Parts A and B, MA, or Medicaid. This file contains information about beneficiary 
residence including: zip code, state and county codes. Files are provided monthly and are 
“frozen” in March of each subsequent calendar year. 
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4.1.1.4 Outpatient and Carrier Claim Files 
 The Outpatient claim file contains claims from institutional outpatient providers 
including: the outpatient department of hospitals, rural health clinics, outpatient rehabilitation 
centers, and other federally qualified health care centers. Emergency room visits that do not 
result in hospitalization are found in the Outpatient file. 
 The Carrier claim file (Part B) contains claims from non-institutional providers including: 
ambulatory surgery centers, clinical laboratories, nurse practitioners, physicians, and physician 
assistants.  
4.1.1.5 MedPar File  
 The MedPar File contains records for inpatient hospital stays and skilled nursing facility 
visits. Emergency room visits that result in hospitalization are identified in the MedPar File. 
4.1.2 Event Ascertainment in Claims 
4.1.2.1 PAD Event Ascertainment in Center for Medicare and Medicare Services Fee-for-
Service Population  
 The following sections will present the specifics on the identification of encounters in the 
proposed study, including the definition of clinical encounters and the definition of PAD. Table 4 
lists the codes used to identify PAD encounters by the various setting where these encounters 
occur. 
4.1.2.2 Identification of Clinical Encounters in our Fee-for-Service Medicare Population   
 Medicare enrollment information will be obtained from the Medicare Beneficiary 
Summary file. The MedPAR file will be used to identify hospitalized encounters and Emergency 
Department visits which resulted in a hospitalization. Time in a skilled nursing facility and home 
visits will be excluded from analyses because these encounters do not classify within traditional 
definitions of hospitalizations or of outpatient clinical care. Ambulatory care encounters and 
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Emergency Department visits that did not result in a hospitalization will be identified using the 
Carrier and Outpatient files.  
4.1.2.3 Identification of Codes Used to Define PAD within Fee-for-Service Medicare 
Population 
 Peripheral artery disease will be identified from a thorough review of available literature. 
An exhaustive list of the codes proposed for this study and the definition of each code is included 
in Appendix 1. 
 Peripheral artery disease subtypes including intermittent claudication and critical limb 
ischemia will also be defined. Intermittent claudication will be defined by ICD-9-CM code 
440.21 (Atherosclerosis of native arteries of the extremities with intermittent claudication) as per 
prior literature on this topic [1]. Critical limb ischemia will include the following ICD-9-CM 
codes per prior literature [1]:  440.22 (Atherosclerosis of native arteries of the extremities with 
rest pain), 440.23 (Atherosclerosis of native arteries of the extremities with ulceration), 440.24 
Atherosclerosis of native arteries of the extremities with gangrene), 707.1* (ulcer of lower limb), 
and 785.4 (gangrene). Included will be codes relevant to open vascular surgical management and 
endovascular management, including bypass grafting and limb amputation procedures. For 
hospitalized encounters, only codes that appear in the primary or secondary position will be 
counted as a PAD event in accordance with prior literature on the topic [162]. Codes that appear 
in any position will be counted as a PAD event in the outpatient setting.  
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Table 4. Classification of clinical encounters from CMS Medicare claims 
Encounter Type Code Source Code Type Code 
Ambulatory Care Visits    
New office visit Carrier HCPCS* 99201-99205 
Established office visit Carrier HCPCS 99211-9215 
Consultation Carrier HCPCS 99241-99245 
New preventive medicine visit Carrier HCPCS 99385-99387 
Established preventive 
medicine visit 
Carrier HCPCS 99395-99397 
FQHC* Outpatient Revenue 
Center 
Code 
See appendix 
Inpatient Visits MedPAR ICD-9-CM See Appendix  
Emergency Department 
Visits 
   
ED visit, admitted to hospital  MedPAR Emergency Room Charge Amount 
field where the amount is > $0 
ED visit, not admitted to 
hospital 
   
ED charge Outpatient Revenue 
Center 
Code 
0450-0459 
ED, professional fee  Outpatient Revenue 
Center 
Code 
0981 
*HCPCS: Healthcare Common Procedure Coding System 
*FQHC: Federally Qualified Healthcare Center 
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4.2 Research Approach for Assessment of Prevalence and Incidence of PAD (Specific Aim 
1) 
4.2.1 Analytic Sample 
 The analytic sample for Specific Aim 1 will exclude 1) participants enrolled in MA 
programs (N=4837), race other than black or white (N=45), and participants that were <65 years 
of age at time of fee-for-service enrollment (N=429). After applying these exclusion criteria, the 
final analytic sample included 10,481 ARIC participants. 
4.2.2 Demographic and Comorbidity Assessment 
 Information on demographics of age, race and gender were obtained from annual 
Medicare beneficiary summary files. A version of the Charlson Comorbidity Index, modified to 
include outpatient codes, was used to identify comorbidity burden in our population. All claims 
(inpatient and outpatient) present in each calendar year were used to calculate an annual 
comorbidity score (Chapter 5, Table 1).  
4.2.3 PAD Event Ascertainment 
 PAD was identified from the MedPAR records and the Carrier and Outpatient claims 
files using ICD-9-CM, CPT-4, HCPCS, and FQHC codes to ascertain PAD-related outpatient 
office visits, outpatient diagnostic tests, inpatient visits, and procedures.  PAD codes were 
chosen from a review of available literature (See Chapter 5, Supplemental Table 2) [169]. 
4.2.4 Prevalence of PAD 
 Annual PAD prevalence was estimated for 2003-2012 using information on PAD 
encounters in the inpatient and outpatient setting. The denominator for annual prevalence 
estimates included cohort participants with continuous enrollment in FFS for the entire year of 
observation or until death. Prevalent inpatient PAD was defined as a record of > 1 hospitalization 
with at least one of the selected PAD codes in any position during each calendar year of 
50 
observation. Prevalent outpatient PAD was defined as > 1 claim with at least one of the selected 
PAD diagnostic or procedure codes identified in claims for outpatient services during each 
calendar year of observation. A sensitivity analysis was conducted using > 2 outpatient claims to 
identify PAD (Chapter 5, Supplemental Table 3). 
 The table below describes the operational definitions to be used for prevalence 
calculations. Included are details relevant to event identification (numerator) and to the 
population being studied (denominator). Prevalence proportions will be calculated.  
Table 5. Operational definitions for numerators and denominators used in prevalence 
calculations 
 Numerator  
 Inpatient Outpatient Denominator 
Prevalence Occurrence of 
PAD-related 
hospitalization; If 
one outpatient 
event precedes an 
inpatient event, 
the event date 
will be the 
inpatient 
discharge date 
One occurrence of the 
selected PAD-specific 
ICD-9-CM, CPT-4, 
HCPCS, and FQHC 
codes 
 
 
Medicare beneficiaries with 
continuous fee-for-service Part A 
and Part B coverage during year 
of observation (2003-2012). 
File source MedPAR File Carrier and Outpatient 
Files 
Master Beneficiary Summary File 
 
4.2.5 Incidence of PAD 
 A two-year look back period was chosen to minimize misclassification of prevalent 
events as incident events [170]; ARIC participants with a PAD-related inpatient or outpatient 
code occurring any time within the previous two years of initial FFS enrollment were excluded 
from annual analyses moving forward. Annual incidence rates (IR) are presented for the years 
2005-2012. The denominator for annual incidence estimates included cohort participants’ time in 
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continuous enrollment during the year of observation or until death if it occurred during the year 
of observation. 
 The table below describes the operational definitions to be used for incidence 
calculations. Included are details relevant to event identification (numerator) and to the 
population being studied (denominator). Person-time will be used to calculate incidence rates. 
Table 6. Operational definitions for numerators and denominators used for incidence analyses 
 Inpatient Outpatient Denominator 
Incidence Initial occurrence of 
PAD-related 
hospitalization with 
no PAD 
hospitalization in the 
preceding 365 days; 
If one outpatient 
event precedes an 
inpatient event, the 
initial event date will 
be the inpatient 
discharge date 
Two consecutive 
occurrences of the 
selected PAD-
specific codes 
occurring within 365 
days of each other 
and at least one day 
apart  
Person-time for beneficiaries 
described for incidence 
proportions 
Source MedPAR File Carrier and 
Outpatient Files 
Master Beneficiary Summary 
File 
4.2.6 Statistical Analysis 
 The ARIC cohort is generally not reflective of the demographic distribution of the United 
States and, as such, several methods of estimate adjustment were considered. Methods 
considered but not pursued included adjusting to the mean age of PAD event and adjusting to the 
internal demographic distribution during a particular year. The method used was direct 
standardization to the age, sex, and race distribution of the 2005 Medicare population.  
 Age-standardized annual period prevalence (2003-2012) of PAD with 95% confidence 
intervals was estimated using direct standardization to the demographic distribution of the 2005 
Medicare population ages > 65. The following age categories were used to standardize the 
prevalence estimates: 65-69, 70-74, 75-79, and > 80 years of age.  Age-standardized incidence 
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(2005-2012) of PAD with 95% confidence intervals was estimated using direct standardization to 
the demographic distribution of the 2005 Medicare population ages > 67. The following age 
categories were used to standardize the prevalence estimates: 67-69, 70-74, 75-79, and > 80 
years of age.  All estimates were attained as overall, by health care setting (inpatient versus 
outpatient setting) and by age, race, gender, and race/gender subgroups. All analyses are 
performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC).  
4.2.7 Strengths and Limitations 
 The proposed study has important strengths that will lead to a contribution in the 
comprehensive understanding of PAD burden. PAD remains an understudied problem of public 
health significance for which there is poor health care practitioner and public awareness 
compared to other cardiovascular diseases [11, 171]. Estimates obtained in this study could 
indicate that PAD is a relatively common disease in the Medicare Fee-for-Service population 
and, as such, could help to increase PAD awareness among practitioners who treat elderly 
populations. Further, by using an administrative data source, this study will provide estimates of 
PAD in the outpatient setting where information in the extant literature concerning prevalence 
and incidence is scarce. Finally, stratifying PAD estimates by race and gender could identify 
high burden groups that could be useful in establishing secondary prevention goals. 
 The study has also several limitations, the strongest of which is its reduced 
generalizability due to exclusion of Medicare beneficiaries enrolled in MA programs. MA 
organizations are not required to provide encounter- or person-level data to CMS Medicare. 
Information concerning health care encounters for MA participants is, therefore, not available 
from Medicare claims. An additional limitation related to the ARIC study is a varying and 
changing level of MA enrollment across the ARIC geographic regions over time; MA enrollment 
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varies from less than 10% in Washington County to greater than 40% in Forsyth.  As our 
analyses were limited to Medicare beneficiaries not enrolled in MA plans, we acknowledge that 
we will have missed events among MA enrollees. Studies have reported that individuals with 
MA are typically a healthier population than an exclusive FFS population [166]; Thus, we are 
limited to making inferences only to individuals exclusively enrolled in Medicare FFS. 
 Other study limitations are specific to the use of administrative claims data. Illness 
severity is not possible to obtain from claims data. It would be helpful, for example, to examine 
prevalence and incidence by severity of claudication, a level of detail that is unobtainable in 
claims. Also related to claims limitations, coding inconsistencies are well documented. It is 
possible that PAD-related diagnosis codes were added to inpatient claims to generate more 
financial profit, a level of upcoding that could lead to falsely elevated estimates.   
4.3 Research Approach for Assessment of Post-Diagnosis Encounters and Case Fatality 
Following a PAD Diagnosis (Specific Aim 2) 
4.3.1 Analytic Sample  
 The analytic sample for Specific Aim 2 will exclude 1) participants enrolled in MA 
programs (N=3677), race other than black or white (N=45), and participants that were <65 years 
of age at time of fee-for-service enrollment (N=418). After applying these exclusion criteria, the 
final analytic sample included 11,652 ARIC participants. 
4.3.2 Cohort Construction 
 CMS Medicare data linked with the ARIC cohort from 2000-2012 was used for this 
study.  A synthetic cohort of Medicare FFS beneficiaries with an initial inpatient or outpatient 
PAD event was constructed to investigate the frequency of inpatient and outpatient encounters 
following a PAD diagnosis.  A two-year look back period was chosen to minimize 
misclassification of incident events and the potential for at least two years of follow-up were 
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required. Therefore, our enrollment included participants with a PAD diagnosis from 2002 to 
2010, with follow-up extending through an administrative censoring date of December 31
st
, 
2012. 
 Inpatient PAD incidence was defined as a hospitalization for PAD at any time during the 
study period. Outpatient PAD was defined as at least two claims for outpatient visits (at least 1 
day apart) with a PAD code listed on the claim within 12 consecutive months (outpatient PAD 
diagnosis). If a singular outpatient event preceded an inpatient event within 365 days, the 
incident event date was the inpatient date of service. Singular outpatient events occurring with no 
hospitalizations or outpatient events within 365 days were not considered incident PAD events. 
4.3.3 Demographic and Comorbidity Assessment 
 Relevant demographic information (race, gender, education level, and family income) 
were self-reported at baseline. Age was calculated at the time of the incident PAD diagnosis. 
Four clinic visits and annual telephone follow-up surveys were used to assess comorbidities of 
income, education, diabetes, smoking history, hyperlipidemia, hypertension, obesity, coronary 
heart disease, stroke, heart failure, end stage renal disease, self-rated health, and adequate access 
to care. 
 Income was defined as the highest level of family income prior to a PAD diagnosis. The 
highest level of education completed prior to PAD diagnosis was used to define the education 
variable. Diabetes mellitus was defined as self-reported history of diabetes at any of the four 
clinic visits, usage of diabetes medication during the two weeks prior to a visit, a fasting blood 
glucose level of > 126 mg/dl, or a non-fasting blood glucose > 200 mg/dl. Hypertension was 
defined as systolic blood pressure > 140 mm Hg or diastolic blood pressure > 90 mm Hg at any 
of the four clinic visits or by antihypertensive medication usage during the two weeks prior to 
any of the clinic visits. Hyperlipidemia was defined as a total cholesterol > 240 mg/dl at any of 
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the four clinic visits. Smoking status was self-reported at each clinic visit and is defined as any 
history or no history for the purposes of this study. Trained technicians measured height and 
weight at each clinic visit. Body mass index was calculated as weight in kilograms divided by 
height squared (in meters). Obesity was defined as BMI > 30.0 kg/m
2
. History of coronary heart 
disease (CHD), stroke, and heart failure prior to incident PAD diagnosis was based on self-report 
at baseline and adjudication of hospitalized events occurring in follow up through the PAD 
diagnosis date. End-stage renal disease was defined as estimated glomerular filtration rate 
(eGFR) <15.0 mL/min/m
2 
using creatinine measurements from the four clinic visits and 
employment of the CKD-EPI equation. Self-rated health was defined as poor, fair, good, or 
excellent. Adequate access to care was defined as any outpatient encounter within one year of the 
incident PAD diagnosis date. 
4.3.4 Event Ascertainment 
 PAD-related outpatient office visits, outpatient diagnostic tests, and inpatient visits and 
procedures were identified from the MedPAR records and the Carrier and Outpatient claims files 
using ICD-9-CM, CPT-4, HCPCS, and FQHC codes. The particular codes chosen were based on 
recommendations from the current literature (See Supplemental Table, Citations). Non PAD-
related outpatient encounters were determined by provider specialty codes including primary 
health care visits, cardiology visits, and podiatry visits (Chapter 6, Supplemental Table).  
4.3.5 Statistical Analysis 
 Specific Aim 2 is designed to estimate the frequency of care and outcomes associated 
with an incident PAD diagnosis in the outpatient or inpatient settings. Analytically the aim will 
be subdivided into: 1) the calculation of age-standardized rates of encounters using direct 
standardization methods and 2) time-to-event using product-limit estimation methods, the 
subdistribution cumulative incidence function, and propensity score modeling.  
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 In the proposed research, Poisson regression models were to be used to calculated age-
adjusted rates of encounters. After careful consideration, an alternative method was suggested. 
Direct standardization was used to estimate age-standardized rates of inpatient and outpatient 
encounters with 95% confidence intervals (CI) following a PAD diagnosis. Rates were 
calculated for PAD and non PAD-related encounters. The denominator for rate estimates 
included cohort participants’ time in continuous FFS enrollment following a PAD diagnosis. 
Estimates were age-standardized to reflect the age, race, and sex distribution of the 2005 
Medicare population ages 67 years and older. Age categories for standardization included 67-69, 
70-74, 75-79 and > 80 years of age. Estimates were calculated by diagnosis location (inpatient, 
outpatient) and within diagnosis location in strata of race and gender.   
 Time to PAD-related encounters (first hospitalization, first re-hospitalization, and first 
outpatient visit) were calculated based on diagnosis location (outpatient vs. inpatient) from the 
date of the initial PAD encounter using product limit estimation methods. Product limit methods 
were chosen over life-table methods because the event times are measured with precision in 
CMS claims [172]. Encounters were censored at the end of follow-up, as determined by death, 
enrollment in MA or at December 31
st
, 2012 (end of our observation period). Analyses 
accounted for competing risk of death, as opposed to censoring for death. Patient death and death 
dates were obtained from the Master Beneficiary File.   
 There are several assumptions related to product limit estimation methods, also called 
Kaplan-Meier estimation methods [172]. Product limit methods assume the population is closed 
and that there are no competing risks. This cohort will not be closed and there will be competing 
risks. As such, I will use a competing risks modeling strategy.  
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 In this study, we have a competing risk of death. It is common in the outcomes literature 
to treat death as a censored event. An assumption of censoring is that it is non-informative, 
which means that subsequent hazard of death and the outcome of interest are independent 
conditional on covariates [172]. In studies where <5% censoring is expected, these competing 
risks might be negligible resulting in negligible bias. However, in our study we expect 
substantial mortality (>25%) among the study population and hypothesize that the censoring is 
informative. Therefore, death should not be treated as a censored event to avoid inducing 
selection bias in our study. This selection bias can result in underestimation of the outcome being 
measured.   
 Analyses, therefore, accounted for death as a competing risk using the cumulative 
incidence function, a method that computes the hazard of failure associated directly with the 
event of interest (i.e. hospitalization) along with the hazard of failure associated with the 
competing risk (i.e. death)[173, 174]. Formula 14 demonstrates the principle used to calculate 
the cumulative incidence function. Median survival times were estimated in race and gender 
strata. 
Formula 14: Cumulative Incidence(t) = ∑
𝑒𝑗
𝑛𝑗−1
𝐾𝑀12(𝑡𝑗)
𝑠
𝑗=1
 
where 𝑒𝑗 = the number of patients who fail from the event of interest at time 𝑡𝑗 
where 𝑛𝑗 = the number of patients known to be at risk of failure beyond time 𝑡𝑗 
where 𝐾𝑀12 = the Kaplan-Meier estimate of survival 
 
 Propensity score models were used to estimate case fatality by diagnosis setting. The 
following directed acyclic graph (DAG), shown below in Figure 7, shows the conceptual 
framework used to determine confounders of the relationship between setting of diagnosis and 
case fatality. The following DAG is designed to depict the possible measured and unmeasured 
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confounding in our study. DAGs are informed by subject matter knowledge and literature review 
[175]. The minimally sufficient adjustment set for this analysis includes all covariates listed 
above (4.3.3). 
 
Figure 7. Directed acyclic graph showing the relationship between race and time-to-PAD event 
4.3.6 Strengths and Limitations 
 This study is the first, to our knowledge, that provides information on the post-diagnosis 
care following a PAD diagnosis in the outpatient setting. This study could find that participants 
with PAD are frequent utilizers of health care services and, as such, could contribute to PAD 
awareness. Differences in post-diagnosis care observed by race and gender groups will confer 
important information to be used in understanding prevention needs. Finally, this study is a 
methodologically replicable study that uses age-standardization techniques and the most recent 
recommendations to define chronic disease events.  
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 Limitations were similar to those anticipated for Specific Aim 1. Our exclusion of MA 
participants means that our findings are not generalizable to individuals with this type of care. 
Our cohort includes participants who survived until at least 2000 and, thus, could be biased 
toward healthier individuals with longer survival. As mentioned before, claims are suggest to the 
biases that arise from using data that reflects billing practices.  
4.4 Calibration and Sensitivity Analyses 
 Administrative claims data reflect billing practices; therefore, diagnostic coding found in 
claims data is not always accurate in relation to documented diagnoses or procedures. To assess 
the performance of using claims to quantify inpatient and outpatient PAD, we used 
hospitalization data and annual follow-up questionnaires.  
 A hospital record abstraction form was developed to evaluate incident hospitalized PAD 
events obtained from discharge data available for ARIC cohort participants.  We chose one year 
(calendar year 2007) for our hospitalization sample due to time and resource concerns.  PAD 
codes in any position on the discharge summary were evaluated. Two reviewers performed 
medical record abstraction and review, with classification and adjudication for disagreement 
when needed, according to a previously established protocol.  Events were classified as definite, 
probable, or unlikely PAD.   
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Table 7. ICD-9-CM hospitalizations and adjudication to identify hospitalized PAD 
 Validated PAD (Adjudication)  
Test Result  Yes No Row sum 
ARIC PAD hospitalization a b  r1  
Non-PAD hospitalization c d r2 
Column sum c1 c2 N 
 
 Comparability ratios (CR) were calculated as an estimate of validity that reflects the 
overall effect of misclassification from using different data sources to calibrate our inpatient 
PAD estimates [176].  Comparability ratios (r1 / c1) and 95% confidence intervals were 
calculated based on the 2x2 table shown below (Table XX).  A range of comparability ratios 
were calculated given a range of sensitivity estimates found in the literature [157, 158, 161]. This 
range of comparability ratios is presented as the range of misclassification associated with using 
ICD-9-CM codes to estimate PAD prevalence and incidence. 
 Calibration factors associated with outpatient PAD occurrence were calculated by 
estimating concordance between information on self-reported PAD events available from the 
ARIC AFU and outpatient PAD identified from the CMS claims.  Information concerning 
outpatient encounters is available in the ARIC cohort study from annual telephone surveys, 
during which study participants are asked the following targeted question:  “Since we last 
contacted you has a doctor said that you have peripheral vascular disease or intermittent 
claudication?” Concordance was assessed by comparing the presence of a PAD outpatient claim 
with a positive answer to this AFU question from 2007-2010.  
  
61 
Table 8. Agreement between CMS outpatient claims and ARIC cohort outpatient events 
 CMS Claims 
ARIC Questionnaire Yes No Row sum 
Yes a b r1 
No c d r2 
Column sum c1 c2 N 
Prevalence and 𝐵𝑖𝑎𝑠 𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐾𝑎𝑝𝑝𝑎 (PABAK) =
√𝑎𝑑 − √𝑏𝑐
√𝑎𝑑 + √𝑏𝑐
 
 
 Concordance was estimated using prevalence and bias adjusted kappa statistics with 95% 
confidence intervals to calibrate our outpatient estimates [177].  The 2x2 table shown below 
(Table XX) was used to calculate PABAK, presented with the unadjusted estimates. A kappa of 
>0.80 was considered excellent agreement [178].  
4.5 Study Power 
 Using the 2000 census data, approximately 103,000 individuals who were 65 years of age 
and older are estimated to have been living in the four catchment areas of ARIC in the year 2000. 
Based on estimates of the MA program penetrance in the ARIC regions, 60% of the 103,000 
people (n=62,000) will be fee-for-service Medicare beneficiaries and eligible for inclusion in our 
study. Further examination of the 2000 census data showed that in that year among those 65 
years of age and older in the study population, 51% were 65-74 years of age, 36% were 75-84 
years of age, and 14% were > 85 years of age. Additionally, 57% were female and 16% were 
black.  
4.5.1 Specific Aim 1  
 Specific Aim 1 is a descriptive analysis and, as such, the focus of this aim should be in 
attaining precise estimates of prevalence and incidence. Based on prior literature, we 
conservatively estimate 10% (n=6200) of individuals in this Medicare FFS population will have 
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prevalent PAD each year. Expected annual prevalent events by race-gender strata are shown 
below in Table 9.  
Table 9. Expected annual prevalent PAD by race-gender groups 
 Race-Gender Groups 
 Black Male 
(7%) 
Black Female  
(9%) 
White Male  
(36%) 
White Female 
(48%) 
Individuals with PAD 434 558 2,232 2,976 
Individuals with no 
PAD 
3,906 5,022 20,088 26,784 
Total population 4,340 5,580 22,320 29,760 
Prevalence with 95% 
CI 
10.0 
(9.2, 10.9) 
10.0 
(9.3, 10.8) 
10.0 
(9.6, 10.4) 
10.0 
(9.7, 10.3) 
Individuals with new* 
PAD 
23 29 116 155 
 
 Based on prior work in which I used ARIC cohort data and ICD-9-CM codes to estimate 
incident hospitalized PAD events from 1987-2010, I conservatively estimate the incidence of 
hospitalized PAD is 2.6 per 1000 persons per year. Extrapolating this estimate to the study 
population of 62,000 beneficiaries, 161.2 annual hospitalized PAD events are expected in the 
four ARIC communities. A conservative estimate is that the incidence of non-hospitalized PAD 
will be the same as the incidence of hospitalized PAD (2.6 per 1000; 161 annual outpatient 
events). Therefore, an annual incidence of 322 clinically diagnosed PAD events is expected. 
Over the six years of enrollment in the study, 1932 events are expected. This information is 
reflected below in Table 10. 
  
63 
 Table 10. Study population estimates for four ARIC communities 
 Table 11 shows the number of PAD events expected among race-gender strata if the PAD 
event distribution is directly correlated to demographic trait distribution.  
Table 11. Expected annual incident PAD by race-gender groups 
 Race-Gender Groups 
 Black Male 
(7%) 
Black Female 
(9%) 
White Male 
(36%) 
White Female 
(48%) 
Individuals with 
new* PAD 
23 29 116 155 
Individuals with no 
new PAD 
4,805 6,178 24,711 32,948 
Total population 4,830 6,210 24,840 33,120 
Incidence with 95% 
CI 
0.5 (0.3, 0.7) 0.5 (0.3, 0.7) 0.5 (0.4, 0.6) 0.5 (0.4, 0.6) 
* New implies incident PAD 
4.5.2 Specific Aim 2 
 I expect 1,932 initial encounters over the duration of enrollment. Table 12 reflects the 
number of expected initial encounters in each of the gender/race strata over the entire enrollment 
period (2004-2009).  
Table 12. Expected PAD events by race-gender strata 
Black (n=309) White (n=1,623) 
Male  Female Male Female 
133 176 698 925 
 
Population 
of the 
ARIC 
Study 
catchment 
areas 
Residents 
>65 years 
of age 
Fee-for-
service 
Medicare 
beneficiaries* 
Incident 
inpatient 
events   
(annual) 
** 
Incident 
outpatient 
events 
(annual) 
Total PAD 
events 
(annual)** 
Total 
PAD 
events 
in 
years 
2004-
2009 
450,000 103,000 62,000 161 161 322 1,932 
* Estimate assumes an overall 40% participation in Medicare Advantage plans across all four 
ARIC geographic regions 
** Estimate assumes an equal annual incidence of PAD in the outpatient and inpatient setting 
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 I expect our data will also not be normally distributed. As such, it is appropriate to 
perform non-parametric tests and to calculate medians with interquartile range (IQR) in place of 
means and 95% confidence intervals. Table 13, below, shows expected medians and IQRs for a 
sample of the outcomes under study. The number of events at one year is chosen to provide an 
appropriate timeframe to measure events. 
Table 13. Expected median and IQR values for race-gender strata following inpatient encounter 
 Black 
Females 
Black Males White 
Females 
White Males 
 Median 
(IQR) 
Median Median Median 
Number 
hospitalizations 
Within one year 
 
2 (1, 2) 
 
2 (1, 2) 
 
1 (0-1) 
 
1 (0, 1) 
Number 
outpatient visits 
Within one year 
 
3 (1, 4) 
 
3 (1, 4) 
 
2 (1-3) 
 
2 (1, 3) 
Time to first 
event (days) 
Re-hospitalization 
 
 
150 (30, 750) 
 
 
160 (25, 800) 
 
 
180 (20, 825) 
 
 
175 (25, 800) 
 
 I hypothesize that the time-to-event analyses will reveal differences by diagnosis location 
and among gender, race, and race/gender substrata. Power is reported for individuals expected to 
have the worst outcomes (black females) compared to a referent group projected to have the best 
outcomes (white males). Using the SAS procedure Proc Power, a cumulative event rate of 50% 
with differential dropout (20% for white men vs. 40% for black women) over three years, I 
estimate 80% power with a 2-sided test and alpha=0.05 to detect a hazard ratio of hospitalization 
of 1.35 when comparing black females to white males. The following figure describes the 
relationship between power (y-axis) and hazard ratio (x-axis) of hospitalization.  
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Figure 8. Estimates of hazard ratios of hospitalization by power 
 Using the same inputs with a cumulative event rate of 25%, I estimate 80% power to 
detect a hazard ratio of surgical intervention of 1.50 for black females compared to white males. 
The following figure describes the relationship between power (y-axis) and hazard ratio (x-axis) 
of surgical intervention. 
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Figure 9. Estimates of hazard ratios of procedure by power 
 Overall, I expect to have adequate power to complete the proposed aims. Estimates of 
incidence are expected to be conservative compared to what will actually be seen in the data. 
Thus, these power curves represent worst case scenarios for detecting hazard ratios. As the 
expected sample size increases, the power to detect differences in outcomes is expected to 
increase. 
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CHAPTER 5. MANUSCRIPT #1: PERIPHERAL ARTERY DISEASE PREVALENCE AND 
INCIDENCE ESTIMATED FROM BOTH OUTPATIENT AND INPATIENT SETTINGS 
AMONG MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN THE ATHEROSCLEROSIS 
RISK IN COMMUNITIES (ARIC) STUDY 
5.1 Introduction 
Peripheral artery disease (PAD) is a progressive atherosclerotic disorder that can lead to 
poor quality of life [13], an increased risk of hospitalization and limb amputation [14], high 
mortality [16] and high costs of care [12]. Early PAD detection in the outpatient setting 
combined with ambulatory follow-up care could help slow the disease progression and reduce 
PAD-related hospitalizations and sequelae [15]. However, the extent to which PAD is managed 
in the outpatient setting is not well documented. 
Reported estimates of clinical PAD prevalence and incidence tend to focus on only 
hospitalized cases [11, 59, 64, 72, 81, 105, 146]. Estimates of disease occurrence both in the 
inpatient and outpatient setting could provide a broader, more comprehensive understanding of 
PAD and could lead to improved resource allocation to prevent PAD-related complications. 
Administrative claims data capture comprehensive services across the spectrum of health care 
settings, and provide an opportunity for a more inclusive assessment of PAD burden.    
We estimated the age-standardized annual period prevalence and incidence of PAD in the 
inpatient and outpatient setting over a ten-year period (2003-2012), using data from the biracial 
Atherosclerosis Risk in Communities (ARIC) study cohort [8] linked with the Centers for 
Medicare and Medicaid Services (CMS) claims information for Medicare fee-for-service (FFS) 
beneficiaries ages 65 years and older. To further inform prevention efforts, we examined 
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differences in estimates of annual PAD period prevalence and incidence across strata of age, 
gender, and race. 
5.2 Methods 
5.2.1 Study Population 
5.2.1.1 The Atherosclerosis Risk in Communities (ARIC) Cohort Study 
 The biracial ARIC cohort, established to examine the etiology of atherosclerosis and its 
clinical manifestations, includes 15,792 participants (45-64 years of age at baseline) enrolled 
between 1987 and 1989. The ARIC cohort was selected by probability sampling from four US 
communities: Washington County, Maryland (MD), Forsyth County, North Carolina (NC), the 
city of Jackson, Mississippi (MS), and the suburb cities of Minneapolis, Minnesota (MN) [8]. 
ARIC participants enrolled continuously for at least one year in Medicare Parts A and B through 
a fee-for-service plan from 2003-2012 were eligible for inclusion. Data were collected on cohort 
participants at five clinic examinations and through annual follow-up telephone interviews.  
5.2.1.2 Linkage of ARIC Cohort Data with CMS Claims 
 An interagency agreement between the National Institute for Heart Lung and Blood 
Disorders (NHLBI) and CMS has enabled Medicare claims information to be obtained for the 
14,899 ARIC cohort participants who were Medicare eligible between the years 1991 and 2012. 
Data for ARIC cohort participants were linked with CMS claims data, matching on participants’ 
social security numbers, gender and date of birth. Of the 14,899 Medicare eligible participants, 
14,702 ARIC cohort IDs (98.7%) were matched successfully.  
 Participant information on enrollment in Medicare FFS was obtained from monthly 
enrollment indicators for Part A, Part B, and MA buy-in available through annual CMS Medicare 
Beneficiary Summary files. Continuous enrollment periods were created to indicate 
uninterrupted CMS Medicare FFS coverage, defined as enrollment in CMS Medicare Part A and 
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Part B and lack of enrollment in a MA plan. Participants contributed data to calendar years in 
which they had uninterrupted FFS coverage. Participants were excluded if they had continuous 
MA enrollment or gaps in FFS coverage due to: 1) missing enrollment information, 2) 
discontinuation of enrollment, or 3) enrollment in a MA plan at any month in the observation 
year. Participants <65 years of age and those of race other than black or white were also 
excluded (see Supplemental Table 1). For those with multiple enrollments periods, the longest 
enrollment period was selected to give the best opportunity to capture relevant claims. The 
enrollment period selected was the first enrollment period in 10,144 participants (97%). The final 
analytic sample included 10,481 ARIC participants with 67,492 person-years of fee-for-service 
enrollment time. 
5.2.1.3 Demographics and Comorbidities  
 Demographic information on age (at beginning of enrollment year), race and gender was 
obtained from annual Medicare beneficiary summary files. Age was categorized as: 65-74 years 
of age and > 75 years of age. The Klabunde adaptation of the Charlson Comorbidity Index (CCI) 
was used to identify comorbidity burden using claims from the inpatient and outpatient settings 
[179, 180].  All claims present in each calendar year (prior to a PAD case) were used to calculate 
an annual CCI score.  
5.2.1.4 Ascertainment of PAD  
 PAD-related outpatient office visits, outpatient diagnostic tests, inpatient visits, and 
procedures were identified from the Medicare Provider Analysis and Review (MedPAR) records 
and the Carrier and Outpatient claims files using International Classification of Diseases, Ninth 
Revision (ICD-9-CM), Current Procedural Terminology, 4
th
 edition (CPT-4), Healthcare 
Common Procedure Coding System (HCPCS), and Federally Qualified Healthcare Center 
(FQHC) codes (See Supplemental Table 2) [169].   
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5.2.1.5 Prevalence of PAD  
 Annual PAD period prevalence was estimated for 2003-2012 using information on any 
PAD encounters in the inpatient and outpatient setting, including both prevalence cases from 
prior years and new incident cases during the year of observation. Overall mean annual 
prevalence, weighted to reflect the distribution of cases each year, also was estimated. The 
denominator for annual period prevalence estimates included cohort participants alive at the 
beginning of the year with continuous enrollment in FFS for the entire year of observation or 
until death. For each year of observation, prevalent inpatient PAD was defined as > 1 
hospitalization with a PAD code in any of the twenty-five diagnosis or procedure positions; 
prevalent outpatient PAD was defined as > 1 claim with PAD diagnosis or procedure codes in 
any of the twelve diagnosis positions or six procedure positions. A sensitivity analysis using > 2 
outpatient claims was conducted to address the possibility of rule-out diagnoses (Supplemental 
Table 3). 
5.2.1.6 Incidence of PAD  
 A two-year look back period was chosen to minimize misclassification of prevalent 
events as incident events [170]; therefore, the shortest enrollment window of ARIC participants 
was >24 months. ARIC participants with a prevalent PAD-related inpatient or outpatient code 
occurring any time within two years of the year in question were excluded from annual incidence 
analyses. Annual incidence rates (IR) are presented for the years 2005-2012. Overall mean 
incidence, weighted to reflect the distribution of events each year, was also estimated. The 
denominator for annual incidence estimates included cohort participants’ time at risk in 
continuous enrollment during the year of observation or until death if it occurred during the year 
of observation.  
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 Annual inpatient PAD incidence was defined as > 1 hospitalization with a PAD-related 
ICD diagnosis or procedure code during each year of observation. Annual outpatient PAD 
incidence was defined as > 2 claims within 12 consecutive months with a PAD-related ICD, 
CPT, HCPCS, or FQHC code; the claims had to occur > 1 day apart and the incident date was 
defined as the date of the second claim. If a singular outpatient encounter preceded an inpatient 
encounter within 365 days, the incident date was the inpatient date of discharge. Singular 
outpatient encounters occurring with no hospitalizations or outpatient encounters within 365 
days were not considered incident PAD. Each individual contributed between 1 to 12 months to 
each yearly estimate of incidence. Time contributed to the study for each ARIC participant was 
converted to and reported in person-years.  
5.2.2 Statistical Analysis 
 Direct standardization was used to estimate age-standardized overall and annual 
prevalence of PAD with 95% confidence intervals (CI) from 2003 to 2012. Direct 
standardization was used to estimate age-standardized overall and annual incidence of PAD (per 
1000 person-years) with 95% CI from 2005 to 2012. Prevalence estimates were age-standardized 
to reflect the age, race, and sex distribution of the 2005 Medicare population ages 65 years and 
older.  Age categories for standardization of prevalence estimates included 65-69, 70-74, 75-79, 
and > 80 years of age. Incidence estimates were age-standardized to reflect the age, race, and sex 
distribution of the 2005 Medicare population ages 67 years and older given a two-year look back 
period for excluding prevalence cases. Estimates were calculated overall, by health care setting 
(inpatient versus outpatient setting) and by age, race, gender, and race/gender subgroups. Age 
categories for incidence estimate standardization included 67-69, 70-74, 75-79, and > 80 years of 
age. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). Written 
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informed consent was obtained from participants and all institutional review boards approved the 
study. 
5.3 Results 
 
 The 10,481 ARIC cohort members who met eligibility requirements generally reflected 
the demographic distribution in the original ARIC cohort at baseline. The majority were female 
(58%) and white (76%) with black males (8%) as the least represented group (Table 14). Mean 
comorbidity scores were similar across race, gender, and race/gender strata. Mean comorbidity 
score differed by age categories, such that participants 75 years of age and older had higher mean 
comorbidity scores as compared to participants 65 to 74 years of age (Table 14).  
5.3.1 Age-standardized Annual Prevalence and Weighted Mean Annual Prevalence of PAD  
 Age-standardized annual and weighted mean annual estimates of the prevalence of PAD 
across all study years (2003-2012), overall and stratified by health care setting are provided in 
Table 15. The weighted mean annual PAD period prevalence was 12.4% (95% CI: 12.2%, 
12.8%). Overall age-standardized prevalence varied modestly from year to year, ranging from 
10.3% (95% CI: 8.6%, 12.0%) to 13.5% (95% CI: 12.4%, 14.6%).  
 Higher annual PAD period prevalence was identified in the outpatient setting as 
compared to the inpatient setting (11.8% vs. 1.6%; Table 15). The majority of all unique PAD 
claims (>70%) identified were from outpatient settings. Prevalence of outpatient PAD claims 
ranged across years of observation from 9.5% (95% CI: 7.9%, 11.2%) in 2003 to 12.9% (95% 
CI: 11.9%, 14.0%) in 2012. By comparison, prevalence of inpatient PAD ranged across years of 
observation from 1.4% (95% CI: 1.1%, 1.7%) in 2005 to 1.8% (95% CI: 1.4%, 2.1%) in 2012.  
 Estimates of annual PAD period prevalence were further stratified by demographic 
groups. Age-standardized annual PAD period prevalence and mean annual prevalence was 
consistently higher among those 75 years and older as compared to those 65 to 74 years (Figure 
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10). Weighted mean annual PAD prevalence among those 75 years and older and those 65 to 74 
was 16.8% and 8.4%, respectively. From 2003 to 2012, annual PAD prevalence in the age group 
75 years and older ranged from 12.5% (95% CI: 9.0%, 15.9%) in 2003 to 18.5% (95% CI: 
17.1%, 20.0%) in 2012. Annual PAD prevalence among those ages 65 to 74 years ranged from 
8.0% (95% CI: 7.2%, 8.8%) to 9.0% (95% CI: 8.0%, 10.0%) over the same time frame. 
 Blacks had a higher mean annual prevalence of PAD compared to whites (15.6% vs. 
11.4%), and had a higher annual prevalence of PAD across most years of the observation period 
(Figure 11). From 2003 to 2012, PAD prevalence among blacks ranged from 13.8% (95% CI: 
10.4%, 17.2%) to 17.3% (95% CI: 15.0%, 19.7%) while PAD prevalence among whites ranged 
from 9.0% (95% CI: 7.1%, 10.9%) to 12.8% (95% CI: 11.6%, 14.0%). Regarding race/gender 
stratification, black females had the highest weighted mean annual PAD prevalence (16.9%), 
followed by black males (13.2%), white males (12.1%), and white females (10.9%; 
Supplemental Table 4).  
 Age-standardized prevalence of PAD did not differ significantly by gender alone in any 
year of observation (2003 to 2012). Overall, females had a higher prevalence of PAD although 
not statistically significant across all years of this study (Supplemental Table 5).  
5.3.2 Age-standardized Annual Incidence and Weighted Mean Annual Incidence of PAD  
 Overall and age-standardized annual estimates of the incidence of PAD across all 
observation years (2005-2012), stratified by health care setting are provided in Table 16. The 
mean age-standardized PAD incidence rate (IR) across all observation years (2005-2012) was 
26.8 (95% CI: 25.1, 28.6) per 1000 person-years. The age-standardized incidence of PAD 
remained relatively consistent across the study period (2005 to 2012), ranging from 25.6 (95% 
CI: 21.0, 30.4) per 1000 person-years in 2007 to 30.3 (95% CI: 24.9, 35.7) per 1000 person-years 
in 2012 (Table 16).  
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 The first PAD-related claim most commonly was found in the outpatient setting (83%), at 
more than 5 times the incidence in the inpatient setting (Table 16). Rates of PAD incidence in the 
outpatient setting per 1000 person-years ranged from 20.0 (95% CI: 15.2, 24.8) to 26.0 (95% CI: 
21.0, 30.9). Records of PAD-related hospitalizations were rare; for the years 2005-2012, the 
annual age-standardized incidence rates per 1000 person-years ranged from 3.2 (95% CI: 1.5, 
4.8) in 2011 to 6.4 (95% CI: 3.4, 9.3) in 2005. 
 Annual estimates of PAD incidence were stratified by demographic groups. Age-
standardized annual PAD incidence was different by age strata at all years examined except 2009 
and 2012 (Figure 12). Incidence of PAD was significantly higher among those 75 years and older 
compared to those 65 to 74 years of age. From 2005 to 2012, estimates of annual PAD incidence 
among those 75 years and older ranged from 31.6 (95% CI: 24.1, 39.2) in 2009 to 37.2 (95% CI: 
29.5, 45.0) per 1000 person-years in 2012. Estimates among those 65-74 years of age ranged 
from 16.2 (95% CI: 12.3, 20.1) per 1000 person-years to 21.7 (95% CI: 14.3, 29.1) per 1000 
person-years over the same time period.  
 PAD incidence rates were different by race (Figure 13), with a higher mean annual 
(2005-2012) PAD incidence among blacks (31.3; 95% CI: 27.3, 35.4) compared to whites (25.4; 
95% CI: 23.5, 27.3). Blacks had a higher incidence rate of PAD than whites across most 
observation years, although annual differences were attenuated due to low precision resulting 
from a small sample size among blacks (Figure 13). Incidence rates of PAD among blacks 
ranged from 28.4 (95% CI: 16.4, 40.3) to 32.7 (95% CI: 21.3, 44.1) per 1000 person-years, while 
incidence of PAD among whites ranged from 23.2 (95% CI: 17.1, 29.4) to 29.6 (95% CI: 23.7, 
35.6) per 1000 person-years. 
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 The age-standardized annual incidence of PAD did not differ significantly by gender 
(Supplemental Table 6). Mean annual incidence of PAD (2005-2012) was higher among black 
males and black women (31.8 and 30.9 per 1000 person-years, respectively) than among white 
males and white females (25.5 and 25.3 per 1000 person-years, respectively), although results 
were not statistically significant. Small sample sizes precluded annual assessment of PAD 
incidence across race/gender groups (Supplemental Figure 1).  
5.4 Discussion 
 
 We found that the majority of all clinical PAD encounters occurred in the outpatient 
setting among a biracial, probability-based sample of four US communities including men and 
women 65 years of age and older with enrollment in a Medicare fee-for-service program.  
Studies which focus exclusively on hospitalized events underreport burden and provide a 
perspective of PAD skewed toward more severe manifestations occurring later in the course of 
the disease.  Blacks had a significantly higher prevalence of PAD prevalence than whites, 
including both men and women. Incidence of PAD was also higher among blacks, although the 
relatively small proportion of blacks in our study (24%) limited our ability to make inferences in 
race- and race/gender- stratified analyses of PAD incidence.   
 While sources of administrative claims are increasingly used to study PAD burden, 
methodologic and source population differences make it difficult to compare PAD estimates 
across studies. In particular, it is well-documented that PAD prevalence increases with age [163, 
169]; however, prior claims-based work did not report age-adjusted estimates of PAD 
prevalence, thus limiting comparisons across populations with differing age groups. For 
example, a recent study using the MarketScan database reported higher annual PAD prevalence 
among Medicare beneficiaries than the present study (14-21% vs. 10%-14%) [169]; however, the 
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population in the MarketScan study was older and had greater comorbidity. Conversely, a study 
of a healthier group of managed care enrollees found a lower prevalence of PAD (2%) than what 
was observed here [14]. In context of these other studies, age-standardized estimates of PAD 
prevalence (overall: 12.4%) in the present study are within the expected range given the 
estimates from younger and older populations.  
 Estimates of PAD incidence are rare in the literature and, as with prevalence studies, are 
difficult to compare due to differing study populations and inconsistency in the definition of 
PAD. Important in using administrative claims data for the estimation of disease incidence is the 
use of an appropriate look-back period for the correct identification of index events. Recent 
analyses suggest that for most chronic diseases a two year look-back period is necessary for the 
exclusion of pre-existing conditions [170]. Studies that do not include a sufficiently long look-
back period have the potential to reflect prevalent disease that is misclassified as incident (up to 
30%) [170]. Results of the current study, in which we employed a two-year look back period, 
suggest that 2-3% (26.8 per 1000 person-years) of Medicare beneficiaries had an incident PAD 
occurrence within any particular observation year (2005-2012). While our incidence estimates 
are lower, they are comparable to existing studies [169]. 
 A significant body of evidence suggests differences in PAD burden by race [181]. Blacks 
were observed to have a higher PAD prevalence than whites in the NHANES, San Diego 
Population, Multi-Ethnic Study of Atherosclerosis (MESA), and Cardiovascular Health (CHS) 
studies [64, 69, 72, 147]. In the current study, we found that the mean annual prevalence and 
incidence of PAD was significantly higher among blacks as compared to whites, which confirms 
these prior observations. The current study adds the finding that PAD burden is higher among 
blacks despite a known access to care issue in this population. This study further adds to 
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estimates of PAD burden by providing race-gender analyses. We observed that black females 
consistently had the highest PAD prevalence while white females had the lowest PAD 
prevalence across all years of observation (2003-2012; Supplemental Table 4). Black males had 
the highest mean PAD incidence followed by black females (Supplemental Figure 1). Findings 
from this study suggest that blacks ages 65 years and older have a higher burden of PAD and 
could, therefore, benefit from prevention efforts targeting individuals well before they become 
age-eligible for Medicare.  
 The American Heart Association (AHA) recently identified gender-specific estimates of 
PAD, particularly for women, as a knowledge gap in the literature. The present study answers a 
challenge from the AHA to produce age-standardized, gender-specific estimates [182]. Males in 
this study had nearly identical age-standardized PAD estimates compared to females overall 
(mean annual prevalence: 12.4% vs. 12.5%; mean annual incidence: 26.9 vs. 26.8 per 1000 
person-years) and at most years of observation. Findings from our study, which identified 
minimal differences in PAD burden by gender, are in accordance with the limited literature 
regarding gender-specific estimates of PAD prevalence and incidence and contribute important 
information to a perceived knowledge gap [105, 163].  
5.4.1 Strengths and Limitations 
 The most important strength of this study is the inclusion of outpatient in addition to 
inpatient clinical encounters in the assessment of prevalent and incident PAD. Prior studies have 
provided limited information on the burden of PAD stratified by the setting of health care 
delivery (inpatient versus outpatient). Although a study by Hirsch et al (2008) found that 
inpatient visits represent up to 90% of PAD-related costs [162], more than 70% of all PAD 
claims in the current study were found in the outpatient records. In addition, more than 80% of 
all incident PAD events were found occurring in the outpatient setting. These estimates are age-
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standardized and look back periods for incidence are in accordance with recent 
recommendations, providing a further strength of this study.  
 As this study was based on inpatient and outpatient care among CMS Medicare enrollees 
in FFS programs, our estimates are not generalizable to Medicare beneficiaries enrolled in MA, 
who have been reported to be healthier than those in FFS [166]. Our estimates reflect cohort 
survivors and we did not attempt to quantify PAD prior to enrollment in fee-for-service in 2003. 
Administrative claims data reflect billing practices and, therefore, diagnostic coding found in 
claims data is not always accurate in relation to documented diagnoses or procedures. Codes 
selected were not independently validated, which could lead to misclassification of PAD 
occurrence. Upcoding might increase billing by as much as 15% [183] and illness severity is not 
readily obtainable from claims data.  
5.4.2 Conclusions 
 This study addresses an important gap in the existing literature by providing estimates of 
PAD in the outpatient setting where the majority of PAD burden was found. Individuals whose 
PAD can be managed in the outpatient setting are an important subgroup for potentially targeted 
interventions to prevent PAD-related hospitalizations and complications, such as limb 
amputation. PAD estimates stratified by race corroborated other population-based studies that 
reported a higher burden among blacks compared to whites; future work should focus on 
identifying effective prevention of PAD and its sequelae in this group.    
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Table 14. ARIC* fee-for-service enrollees by year and demographic groups, 2003-2012 
 2003 
N=7,293 
2004 
N=7,678 
2005 
N=7,708 
2006 
N=7,372 
2007 
N=7,060 
2008 
N=6,995 
2009 
N=6,504 
2010 
N=6,183 
2011 
N=5,914 
2012 
N=5,546 
Age, % 
65-74 
> 75 
 
72 
28 
 
69 
31 
 
66 
34 
 
63 
37 
 
60 
40 
 
57 
43 
 
54 
46 
 
49 
51 
 
44 
56 
 
40 
60 
Gender, % 
Female 
Male 
 
57 
43 
 
57 
43 
 
58 
42 
 
57 
43 
 
58 
42 
 
58 
42 
 
59 
41 
 
60 
40 
 
60 
40 
 
61 
39 
Race, % 
Black 
White 
 
26 
74 
 
26 
74 
 
26 
74 
 
23 
77 
 
21 
79 
 
22 
78 
 
23 
77 
 
24 
76 
 
24 
76 
 
24 
76 
Race/gender, 
% 
Black Female 
Black Male 
White Female 
White Male 
 
17 
9 
40 
34 
 
17 
9 
40 
34 
 
18 
9 
40 
33 
 
15 
8 
42 
35 
 
14 
7 
44 
35 
 
14 
7 
44 
34 
 
15 
8 
45 
32 
 
16 
8 
44 
32 
 
16 
8 
44 
32 
 
16 
8 
44 
32 
Overall mean 
comorbidity 
score
†
 
(standard 
deviation) 
1.7 (2.2) 1.8 (2.3) 1.9 (2.2) 1.9 (2.2) 2.1 (2.3) 2.1 (2.3) 2.3 (2.5) 2.4 (2.5) 2.5 (2.5) 2.6 (2.6) 
Overall 
median 
comorbidity 
score
+ 
(IQR) 
1 (0, 3) 1 (0, 3) 1 (0, 3) 1 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 4) 2 (1, 4) 
*
Atherosclerosis Risk in Communities (ARIC) cohort study; 
†
 Klabunde adaptation of Charlson comorbidity index 
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Table 15. Age-standardized* overall and annual prevalence (%) of peripheral artery disease 
claims, overall and by health care setting. The ARIC† study (2003-2012) 
 Prevalence % (95% CI) 
  Overall Outpatient Setting Inpatient Setting 
2003 10.3 (8.6, 12.0) 9.5 (7.9, 11.2) 1.5 (1.0, 1.9) 
2004 11.2 (10.0, 12.4) 10.4 (9.3, 11.6) 1.8 (1.3, 2.3) 
2005 11.4 (10.5, 12.4) 10.8 (9.8, 11.7) 1.4 (1.1, 1.7) 
2006 12.1 (11.1, 13.0) 11.5 (10.6, 12.4) 1.8 (1.4, 2.1) 
2007 12.3 (11.4, 13.2) 11.5 (10.7, 12.4) 1.4 (1.1, 1.7) 
2008 11.8 (10.9, 12.6) 11.2 (10.4, 12.0) 1.6 (1.3, 1.9) 
2009 12.6 (11.7, 13.4) 12.0 (11.1, 12.8) 1.4 (1.1, 1.7) 
2010 13.2 (12.3, 14.1) 12.7 (11.8, 13.5) 1.4 (1.1, 1.7) 
2011 13.1 (12.2, 14.0) 12.7 (11.7, 13.5) 1.6 (1.3, 1.9) 
2012 13.5 (12.4, 14.6) 12.9 (11.9, 14.0) 1.8 (1.4, 2.3) 
Weighted Mean 12.4 (12.2, 12.8) 11.8 (11.5, 12.1) 1.6 (1.5, 1.7) 
*
 Standardized to reflect age distribution of 2005 Medicare population; 
†
 Atherosclerosis Risk in 
Communities (ARIC) cohort study 
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Table 16. Age-standardized* overall and annual incidence (per 1000 person-years) of peripheral 
artery disease claims, overall and by health care setting of incident claim. The ARIC† study 
(2005-2012) 
 Overall  Outpatient Inpatient 
  Age-standardized rate
‡ 
Age-standardized rate
 ‡
 Age-standardized rate
 ‡
 
2005 26.6 (20.7, 32.6) 20.3 (15.1, 25.4) 6.4 (3.4, 9.3) 
2006 25.8 (20.3, 31.3) 20.0 (15.2, 24.8) 5.8 (3.1, 8.5) 
2007 25.6 (20.8, 30.4) 21.5 (17.2, 25.9) 4.0 (2.0, 6.1) 
2008 26.0 (21.0, 31.0) 21.2 (16.7, 25.7) 4.8 (2.7, 6.9) 
2009 25.6 (20.9, 30.3) 20.6 (16.4, 24.8) 5.0 (2.9, 7.1) 
2010 29.3 (24.2, 34.4) 25.9 (21.1, 30.7) 3.4 (1.7, 5.0) 
2011 26.5 (21.7, 31.4) 23.3 (18.8, 27.9) 3.2 (1.5, 4.8) 
2012 30.3 (24.9, 35.7) 26.0 (21.0, 30.9) 4.3 (3.7, 5.1) 
Weighted Mean 26.8 (25.1, 28.6) 22.4 (20.8, 24.0) 4.4 (3.7, 5.1) 
*
 Standardized to reflect age distribution of 2005 Medicare population; 
†
 Atherosclerosis Risk in 
Communities (ARIC) cohort study; 
‡ 
rates are per 1000 person-years 
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ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population 
Figure 10. Age-standardized annual prevalence of PAD, by age groups. The ARIC Study, 2003-2012 
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ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population 
Figure 11. Age-standardized annual prevalence (%) of PAD, by race groups. The ARIC Study, 2003-2012  
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ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population; rates are per 1000 person-
years  
Figure 12. Age-standardized annual incidence (per 1000 person-years) of PAD, by age groups. The ARIC Study, 2005-2012 
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ARIC= Atherosclerosis Risk in Communities; Estimates are age-standardized to 2005 population; rates are per 1000 person-years 
Figure 13. Age-standardized annual incidence of PAD (per 1000 person-years), by race groups. The ARIC study, 2005-2012 
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Supplemental Table 1. Exclusion criteria to arrive at final dataset. The ARIC Study, 2003-2012 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Total in 
dataset 
9,948 10,380 10,821 11,250 11,563 11,657 11,440 11,085 10,718 10,355 
Exclusions for  
HMO 2,013 2,140 2,640 3,478 4,200 4,495 4,863 4,856 4,759 4,670 
race 39 44 44 45 41 40 41 41 40 37 
age <65 603 518 429 355 262 127 32 5 5 2 
Final 
Enrollees 
7,293 7,678 7,708 7,372 7,060 6,995 6,504 6,183 5,914 5,546 
 ARIC= Atherosclerosis Risk in Communities 
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Supplemental Table 2. International Classification of Diseases, Ninth Revision (ICD-9-CM), Current Procedural Terminology, 4th 
edition (CPT-4), Healthcare Common Procedure Coding System (HCPCS), and Federally Qualified Healthcare Revenue Center 
(FQHC) codes used to identify peripheral artery disease in claims 
Code Type Codes 
ICD-9-CM 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 
440.32, 440.4, 440.8, 440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
 
* 38.08, 38.16,, 38.18, 38.38, 38.48, 39.25, 39.29, 39.49, 39.50, 39.56, 39.57, 39.58, 39.90, 84.10, 84.12, 84.13, 
84.14, 84.15, 84.16, 84.17, 84.18, 84.3, 84.91 
HCPCS/ 
CPT-4 
27295, 27590, 27591, 27592, 27594, 27596, 27598,27599,27880, 27881, 27882, 27888, 27889, 28800, 28805, 28810, 
28820, 28825, 35221, 35226, 35256, 35286, 35302, 35303, 35304, 35305, 35306, 35331, 35351, 35355, 35361, 
35363, 35371, 35372, 35381, 35452, 35454, 35456, 35459, 35470, 35472, 35473, 35474, 35480, 35481, 35482, 
35483, 35485, 35490, 35491, 35492, 35493, 35495, 35500, 35521, 35533, 35537, 35538, 35539, 35540, 35541, 
35546, 35548, 35549, 35551, 35556, 35558, 35563, 35565, 35566, 35583, 35585, 35587, 35621, 35623, 35646, 
35647, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 35671, 35681, 35682, 35700, 35875, 35876, 35879, 
35881, 35883, 35884, 35903 
 
* 35683, 35686, 35571, 72191, 72198, 73706, 73725, 74175, 74185, 75630, 75631, 75635, 75710, 75711, 75712, 
75716, 75717, 75718,  93922, 93924, 93925, 93926, 93978, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 
99213, 99214, 99215, 99216,  99241, 99242, 99243, 99244, 99245, 99385, 99386, 99387, 99395, 99396, 99397 
 
Revenue 
Center 
Codes 
*0320,0321,0322,0323,0324,0329,0360,0361,0370,0371,0372,0379,0402,0490,0499,0510,0517,0519,0520,0521,061
0,0616,0710,0760, 0761,0762,0769,0921 
* Must be accompanied with a PAD-related ICD-9-CM code 
  
  
8
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Supplemental Table 3. Sensitivity analysis comparing requiring two outpatient claims versus 
 
Outpatient PAD Prevalence
+ 
% 
(95% CI) 
Outpatient PAD Prevalence
* 
% 
(95% CI) 
2003 4.0 (3.1, 4.9) 9.5 (7.9, 11.2) 
2004 6.7 (5.7, 7.6) 10.4 (9.3, 11.6) 
2005 6.7 (5.9, 7.4) 10.8 (9.8, 11.7) 
2006 7.2 (6.5, 7.9) 11.5 (10.6, 12.4) 
2007 7.3 (6.6, 7.9) 11.5 (10.7, 12.4) 
2008 7.6 (6.9, 8.2) 11.2 (10.4, 12.0) 
2009 8.0 (7.4, 8.8) 12.0 (11.1, 12.8) 
2010 8.7 (8.0, 9.5) 12.7 (11.8, 13.5) 
2011 9.5 (8.7, 10.3) 12.7 (11.7, 13.5) 
2012 10.0 (9.1, 10.9) 12.9 (11.9, 14.0) 
Weighted Mean 7.9 (7.7, 8.2) 11.8 (11.5, 12.1) 
 + Requires two outpatient claims in a year for prevalence estimates; * Requires one outpatient claim for prevalence estimates; ARIC= 
Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population 
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Supplemental Table 4. Age-standardized annual prevalence of peripheral artery disease in the inpatient and outpatient setting by race-
sex groups. The ARIC Study, 2003-2012 
 White Males White Females Black Males Black Females 
 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
2003 9.6 7.4, 11.8 8.8 5.6, 12.0 10.1 6.6, 13.6 16.2 10.8, 21.6 
2004 10.9 9.1, 12.8 9.4 7.4, 11.3 10.5 7.8, 13.3 16.6 12.7, 20.4 
2005 11.2 9.7, 12.8 9.4 7.9, 10.8 13.5 10.5, 16.4 15.4 12.3, 18.4 
2006 12.6 11.0, 14.1 9.2 7.9, 10.5 14.1 10.9, 17.3 16.7 13.7, 19.8 
2007 12.0 10.6, 13.4 10.2 8.9, 11.4 15.0 11.5, 18.5 18.7 15.5, 21.9 
2008 11.7 10.3, 13.1 10.0 8.8, 11.2 15.3 11.8, 18.8 15.0 12.3, 17.7 
2009 12.2 10.7, 13.7 10.9 9.6, 12.1 14.6 11.3, 17.9 16.5 13.8, 19.1 
2010 13.0 11.4, 14.6 11.7 10.4, 13.0 12.9 9.8, 16.1 17.8 15.1, 20.6 
2011 12.1 10.5, 13.8 12.4 11.0, 13.7 11.6 8.4, 14.8 17.2 14.4, 19.9 
2012 12.3 10.4, 14.2 13.3 11.7, 14.8 13.6 9.3, 17.9 16.2 13.1, 19.2 
Weighted 
Mean 12.1 11.6, 12.5 10.9 10.4, 11.3 13.2 12.2, 14.2 16.9 16.0, 17.8 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population 
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Supplemental Table 5. Age-standardized annual prevalence of peripheral artery disease in the 
inpatient and outpatient setting by gender. The ARIC Study, 2003-2012 
 Male Female 
 Prevalence % 95% CI Prevalence % 95% CI 
2003 9.7 7.8, 11.7 11.1 8.2, 13.9 
2004 10.8 9.2, 11.7 11.6 9.8, 13.4 
2005 11.8 10.4, 13.2  11.1 9.8, 12.5 
2006 13.0 11.6, 14.4 11.1 10.9, 12.3 
2007 12.6 11.3, 13.9 12.1 10.1, 13.3 
2008 12.4 11.1, 13.7 11.2 11.2, 13.6 
2009 12.7 11.4, 14.1 12.4 12.1, 14.6 
2010 13.1 11.7, 14.5 13.4 12.5, 15.0 
2011 12.2 10.7, 13.6 13.8 12.5, 15.0 
2012 12.8 11.0, 14.5 14.2 12.8, 15.6 
Weighted Mean 12.4 12.0, 12.8 12.6 12.1, 12.9 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare 
population 
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Supplemental Table 6. Age-standardized annual incidence of peripheral artery disease in the 
inpatient and outpatient setting by gender. The ARIC Study, 2005-2012 
  Male Female 
  Events 
Person-
time 
Age-standardized 
rate Events 
Person-
time 
Age-standardized 
rate 
2005 66 2,667 31.5 (22.0, 41.0) 72 3,702 22.1 (15.0, 29.2) 
2006 57 2,530 31.1 (22.0, 40.1) 63 3,512 20.5 (14.2, 26.8) 
2007 64 2,391 28.7 (21.1, 36.3) 70 3,382 23.4 (17.3, 29.5) 
2008 51 2,319 25.2 (18.0, 32.4) 70 3,352 26.6 (19.7, 33.5) 
2009 57 2,096 28.0 (20.6, 35.4) 66 3,106 24.2 (18.0, 30.5) 
2010 50 1,949 26.2 (18.9, 33.5) 84 2,944 31.6 (24.6, 38.7) 
2011 41 1,817 23.2 (16.0, 30.4) 76 2,786 29.0 (22.4, 35.7) 
2012 48 1,655 27.4 (19.2, 35.6) 82 2,561 32.8 (25.5, 40.1) 
Weighted 
Mean 434 17,423 26.9 (24.3, 29.5) 583 25,346 26.8 (24.5, 29.2) 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare 
population 
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ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare 
population 
Supplemental Figure 1. Age-standardized annual incidence of peripheral artery disease in the 
inpatient and outpatient setting among four race/gender groups. The ARIC Study, 2005-2012 
 
 
0
10
20
30
40
50
60
70
80
90
100
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013A
ge
-s
ta
n
d
ar
d
iz
ed
 in
ci
d
en
ce
 a
n
d
 9
5
%
 C
I  
Year 
Age-standardized Incidence for Blacks,  
2005-2012 
Black Males
Black Females
0
10
20
30
40
50
60
70
80
90
100
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
A
ge
-s
ta
n
d
ar
d
iz
e
d
 in
ci
d
en
ce
 a
n
d
 9
5
%
 C
I 
Year 
Age-standardized Incidence for Whites,  
2005-2012 
White Males
White Females
 93 
CHAPTER 6. MANUSCRIPT #2: FREQUENCY OF CARE AND MORTALITY 
FOLLOWING AN INCIDENT DIAGNOSIS OF PERIPHERAL ARTERY DISEASE IN THE 
INPATIENT OR OUTPATIENT SETTING. THE ARIC STUDY. 
6.1 Introduction 
 Peripheral artery disease (PAD) is a prevalent and disabling atherosclerotic disorder that 
disproportionately affects the elderly and minority populations in the United States [64, 147]. Up 
to 25% of patients with symptomatic PAD may progress to limb-threatening clinical 
manifestations that are associated with high health care costs and frequent PAD-related 
procedures [15, 184]. In particular, hospitalization costs associated with PAD-related 
revascularization and limb amputation procedures are more than $11 billion annually in the 
United States. Long-term health status following these procedures is poor [15].  
 While prognosis for patients following a PAD-related procedure is well described [5, 7], 
little is known about the outpatient and inpatient clinical care and outcomes following an initial 
PAD diagnosis. In particular, the post diagnosis care for individuals with PAD, from initial 
diagnosis in the outpatient setting - through clinic visits, admissions, and procedures – has not 
been characterized. Administrative claims data, which contain diagnostic and procedure codes 
from inpatient and outpatient encounters, provide an opportunity to estimate the frequency of 
care of PAD from the health care setting of first diagnosis through follow-up care at both the 
outpatient and inpatient levels.   
 The first objective of this study was to characterize the frequency of care for study 
participants overall and by gender and race following an incident PAD diagnosis in the 
outpatient or inpatient setting. Our second objective was to estimate 30-day, 1-year, and 2-year 
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mortality associated with an initial PAD diagnosis, by diagnosis setting. To accomplish these 
aims, we used data from the biracial Atherosclerosis Risk in Communities (ARIC) study cohort 
[8] linked with Center for Medicare and Medicaid Services (CMS) claims data.   
6.2 Methods 
6.2.1 Study Population 
 
6.2.1.1 The Atherosclerosis Risk in Communities (ARIC) Cohort Study 
 The biracial ARIC cohort, established to examine the etiology of atherosclerosis and its 
clinical manifestations, includes 15,792 participants (45-64 years of age at baseline) enrolled 
between 1987 and 1989. The ARIC cohort was selected by probability sampling from four US 
communities: Washington County, Maryland (MD), Forsyth County, North Carolina (NC), the 
city of Jackson, Mississippi (MS), and the suburb cities of Minneapolis, Minnesota (MN) [8]. 
Eligible for inclusion in this study were ARIC participants enrolled continuously for at least two 
years in Medicare Parts A and B through a fee-for-service plan from 2000-2012. Data were 
collected on cohort participants at five clinic examinations and through annual follow-up 
telephone interviews. Information from visits 1-4, which occurred at three year intervals and 
concluded in 1999, is included in the present study. 
6.2.1.2 Linkage of Cohort Data with Administrative Claims 
 Data for ARIC cohort participants were linked with the Centers for Medicare and 
Medicaid Services (CMS) claims data for the years 1991-2012 using a finder file that included 
participants’ social security numbers, gender and date of birth. A total of 14,899 Medicare 
eligible ARIC study participants were identified, of which 14,702 ARIC cohort IDs (98.7 % 
match) were matched successfully indicating eligibility for CMS Medicare coverage.  
 Information concerning ARIC study participant enrollment in fee-for-service (FFS) 
Medicare was obtained from monthly indicators of enrollment in Part A, Part B, and Medicaid 
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buy-in available from annual CMS Medicare Beneficiary Summary files. Continuous enrollment 
periods were created to indicate uninterrupted CMS Medicare FFS coverage, defined as 
enrollment in CMS Medicare Part A and Part B and lack of enrollment in a Medicare Advantage 
(HMO) plan. Enrollment status prior to 2000 was not considered for this analysis. Study 
participants with missing enrollment information and those with continuous and exclusive 
Medicare Advantage enrollment were excluded from the study. Also excluded from analyses 
were participants <65 years of age and those of race other than black or white. For each study 
participant the longest enrollment period was selected to give the best opportunity to capture 
relevant claims.  
6.2.1.3 Demographics and Comorbidities 
 Participant race, gender, education level and family income were self-reported at 
baseline. Age was calculated at the time of incident PAD event. Participant information 
regarding comorbid conditions was available from four clinic visits and annual telephone follow-
up surveys. Diabetes mellitus was defined as self-reported history of diabetes at any of the four 
clinic visits or self-report questionnaire, usage of diabetes medication during the two weeks prior 
to a visit, a fasting blood glucose level of > 126 mg/dl, or a non-fasting blood glucose > 200 
mg/dl. Hypertension was defined as systolic blood pressure > 140 mm Hg or diastolic blood 
pressure > 90 mm Hg at any of the four clinic visits or by antihypertensive medication usage 
during the two weeks prior to any of the clinic visits or via self-report questionnaire. 
Hyperlipidemia was defined as a total cholesterol > 240 mg/dl at any of the four clinic visits or 
via self-report questionnaire. Smoking status was self-reported at each clinic visit and is defined 
as any history or no history for the purposes of this study. Trained technicians measured height 
and weight at each clinic visit. Body mass index was calculated as weight in kilograms divided 
by height squared (in meters). Obesity was defined as BMI > 30.0 kg/m
2
. History of coronary 
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heart disease (CHD), stroke, and heart failure prior to incident PAD diagnosis was based on self-
report at baseline and adjudication of hospitalized events occurring in follow up from 2005 
through the PAD diagnosis date. End-stage renal disease was defined as estimated glomerular 
filtration rate (eGFR) <15.0 mL/min/m
2 
using creatinine measurements from the four clinic visits 
and employment of the CKD-EPI equation. Self-rated health (via self-report questionnaire) was 
defined as poor, fair, good, or excellent, and the lowest rating was used. Adequate access to care 
was defined as any outpatient encounter within one year of the incident PAD diagnosis date.     
6.2.1.4 Ascertainment of Encounters in the Claims 
 PAD-related outpatient office visits and outpatient diagnostic tests were identified from: 
1) the physician claims (Carrier) files as claims with PAD-related diagnostic and billing codes 
for new and established office visits and preventive medicine visits and 2) from facility claims 
(Outpatient) files as claims with PAD-related codes for visits to Federally Qualified Healthcare 
centers. Hospitalizations (e.g. inpatient visits and procedures) were identified from the Medicare 
Provider Analysis and Review (MedPAR) records. PAD occurrence was defined using 
International Classification of Diseases, Ninth Revision (ICD-9-CM) and Healthcare Common 
Procedure Coding System (HCPCS) codes selected based upon a review of the current literature 
[185]. Codes in any position on the records were considered for both inpatient and outpatient 
visits. Provider specialty codes were used to identify outpatient visits to primary care providers, 
cardiology visits, and podiatry visits. All discharge ICD-9 codes for the incident PAD 
hospitalizations were grouped into categories of comorbid conditions using definitions provided 
by Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse 
(Supplemental Table 7). 
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6.2.1.5 Cohort Construction 
 A synthetic cohort of ARIC participants enrolled in Medicare FFS beneficiaries who had 
an incident inpatient or outpatient PAD diagnosis was constructed to investigate the frequency of 
inpatient and outpatient encounters following a PAD diagnosis. A two-year look back period 
from the date of first PAD occurrence was chosen to minimize misclassification of incident 
events [170]. This two-year look back has been shown to reduce misclassification of incidence 
among chronic diseases to less than 10% [170]. In addition, FFS eligibility for at least two years 
of follow-up after the incident diagnosis was required. Therefore, the analytical study population 
included ARIC study participants with a PAD diagnosis from 2002 to 2010, with follow-up 
extending through an administrative censoring date of December 31
st
, 2012. 
 An incident inpatient PAD diagnosis was defined as a hospitalization for PAD at any 
time during the study period. An outpatient PAD diagnosis was defined as at least two outpatient 
claims with a PAD-related code for events at least 1 day apart occurring within 12 consecutive 
months. If a singular outpatient event preceded an inpatient event within 365 days, the event was 
classified as an inpatient PAD diagnosis with the incident event date as the inpatient date of 
discharge. Single PAD-related outpatient events occurring with no PAD-related hospitalizations 
or PAD-related outpatient events within 365 days were not considered incident PAD events. 
6.2.2 Statistical Analysis 
 Direct standardization was used to estimate age-standardized rates of inpatient and 
outpatient encounters with 95% confidence intervals (CI) following an initial PAD diagnosis. 
The denominator for rate estimates included cohort participants’ time in continuous FFS 
enrollment following an initial PAD diagnosis. Estimates were age-standardized to reflect the 
age, race, and sex distribution of the 2005 Medicare population ages 67 years and older. Age 
categories for standardization included 67-69, 70-74, 75-79 and > 80 years of age at the time of 
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PAD diagnosis. Estimates were calculated by diagnosis location (inpatient, outpatient) and 
within diagnosis location in strata of race and gender.   
 Analyses for time to initial hospitalization or rehospitalization accounted for death as a 
competing risk using the cumulative incidence function, a method that computes the incidence of 
failure associated directly with the event of interest (i.e. hospitalization) along with the incidence 
of failure associated with the competing risk (i.e. death) [173, 174]. Estimates were calculated by 
initial diagnosis location and within diagnosis location in strata of race and gender. The end of 
follow-up was determined by death, enrollment in Medicare Advantage or at December 31
st
, 
2012 (end of study observation period). Beneficiaries’ death dates were obtained from the Master 
Beneficiary File. Propensity score models were used to adjust for confounding in estimates of 
mortality by using standardized mortality ratio weighting [186]; individuals diagnosed with PAD 
in the inpatient setting were weighted to reflect the distribution of covariates among individuals 
diagnosed with PAD in the outpatient setting. Covariates included age, gender, race, income, 
education, diabetes, smoking history, hyperlipidemia, hypertension, obesity, coronary heart 
disease, stroke, heart failure, end stage renal disease, self-rated health, and adequate access to 
care. The distribution of propensity scores was examined and non-overlapping propensity scores 
were trimmed from mortality analyses (n=21). All analyses were completed using SAS version 
9.4 (SAS Institute Inc., Cary, NC). Written informed consent was obtained from all participants 
and all institutional review boards approved the ARIC study. This study includes secondary data 
analysis of existing data and was approved by the institutional review board of UNC. 
6.3 Results 
 The final analytic sample included 11,652 ARIC participants with 86,228 person-years of 
fee-for-service enrollment time. Median enrollment time was 6.3 years. We observed 1,086 
incident diagnoses of PAD during the study period (2002-2010) including 873 (80.4%) incident 
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PAD cases diagnosed in the outpatient setting and 213 (19.6%) incident PAD cases diagnosed in 
the inpatient setting. Table 17 describes demographic and comorbid traits, stratified by initial 
PAD diagnosis location (outpatient vs. inpatient). Also included in Table 17 are demographic 
and comorbid traits among fee-for-service participants who did not have a PAD diagnosis during 
the study observation period (N=10,566). Compared to those with incident outpatient PAD, a 
larger proportion of study participants with incident inpatient PAD reported a history of major 
circulatory system disorders including CHD, stroke, and heart failure. Those with incident 
outpatient PAD were more likely to be female and have a history of diabetes and hypertension 
compared to those with incident inpatient PAD. 
 Among the 213 participants diagnosed with PAD in the inpatient setting, 37 (17.4%) 
were hospitalized with a primary diagnosis of PAD (Table 18). A PAD-related code was present 
in the first three or five positions, respectively, in 71 (33.3%) and 110 (51.6%) of the 213 
incident hospitalizations. Participants diagnosed with PAD in the inpatient setting frequently had 
a concomitant code for ischemic heart disease (39.0%), diabetes (23.9%), chronic kidney disease 
(17.4%), heart failure (16.9%), and atrial fibrillation (12.2%). For 38% (81/213) of the incident 
PAD hospitalizations the primary discharge diagnosis was a circulatory system related condition 
(including PAD). Respiratory conditions (10.3%), digestive system diseases (8.9%), 
musculoskeletal diseases (7.0%), and neoplasms (6.6%) were the most common non-
cardiovascular disease primary discharge diagnoses.  
6.3.1 Age-standardized Rates of Post-Diagnosis Outpatient and Inpatient Encounters 
 Among individuals diagnosed with PAD in the outpatient setting, we observed an age-
standardized rate of 2.15 (95% CI: 2.10, 2.21) PAD-related outpatient encounters per person year 
over the course of study follow-up (2002-2012; Table 17). There were no race or gender 
differences in rates of PAD-related outpatient encounters per person-year (Figure 14). The 
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highest rates of all-cause outpatient encounters were for primary care provider visits (PCP; age-
standardized rate: 6.36 per person-year; 95% CI: 6.26, 6.45; Figure 15). Age-standardized rates 
of outpatient cardiology encounters were 1.94 (95% CI: 1.89, 2.0) encounters per person-year. 
Cardiology encounters per person-year were lower among blacks (1.20; 95% CI: 1.12, 1.28) as 
compared to whites (2.18; 95% CI: 2.12, 2.25) and among females (1.48; 95% CI: 1.43, 1.55) as 
compared to males (2.27; 95% CI: 2.21, 2.35; Figure 16). Individuals with PAD diagnosed in the 
outpatient setting had an age-standardized rate of 0.10 (95% CI: 0.09, 0.11) PAD-related 
hospitalizations and 0.17 (95% CI: 0.16, 0.19) all-cause hospitalizations per person-year over the 
course of follow-up from 2002 to 2012.   
 Individuals with PAD diagnosed in the inpatient setting had an age-standardized rate of 
1.02 (95% CI: 0.94, 1.10) PAD-related outpatient encounters per person year following a PAD 
diagnosis (Figure 14). Age-standardized rates of PAD-related outpatient encounters per person-
year among blacks and whites were 1.52 (95% CI: 1.28, 1.74) and 0.90 (95% CI: 0.82, 0.99), 
respectively. Among gender strata, males had 1.04 (95% CI: 0.93, 1.16) and females had 1.03 
(95% CI: 0.92, 1.14) PAD-related outpatient encounters per person-year. The highest rates of 
outpatient encounters were to primary care providers (7.43 per person-year; 95% CI: 7.21, 7.64; 
Figure 15). Age-standardized rates of cardiology care were 2.29 (95% CI: 2.17, 2.40) encounters 
per person-year. Outpatient cardiology encounters per 1.76 (95% CI: 1.53, 2.0) person-year 
among blacks (1.76; 95% CI: 1.53, 2.0) and 2.32 (95% CI: 2.20, 2.45) among whites and were 
similar among females (2.41; 95% CI: 2.23, 2.59) and males (2.14; 95% CI: 1.99, 2.28; Figure 
16). Individuals with PAD diagnosed in the outpatient setting had an age-standardized rate of 
0.17 (95% CI: 0.14, 0.21) PAD-related hospitalizations and 0.30 (95% CI: 0.26, 0.34) all-cause 
hospitalizations per person-year after the PAD diagnosis.   
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6.3.2 Hospitalization and Re-Hospitalization Following an Incident PAD diagnosis 
 Cumulative one-year incidence of first PAD-related and first all-cause hospitalization 
among those with PAD diagnosed in the outpatient setting was 6.4% (95% CI: 4.8, 8.1) and 
32.2% (95% CI: 29.0, 35.2), respectively (Table 19). Incidence of first PAD-related 
hospitalization was similar among blacks (7.6%; 95% CI: 4.2, 10.9) as compared to whites 
(6.0%; 95% CI: 4.1, 7.8) and among males (9.0%; 95% CI: 6.0, 11.8) as compared to females 
(4.6%; 95% CI: 2.7, 6.4). Incidence of first all-cause hospitalization was also similar among 
blacks (38.3%; 95% CI: 31.8, 44.2) as compared to whites (29.8%; 95% CI: 26.2, 33.3) and 
among males (35.3%; 95% CI: 30.2, 40.0) as compared to females (29.9%; 95% CI: 25.8, 33.8).  
 Cumulative incidence of first PAD-related and first all-cause hospitalization among those 
with PAD diagnosed in the inpatient setting was 14.2% (95% CI: 9.3, 18.7) and 43.4% (95% CI: 
36.3, 49.7) at one year, respectively (Table 20). Incidence of PAD-related rehospitalization at 
one year was higher among blacks (21.4%; 95% CI: 9.9, 31.5) as compared to whites (11.6%; 
6.4, 16.5), although estimates were imprecise. Incidence of PAD-related rehospitalization at one 
year was similar among males (14.3%; 95% CI: 7.6, 20.6) and females (13.9%; 95% CI: 6.9, 
20.4). All-cause hospitalization at one year was higher, although not statistically significant, 
among blacks (55.1%; 95% CI: 40.0, 66.4) as compared to whites (38.7%; 95% CI: 34.6, 53.1). 
There were no differences detected in all-cause hospitalization at one year when comparing 
males (44.6%; 95% CI: 34.6, 53.1) to females (41.8%; 95% CI: 31.3, 50.6).  
6.3.3 Mortality Following an Incident PAD Diagnosis 
 Overall age-standardized mortality was 1.8% (95% CI: 1.0, 2.5), 8.9% (95% CI: 7.2, 
10.5), and 16.6% (95% CI: 14.4, 18.7) at 30 days, one year and two years after PAD diagnosis in 
any setting (Table 21). Thirty day, one-year and two-year age-standardized mortality was 0.8% 
(95% CI: 0.2, 1.4), 7.1% (95% CI: 5.4, 8.7) and 15.3% (95% CI: 12.9, 17.6), respectively, among 
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those with incident outpatient PAD diagnosis. Thirty-day, one-year and two-year age-
standardized mortality was 5.7% (95% CI: 2.6, 8.7), 16.0% (11.0, 21.1) and 21.5% (15.8, 27.2) 
respectively, among those with incident inpatient PAD diagnosis. Propensity score adjusted 
mortality at one-year and two years (Figure 17) was 6.3% (95% CI: 4.8, 7.7) and 13.7% (95% 
CI: 11.4, 15.9) among those with incident outpatient PAD diagnosis. Propensity score adjusted 
mortality at one-year and two years was 14.7% (95% CI: 9.9, 19.3) and 19.9% (95% CI: 14.3, 
25.5), among those with incident inpatient PAD diagnosis.   
6.4 Discussion  
 The present study is among the first to examine the incidence of PAD diagnosis across 
different care settings and to examine frequency of health care encounters following a PAD 
diagnosis. Of 1,086 study participants enrolled in FFS CMS Medicare who had an incident PAD 
diagnosis, we found that 80% (873/1086) were initially diagnosed with PAD in the outpatient 
setting. PAD-related hospitalizations at one year were rare (6.4%) among those with an incident 
outpatient PAD diagnosis, although outpatient encounters with primary care providers, 
cardiologists, podiatrists, as well as encounters with PAD-related codes were relatively frequent 
compared to national rates [187]. Minimal differences for follow-up encounters were observed in 
analyses stratified by race and gender, although blacks experienced lower rates of follow-up 
cardiology encounters as compared to whites. Participants with an incident inpatient PAD 
diagnosis had a poor short-term prognosis, with a 30-day mortality of nearly 6% and a rate of all-
cause rehospitalization which was close to 50% within one year. Our findings suggest a poor 
overall prognosis, including high mortality and high incidence of rehospitalization for 
participants diagnosed with incident PAD in the inpatient setting as compared to participants 
diagnosed with incident PAD in the outpatient setting.  
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 Characteristics and pre-diagnosis comorbid conditions of ARIC Study participants with 
PAD identify similar risk factors as other studies of PAD [12, 25]. Diabetes (43%) and 
hypertension (84%) were more common in the current study population than among Medicare 
beneficiaries in a recent study based on the MarketScan database (Diabetes: 16%; Hypertension: 
54%); however, the MarketScan-based analyses was not limited to fee-for-service participants 
and relied only on claims to describe prevalence of comorbid conditions [185]. The rich 
covariate detail available in the ARIC study from clinic visits and self-report questionnaires 
provided supplemental data that is unavailable in claims and, as such,  could explain some of the 
difference in the prevalence of comorbid conditions. Participants with an incident PAD diagnosis 
in the inpatient setting were particularly likely to have coexisting circulatory system diseases 
(45%), a finding that is in accordance with estimates from the REACH registry in which 65% of 
individuals with PAD had clinical evidence of either coronary or cerebrovascular disease [17]. 
The estimated proportion of participants with of CHD, stroke, and heart failure from the current 
study represent major circulatory system events and are likely an underestimation of the actual 
number of participants with circulatory system diseases. Kroger et al (2009) observed an inverse 
relationship between education and income and PAD in a population-based study using ankle-
brachial index <0.9 to define PAD [67]. Our study, which confirms these observations and 
extends them to the care of PAD in the inpatient or outpatient setting, further underscores 
disparities in the development of PAD which are similar to disparities observed in the 
development of other cardiovascular diseases [188].  
 We found that individuals diagnosed with PAD in the outpatient setting had more than 
twice the number of PAD-related post-diagnosis outpatient encounters per person-year than 
individuals diagnosed with PAD in the inpatient setting. While guidelines concerning appropriate 
 104 
timing of healthcare encounters following an incident PAD diagnosis have not been established, 
most guideline recommendations for care following a hospitalized CVD event suggest contact 
with a provider within six weeks [189, 190]. The very long median time to first PAD-related 
outpatient visit following an incident diagnosis in the inpatient setting (849 days), which we 
observed in this study, suggests that those with an inpatient PAD diagnosis may constitute a 
population of individuals who are not receiving appropriate PAD-related care [191].   
 While our observations regarding differences in post-diagnosis PAD-related follow-up 
care by diagnosis setting are meaningful, there are several factors to consider that could 
influence these findings. First, nearly half of the incident inpatient PAD diagnoses included a 
PAD code in the eleventh position or beyond implying that PAD was only a distal cause of the 
hospitalization or that the PAD code represented prevalent disease. Participants diagnosed with 
PAD in the inpatient setting, therefore, might be less likely to have PAD severe enough to 
require follow-up care as compared to participants diagnosed with PAD in the outpatient setting; 
only four code positions are included in outpatient records, thus reducing the opportunities for 
inappropriate inclusion of a PAD code. Second, the greater prevalence of comorbid conditions 
that may necessitate frequent outpatient follow-up – such as diabetes and hypertension – 
identified among participants diagnosed with PAD in the outpatient, as compared to the inpatient 
setting, suggests that the two groups of study participants with a PAD diagnosis may utilize 
health care differently. Individuals with diabetes, who are frequent utilizers of outpatient 
services, are more likely to be screened for PAD in the outpatient setting and might be more 
likely to have PAD-related outpatient follow-up given a positive finding [136]. Finally, our 
assessment of post-diagnosis follow-up care was constrained for the inpatient setting by a 
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relatively high proportion of participants discharged to a nursing home (13%), where follow-up 
specialty care is unlikely.  
 Although we observed that study participants with inpatient PAD diagnosis had few post-
diagnosis PAD-related outpatient encounters, our findings suggest that participants with an 
incident PAD diagnosis in either setting are high utilizers of all-type outpatient health care 
services. In comparison with a census-based Medicare-aged general population (including all 
diagnoses) derived from a national ambulatory health care survey (NAMCS), participants with a 
PAD diagnosis, identified in the present study, had, on average, 5 times the number of post-
diagnosis outpatient encounters per person-year (31.6 vs 5.9) [187]. The ARIC study participants 
with a PAD diagnosis also experienced more than twice the rate of encounters per person-year 
with primary care providers than the general population of the NAMCS survey, possibly due to 
the coexisting comorbidity burden. Our overall outpatient encounter estimates were also slightly 
higher than estimates obtained from a recent claims-based study of working-aged Japanese 
patients with PAD that identified 25 all-cause outpatient encounters in the first year following a 
PAD diagnosis [192].  
 Examination of follow-up outpatient encounters with different types of providers 
revealed few differences in rates of care by race and gender. This study contributes information 
toward a knowledge gap in incidence and rates of post PAD diagnosis care, especially among 
women [182]. Differences in gender-specific estimates, which found that women were less likely 
to have follow-up cardiology care after an incident outpatient PAD diagnosis, concurs with 
previous literature not specific to PAD patients [193]. We also found that blacks were less likely 
than whites to have outpatient cardiology encounters following a PAD diagnosis, a finding that 
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complement data from extant literature suggesting race disparities in receipt of appropriate 
inpatient cardiology care [193]. 
 Previous studies have suggested that diagnosis of CVD in the inpatient setting, as 
compared to the outpatient setting, portends worse outcomes [194, 195]. Results of the current 
study extend this observation to PAD. We found that five-year mortality was higher among 
participants with a PAD diagnosis in the inpatient setting (51.3%; 95% CI: 44.4, 58.3) as 
compared to the outpatient setting (34.4%; 95% CI: 31.1, 37.8).  We used propensity score 
methods to adjust for demographic characteristics, comorbidities, disease severity, access to care, 
and health status observed for participants diagnosed with PAD in the inpatient and outpatient 
settings, and differences in survival between the two groups persisted. However, our comparison 
of mortality by setting is limited by the observational nature of our study and our inability to 
control for residual confounding. It is also important to note that participants from these two 
settings of diagnosis differ significantly by a variety of comorbid conditions and their respective 
risk profiles likely drive much of the mortality gap we observed. For example, the overall 
frequency of concomitant conditions associated with high mortality including ischemic heart 
disease, diabetes, chronic kidney disease, heart failure, and atrial fibrillation was much higher 
among those diagnosed with PAD in the inpatient setting (Table 18). While the intention of our 
study is to present descriptive information concerning mortality and hospitalizations by setting of 
diagnosis, findings from our study do suggest that identification of PAD in the outpatient setting, 
which presumably occurs at an early stage of the disease, is favorable.   
6.4.1 Strengths and Limitations  
 An important strength of this study is the inclusion of outpatient in addition to inpatient 
clinical encounters in the assessment of the frequency of encounters following an incident PAD 
diagnosis. Furthermore, prior studies have provided limited information on the health care 
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encounters for individuals with PAD, stratified by the setting of health care delivery (inpatient 
vs. outpatient). These estimates are age-standardized and look back periods for incidence are in 
accordance with recent recommendations [170], providing a further strength to this study.  
 As this analysis was based on inpatient and outpatient are among CMS Medicare 
enrollees in FFS programs, our estimates are not generalizable to Medicare beneficiaries enrolled 
in managed care programs and who have been reported to be healthier than those in FFS [166]. 
Generalizability of this study is further limited because our estimates reflect cohort survivors in a 
closed cohort. We did not attempt to quantify PAD prevalence prior to enrollment in fee-for-
service in 2000 and it is possible that we did not capture the true PAD incidence. Administrative 
claims data reflect billing practices and, therefore, diagnostic coding found in claims data is not 
always accurate in relation to documented diagnoses or procedures. Diagnostic and procedure 
codes selected for the identification of PAD events were not independently validated, which 
could lead to misclassification of PAD occurrence. Lastly, PAD was the primary diagnosis code 
in only 17% of these hospitalizations. With a larger sample size, our definition of PAD 
hospitalization could have been limited to include only those where PAD was listed in the top 
three code positions.   
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6.4.2 Conclusions 
 This study addresses an important gap in existing literature by providing an assessment of 
the frequency of care following a PAD diagnosis in the outpatient or inpatient setting. 
Individuals with PAD, regardless of the setting of diagnosis, have frequent outpatient encounters 
with a variety of health care providers following the incident disease diagnosis. We found few 
differences in race- and gender-specific estimates of post-diagnosis care, although we did find 
that blacks and women were less likely than whites and men, respectively, to have post-diagnosis 
cardiology care. Lastly, we found a higher mortality among individuals diagnosed with PAD in 
the inpatient setting.  
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Table 17. Characteristics of fee-for-service participants without an incident PAD diagnosis (N=10,566) and those with an incident 
PAD diagnosis in the outpatient (N=873) or inpatient setting (N=213). The Atherosclerosis Risk in Communities Study, 2002-2010. 
 
PAD status 
 No PAD  
(N=10,566)  
Incident Outpatient PAD 
(N=873) 
Incident Inpatient PAD 
(N=213) 
Mean Age at Diagnosis, SD NA 74.9 (4.9) 74.4 (4.6) 
Gender, % Female 57.4 (56.4, 58.3) 57.6 (54.3, 60.9) 47.0 (40.1, 53.9) 
Race, % Black 27.9 (27.1, 28.8) 27.3 (24.3, 30.4) 26.4 (20.6, 32.9) 
Income, % 
Low (<$35,000) 
Mid ($35,000-$49,999) 
High (> $50,000) 
 
34.5 (33.6, 35.4) 
19.4 (18.7, 20.2) 
46.1 (45.2, 47.1) 
 
53.8 (50.4, 57.2) 
19.2 (16.6, 22.0) 
27.0 (24.1, 30.1) 
 
55.2 (48.2, 62.0) 
17.5 (12.6, 23.2) 
27.3 (21.5, 33.9) 
Education, < High School, % 22.2 (21.4, 23.0) 28.2 (25.2, 31.3) 28.3 (22.3, 34.9) 
Diabetes*, % 20.0 (19.2, 20.7) 47.1 (43.7, 50.5) 26.3 (20.5, 32.7) 
Smoking History
†
, % 66.4 (65.5, 67.3)  67.1 (63.9, 70.2) 74.7 (68.3, 80.3) 
Hyperlipidemia
‡
, % 70.9 (70.1, 71.8)  75.8 (72.9, 78.6)
  
73.2 (66.8, 79.1) 
Hypertension
§ 
, % 52.4 (51.4, 53.4)  87.5 (85.1, 89.6)
  
70.0 (63.3, 76.0) 
Obesity
#
, % 39.8 (38.8, 40.7) 50.2 (46.8, 53.5) 50.0 (42.9, 56.7) 
History of CHD
**
 , % 11.6 (11.0, 12.2) 15.4 (13.0, 17.9) 24.9 (19.2, 31.3) 
History of Stroke
††
, % 8.3 (7.8, 8.9) 9.4 (7.5, 11.5) 17.4 (12.5, 23.1) 
History of Heart Failure
‡‡
 % 16.2 (15.5, 16.9) 17.4 (15.0, 20.0) 35.7 (29.3, 42.5) 
End Stage Renal Disease§§
 0.7 (0.5, 0.9) 0.2 (0.0, 0.8) 0.9 (0.1, 3.4) 
Self-Rated Health, Poor
## 27.0 (26.1, 27.8) 27.6 (24.7, 30.7) 35.2 (28.8, 42.0) 
*Diabetes defined as self-reported history of diabetes at any of the four clinic visits or diabetes medication during two weeks prior to 
visit or fasting glucose > 126 mg/dl fasting or a nonfasting blood glucose > 200 mg/dl; 
† 
Smoking History is defined as any history or 
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no history; 
‡
 Hyperlipidemia defined as total cholesterol > 240 mg/dl ; 
 §
 Hypertension defined as systolic blood pressure > 140 mm 
Hg or diastolic blood pressure > 90 mm Hg or antihypertensive medication usage during two weeks prior to any of the four clinic 
visits;
  
# Obesity defined as body mass index > 30 kg/m
2
 ; ** History of CHD (coronary heart disease) defined as history of 
myocardial infarction, coronary revascularization during any time during follow-up but prior to incident PAD diagnosis date; 
††
History of stroke defined as prevalent or incident stroke prior to incident PAD diagnosis date;
 ‡‡ 
History of Heart Failure defined as 
prevalent or incident heart failure prior to incident PAD diagnosis date;
 §§
 End-stage renal disease defined as eGFR <15.0 mL/min/m
2
 
using the CKD-EPI equation; 
##
 Self-rated health defined as poor, fair, good, excellent 
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Table 18. Primary diagnoses and comorbid conditions for incident PAD hospitalizations. The Atherosclerosis Risk in Communities 
Study, 2002-2010 (N=213) 
Primary Discharge Diagnosis Grouped by ICD-9-CM Chapter Incident Inpatient PAD  
Diseases of the circulatory system (390–459) 
PAD-related code in primary position 
38.0% 
17.4% 
Non-circulatory system disorders (001-389, 580-999, V01-V89, 
E800-E999, Procedures 00-99) 
62.0% 
Comorbid conditions and procedures* (ICD-9-CM code(s))  
 Ischemic heart disease 39.0% 
 Acute myocardial infarction  3.3% 
 Atrial fibrillation  12.2% 
 Heart Failure 16.9% 
 Stroke 6.1% 
 Chronic Kidney Disease 17.4% 
 Diabetes 23.9% 
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Table 19. Age-standardized* cumulative incidence of first PAD and all-cause hospitalizations (95% CI) at 1 year and 2 years 
following incident PAD diagnosis among participants diagnosed in the outpatient setting. The ARIC study (2002-2012). 
 Incident Outpatient PAD (n=873) 
 First PAD 
Hospitalization at 
One Year 
First PAD 
Hospitalization at 
Two Years 
First All-Cause 
Hospitalization at 
One Year 
First All-Cause 
Hospitalization at 
Two Years 
Overall 6.4  
(4.8, 8.1) 
9.5  
(7.6, 11.5) 
32.2  
(29.0, 35.2) 
48.4  
(44.9, 51.6) 
Black 7.6 
(4.2, 10.9) 
10.7 
(6.7, 14.6) 
38.3  
(31.8, 44.2) 
52.6  
(45.7, 58.6) 
White 6.0  
(4.1, 7.8) 
9.1  
(6.8, 11.3) 
29.8  
(26.2, 33.3) 
46.8  
(42.7, 50.5) 
Males 9.0  
(6.0, 11.8) 
11.8 
(8.4, 15.0) 
35.3  
(30.2, 40.0) 
49.4 
 (44.0, 54.3) 
Females 4.6  
(2.7, 6.4) 
7.9 
(5.5, 10.2) 
29.9  
(25.8, 33.8) 
47.6  
(43.0, 51.8) 
* 
Standardized to reflect age, race and sex distribution of 2005 Medicare population; Age strata included 67-69, 70-74, 75-79, and > 
80. 
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Table 20. Age-standardized* cumulative incidence of first PAD and all-cause hospitalizations (95% CI) at 1 year and 2 years 
following incident PAD diagnosis among participants diagnosed in the inpatient setting. The ARIC study (2002-2012). 
 Incident Inpatient PAD (n=213) 
 First PAD 
Rehospitalization at 
One Year 
First PAD 
Rehospitalization at 
Two Years 
First All-Cause 
Rehospitalization at 
One Year 
First All-Cause 
Rehospitalization at 
Two Years 
Overall 14.2  
(9.3, 18.7) 
20.0  
(14.4, 25.2) 
43.4  
(36.3, 49.7) 
61.3  
(54.1, 67.4) 
Black 21.4  
(9.9, 31.5) 
30.7  
(17.4, 41.9) 
55.1 
(40.0, 66.4) 
75.4  
(60.9, 84.5) 
White 11.6  
(6.4, 16.5) 
16.2  
(10.2, 21.9) 
38.7 
(30.5, 45.9) 
55.8  
(47.2, 63.0) 
Males 14.3  
(7.6, 20.6) 
21.7  
(13.6, 29.0) 
44.6  
(34.6, 53.1) 
60.5  
(50.2, 68.7) 
 Females 13.9  
(6.9, 20.4) 
18.1  
(10.1, 25.3) 
41.8 
(31.3, 50.6) 
61.8  
(51.0, 70.2) 
* 
Standardized to reflect age, race and sex distribution of 2005 Medicare population; Age strata included 67-69, 70-74, 75-79, and > 
80. 
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Table 21. Mortality at 30-days, 1-year, and 2-years after incident PAD diagnosis in the outpatient (N=873) or inpatient (N=213) 
setting. The Atherosclerosis Risk in Communities Study, 2002-2010. 
 30-day mortality  
(95% CI) 
1-year mortality  
(95% CI) 
2-year mortality   
(95% CI) 
  Age-standardized 
model
*
 
Full model
†
 Age-
standardized 
model
*
 
Full model
†
 Age-
standardized 
model
*
 
Full model
†
 
Overall 
(N=1086) 
1.8  
(1.0, 2.5) 
1.5  
(0.8, 2.1) 
8.9 
(7.2, 10.5) 
7.8  
(6.1, 9.2) 
16.6 
(14.4, 18.7) 
15.1  
(13.0, 17.2) 
Incident 
Outpatient 
(N=873) 
0.8  
(0.2,1.4) 
0.7  
(0.2, 1.2) 
7.1  
(5.4, 8.7) 
6.3 
(4.8, 7.7) 
15.3  
(12.9, 17.6) 
13.7 
(11.4, 15.9) 
Incident 
Inpatient 
(N=213) 
5.7 
(2.6, 8.7) 
4.7  
(2.0, 7.3) 
16.0 
(11.0, 21.1) 
14.7 
(9.9, 19.3) 
21.5 
(15.8, 27.2) 
19.9 
(14.3, 25.5) 
* 
Standardized to reflect age, race and sex distribution of 2005 Medicare population; Age strata included 67-69, 70-74, 75-79, and > 
80.  
+
 Full adjusted model includes age, race, sex, income, education, diabetes, smoking, hyperlipidemia, hypertension, obesity, CHD, 
stroke, heart failure, ESRD, disease severity, self-rated health, and any-cause office visit in 1 year prior to diagnosis; Propensity 
models use 202 incident inpatient PAD events and 862 incident outpatient PAD events due to nonoverlap of 22 observations. 
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Figure 14. Age-standardized rates of race- and gender-specific PAD-related outpatient encounters (per person-year) following a PAD 
diagnosis, by diagnosis setting.  The ARIC study, 2002-2012  
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Figure 15. Age-standardized rates of race- and gender-specific outpatient primary care encounters (per person-year) following a PAD 
diagnosis, by diagnosis setting. The ARIC study, 2002-2012  
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Figure 16. Age-standardized rates of race- and gender-specific outpatient cardiology encounters (per person-year) following a PAD 
diagnosis, by diagnosis setting. The ARIC study, 2002-2012  
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Figure 17. Propensity Score-Adjusted* Cumulative Mortality, by setting 
 
  
*
 Propensity model includes age, race, sex, income, education, diabetes, smoking, hyperlipidemia, hypertension, obesity, CHD, 
stroke, heart failure, ESRD, disease severity, any-cause office visit in 1 year prior to diagnosis, and self-rated health 
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Supplemental Table 7. International Classification of Diseases, Ninth Revision (ICD-9-CM), Current Procedural Terminology, 4th 
edition (CPT-4), Healthcare Common Procedure Coding System (HCPCS), and Federally Qualified Healthcare Revenue Center 
(FQHC) codes used to identify peripheral artery disease and provider specialty visits in claims. 
Code Type Codes 
ICD-9-CM 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 440.32, 
440.4, 440.8, 440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
 
* 38.08, 38.16,, 38.18, 38.38, 38.48, 39.25, 39.29, 39.49, 39.50, 39.56, 39.57, 39.58, 39.90, 84.10, 84.12, 84.13, 84.14, 84.15 , 
84.16, 84.17, 84.18, 84.3, 84.91 
HCPCS/CPT-4 27295, 27590, 27591, 27592, 27594, 27596, 27598,27599,27880, 27881, 27882, 27888, 27889, 28800, 28805, 28810, 28820, 
28825, 35221, 35226, 35256, 35286, 35302, 35303, 35304, 35305, 35306, 35331, 35351, 35355, 35361, 35363, 35371, 35372, 
35381, 35452, 35454, 35456, 35459, 35470, 35472, 35473, 35474, 35480, 35481, 35482, 35483, 35485, 35490, 35491, 35492, 
35493, 35495, 35500, 35521, 35533, 35537, 35538, 35539, 35540, 35541, 35546, 35548, 35549, 35551, 35556, 35558, 35563, 
35565, 35566, 35583, 35585, 35587, 35621, 35623, 35646, 35647, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 35671, 
35681, 35682, 35700, 35875, 35876, 35879, 35881, 35883, 35884, 35903 
 
* 35683, 35686, 35571, 72191, 72198, 73706, 73725, 74175, 74185, 75630, 75631, 75635, 75710, 75711, 75712, 75716, 
75717, 75718, 93922, 93924, 93925, 93926, 93978, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 
99216, 99241, 99242, 99243, 99244, 99245, 99385, 99386, 99387, 99395, 99396, 99397 
 
Revenue Center Codes *0320,0321,0322,0323,0324,0329,0360,0361,0370,0371,0372,0379,0402,0490,0499,0510,0517,0519,0520,0521,0610,0616,07
10,0760, 0761,0762,0769,0921 
Provider Specialty Codes 
Primary Care Provider 
Cardiology 
Podiatry 
 
01, 08, 11, 50, 70 
06 
48 
* Must be accompanied with a PAD-related ICD-9-CM code 
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Supplemental Table 8. Median count of PAD-related encounters following a diagnosis of PAD in the outpatient or inpatient setting. 
The Atherosclerosis Risk in Communities Study, 2002-2010. 
 Incident Outpatient PAD  
(N=873) 
Incident Inpatient PAD 
(N=213) 
Median number of PAD-related outpatient visits (Q1, Q3)  
     Within six months of diagnosis 
     Within a year of diagnosis 
     Within two years of diagnosis 
 
1 (0, 2) 
2 (0, 3) 
3 (1, 6) 
 
0 (0, 1) 
1 (0, 2) 
1 (0, 3) 
Median number of primary care outpatient visits (Q1, Q3)  
     Within six months of diagnosis 
     Within a year of diagnosis 
     Within two years of diagnosis 
 
2 (1, 4) 
4 (2, 8) 
9 (4, 14) 
 
2 (1, 4) 
4 (1, 7) 
8 (3, 13) 
Median number of cardiology outpatient visits (Q1, Q3)  
     Within six months of diagnosis 
     Within a year of diagnosis 
     Within two years of diagnosis 
 
0 (0, 1) 
0 (0, 2) 
1 (0, 3) 
 
0 (0, 1) 
0 (0, 2) 
1 (0, 4) 
Median number of podiatry outpatient visits (Q1, Q3)  
     Within six months of diagnosis 
     Within a year of diagnosis 
     Within two years of diagnosis 
 
0 (0, 2) 
1 (0, 3) 
1 (0, 6) 
 
0 (0, 0) 
0 (0, 0) 
0 (0, 1) 
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CHAPTER 7. CONCLUSIONS AND PUBLIC HEALTH IMPLICATIONS 
Peripheral artery disease is a disabling atherosclerotic disorder that is expected to 
increase in prevalence as the population ages. Current estimates of PAD burden have not 
considered the setting of clinical encounter (inpatient versus outpatient setting) and estimates of 
outpatient burden are rare. The limited information regarding outpatient PAD clinical encounters 
has been a barrier to our understanding of the post-diagnosis health care associated with PAD, 
from initial diagnosis through clinic visits, admissions, and procedures. The specific aims of this 
dissertation, therefore, were to 1) estimate the prevalence and incidence of peripheral artery 
disease in the outpatient and inpatient settings; and 2) to estimate the frequency of health care 
encounters and mortality following an incident PAD diagnosis in the outpatient or inpatient 
setting. 
7.1 Methodologic Challenges Addressed 
 The existing literature regarding PAD burden contains widely varying estimates obtained 
using a variety of detection methods,  including ankle-brachial index measurement [41, 64] and 
self-report questionnaires [11, 67]. Administrative claims data sources are increasingly being 
used for research purposes and offer an opportunity to apply consistent disease definitions across 
studies [185]. Our study, in which we used PAD-related diagnostic codes identified from extant 
claims-based research, improves on the methodological sophistication of claims-based PAD 
research by providing burden estimates stratified by setting of diagnosis and by presenting data 
on the post-diagnosis care associated with a PAD diagnosis. Further methodologic improvements 
in our work apply to: 1) age standardizing to the age, race, and sex distribution of the Medicare 
 122 
population, 2) reducing misclassification bias through the use a washout (look-back) period 
according to current recommendations (2 years) to distinguish incident from prevalent cases of 
PAD [170], and 3) the use of codes from prior claims-based studies [169].  This study, therefore, 
represents reproducible and rigorous methodology and is accessible to the wider community of 
investigators.  
As a further methodologic point of significance, the literature commonly treats death as a 
non-informative censored event, meaning that subsequent hazard of death and the outcome of 
interest are independent conditional on covariates. We expected substantial mortality associated 
with a diagnosis of PAD, as well as informative censoring. Therefore, death was not treated as a 
censored event to avoid selection bias that could have led to mis-estimation of the outcome, and 
our analyses accounted for death as a competing risk using the cumulative incidence function.  
This analytic approach appears to be unique in the study of PAD. 
7.2 The Advantage of Linkage with the ARIC Cohort 
We further contribute to the extant claims-based assessments of PAD outcomes by our 
inclusion of comorbidity data. Prior claims-based studies of PAD have been based on 
information available in the claims data to estimate comorbid conditions [185], and as such, 
often  lacked critical information on covariates related to PAD.  Because our  study linked a well 
characterized longitudinal cohort study (ARIC) to CMS Medicare claims data we were able to 
draw on the rich level of information available for covariates from cohort examination visits and 
annual follow-up questionnaires [8].  As examples, we were able to include in this analysis 
important demographic traits, such as race, which are frequently missing in claims data [196], as 
well as information on the relationship of socioeconomic status to PAD, as we found that more 
than half of individuals with PAD had a low family income (<$35,000/year) and about 30% had 
less than a high school education. We were also able to use as study outcomes heart failure, 
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stroke, and coronary heart disease events from the cohort, classified according to a standardized 
protocol and reviewed by a panel of clinical experts, which increased the validity of our 
estimates relative to the use of ICD codes to define events, as often done with claims data.  
Lastly, the linkage of the ARIC cohort to the CMS claims data provided the opportunity to 
ascertain key differences between individuals diagnosed with PAD in the inpatient versus 
outpatient settings that would not have been possible from claims data alone. 
7.3 High Estimates of Burden and Frequency of Care Could Raise Awareness about PAD 
 Despite the known coexistence of PAD with other major circulatory system disorders 
[17, 34], health professional and public awareness of PAD is low in comparison with the 
awareness of  diseases such as stroke, CHD, heart failure, and atrial fibrillation [11, 171].  
Interestingly, our PAD prevalence estimates are similar to recent assessments of prevalence of 
stroke (5-6% in 60-79 year olds; 14-16% in 80+ year olds) and CHD (10-20% in 60-79 year 
olds, 19-32% in 80+ year olds) [181].  These findings support the National Cholesterol 
Education Program guidelines from the Adult Treatment Panel III, which considers the risk of 
ischemic events in those with PAD to be equivalent to the risk among those with CHD [197]. 
Still, while these estimates suggest a significant PAD burden, clinicians often do not evaluate for 
the presence of PAD. Furthermore, up to 50% of individuals with PAD are asymptomatic and 
might not be actively seeking PAD-related care [11].  Our claims-based estimates, which capture 
PAD in a clinical setting and would be unlikely to include asymptomatic PAD, therefore, are 
likely an underestimation of the prevalence and incidence of PAD in the Medicare-aged 
population.  While we found an overall mean age-standardized prevalence of 12.4% in those 65 
years of age and older, the prevalence of PAD could be much higher if asymptomatic disease had 
been identified. Still, participants with known PAD in our study were frequent utilizers of health 
care and had high mortality rates, particularly following an inpatient diagnosis.  By pointing to 
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the burden, utilization and mortality associated with PAD, we hope that the publications based 
on this dissertation work will bring increased awareness of PAD and that our work could lead to 
better identification and management of this important disease. 
7.4 High Mortality and Frequent Hospitalizations Following Inpatient PAD Diagnosis 
Highlights the Potential Importance of Early Identification, Screening, and Risk Factor 
Modification  
Participants with PAD frequently have coexisting symptomatic coronary or 
cerebrovascular disease and up to half could have underlying asymptomatic CVD [17].  These 
coexisting diseases share a risk factor profile, thus, controlling modifiable risk factors among 
participants with PAD can not only help prevent PAD progression, but could be beneficial in 
delaying myocardial infarction, stroke, and reducing cardiovascular-related mortality [35]. 
Despite the significance of PAD to individuals (reduced quality of life, frequent hospitalizations, 
high risk of death) and to the health care system, particularly if not identified early, the US Task 
Preventive Services Task Force (USPSTF) has recommended against routine screening for PAD 
[198]). The USPSTF concluded that screening led to marginal benefits to those with PAD while 
inducing unnecessary harms to the individual. We (and others) take issue with the Task Force 
recommendation, which uses improvement in leg symptoms as its benefits measure [199]. We 
would argue that screening for PAD, which requires a simple (and largely risk-free) ABI test 
(section 3.4), could lead to early identification of these atherosclerotic diseases and patients 
could be placed into a lifestyle intervention program and managed with guideline recommended 
medications, to reduce the risk of these major cardiovascular adverse events [200].  While we 
agree with the USPSTF that routine screening on the entire population would produce little 
benefit, at a minimum, we concur with the American Diabetes Association’s recommendation 
that all diabetics be screened for PAD every five years for life [136].  In addition,  when paired 
with other recent PAD studies our results suggest the potential benefit of periodic screening for 
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PAD of high risk individuals 65 years of age and older, including smokers and those with a 
history of CVD, particularly given the increased risk of adverse cardiovascular events that 
individuals with PAD are known to have [35].  We note however that our data do not directly 
address the pros and cons of screening strategies of this kind. 
7.5 Limitations Leading to Future Work  
Limitations we experienced in our research point to areas of future work. Our original 
aims included consideration of burden and post-diagnosis care estimates by PAD subtypes, 
including lifestyle-limiting claudication and critical limb ischemia. Were however limited to 
claims data for the ARIC cohort, to the exclusion of the broader epidemiologic community 
surveillance data, resulting in a study size too small to stratify by subtype. CLI remains a disease 
for which there is a significant need for research regarding incidence and outcomes, particularly 
as the locus of PAD management is shifting to outpatient settings.  
We encountered similar sample size issues in our estimates stratified by race-gender 
groups, limiting our ability to draw conclusions regarding disparities in PAD and PAD-related 
care.  Our overall findings do point to racial differences in the prevalence and incidence of PAD, 
with blacks having higher burden as compared to whites. Blacks had a lower time to first 
hospitalization as compared to whites, although confidence intervals were imprecise. The 
analysis we conducted should be replicated in other settings and with larger sample sizes. 
7.6 Validation Studies and PAD Misclassification 
To date there have been no studies that validate a full range of diagnostic codes used to 
quantify inpatient and outpatient PAD, an important gap in the current literature [158].  As part 
of this dissertation research the classification of PAD based on claims records was compared to 
information from hospitalization record abstraction and self-reported PAD on annual telephone 
interviews of the ARIC cohort members.   We developed a hospital record abstraction form (see 
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Appendix 1) to evaluate incident hospitalized PAD events obtained from hospital discharge data 
available for ARIC cohort participants.  Comparability ratios were calculated from these data as 
a direct estimate of the bias from using ICD-9-CM codes to define inpatient PAD events (under 
the assumption that our validation protocol is the gold standard). We found that misclassification 
of PAD using ICD-9-CM codes, particularly those in the primary or second position, is minimal. 
We also estimated calibration factors associated with outpatient PAD occurrence by estimating 
concordance between information on self-reported PAD events available from the ARIC annual 
follow-up (AFU) and outpatient PAD identified from the CMS claims. Poor agreement was 
found between claims-based outpatient PAD and the self-reported, physician-diagnosed PAD 
and/or lower extremity revascularization, suggesting the need for a more comprehensive 
evaluation of the reproducibility and accuracy of self-report to identify PAD recorded in CMS 
Medicare claims records. 
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7.7 Conclusion   
Individuals aged 65 years and older enrolled in CMS claims for fee-for-service program 
experience high prevalence and incidence of PAD, particularly for PAD identified in the 
outpatient setting:  the mean age-standardized prevalence and incidence of outpatient PAD were 
11.8% and 22.4 per 1000 person-years, respectively.  Black individuals have higher mean age-
standardized prevalence and incidence compared to whites, 15.6% vs. 11.4%, and 31.3 vs. 25.4 
per 1000 person-years, respectively. Individuals diagnosed in the outpatient setting have lower 
mortality than individuals diagnosed in the inpatient setting. Individuals who are initially 
managed in the outpatient setting represent a group that could be targeted to prevent expensive 
hospitalizations, PAD-related complications such as limb amputation, and major cardiovascular 
events. Effective prevention of PAD and its sequelae in blacks represents an important area of 
persisting disparities to be addressed. Finally, up to half of individuals with PAD remain 
asymptomatic, a group with subclinical disease for whom early detection via screening could 
lead to preventive care and management to lower risks of long-term adverse health outcomes. 
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APPENDIX 1: CALIBRATION ANALYSES 
Inpatient Calibration 
 
 All incident hospitalized PAD events (n=71) that took place during the calendar year 2007 
among ARIC cohort participants were eligible for review. Sixty-four (90.1%) of the 71 requested 
records were located at the ARIC field centers and sent securely to the investigators. Records for 
two events were incomplete and were excluded from this analysis. Five additional records were 
excluded from this analysis because they were part of the training/calibration of reviewers. The 
remaining fifty-seven records were examined and classified by two reviewers. Forty events were 
classified as definite/probable PAD, establishing a positive predictive value of 70.2% (40/57). 
Appendix Table 1. Adjudication of PAD-related hospitalizations 
 Validated PAD (Adjudication)  
Test Result  Yes No Row sum 
ARIC PAD hospitalization a = 40 b = 17 r1 = 57 
ARIC Non-PAD hospitalization c = 20 d = 523 r2 = 543 
Column sum c1 = 60 c2 = 540 N = 600* 
* N can vary depending on prevalence assumption 
 
 Given a sensitivity of 0.67 we calculate an expected specificity of 0.97 and a comparability 
ratio of 0.95. The comparability ratio is a direct estimate of the bias found in using ICD-9-CM 
codes to define PAD events (under the assumption that our validation protocol is the gold 
standard and correct). With a comparability ratio of 0.95 (for sensitivity=0.67), inpatient PAD 
defined by ICD-9-CM codes (as they are in CMS claims) underestimates events by 5% in our 
ARIC population.    
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Appendix Table 2. Comparability ratios based on empirical estimates of sensitivity from 
literature 
Given estimated 
sensitivity 
a b c d Calculated 
specificity 
Calculated 
comparability ratio 
0.40 40 17 60 483 0.97 0.57 (57/100) 
0.50 40 17 40 503 0.97 0.71 (57/80) 
0.60 40 17 27 516 0.94 0.85 (57/67) 
0.70 40 17 17 526 0.93 1.0 (57/57) 
0.80 40 17 10 533 0.91 1.14 (57/50) 
 
Outpatient Calibration 
 
 We estimated the concordance between PAD events in the CMS claims and a positive 
answer to the PAD-related question in the self-reported ARIC annual follow-up questionnaire.  
Among 7136 participants, we found 183 positive PAD events in the AFU. Of those 183 events, 
76 were simultaneously identified in the claims. Another 717 events were identified in claims 
that were not found in ARIC AFU responses. Overall, we found a prevalence and bias adjusted 
kappa (PABAK) of 0.42. We found poor agreement between claims and the self-report AFU to 
identify PAD events. 
Appendix Table 3. Agreement between self-report PAD and PAD identified in claims 
 PAD Event in Claims 
Questionnaire  Yes No Row sum 
Positive  a = 76 b =107  r1 = 183 
Negative c = 717 d = 6236 r2 = 6953 
Column sum c1 = 793 c2 = 6343 N = 7136 
PABAK=0.42 
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PERIPHERAL ARTERY DISEASE DIAGNOSIS (PADX) FORM 
 
a. Reviewer initials:                 b. Event ID:   
 
 
 Yes, 
current 
Yes, 
history 
No/ 
 NR 
1. Did the patient ever have any of the following 
diagnoses/symptoms:          
   
     1a. Claudication (LE pain with walking)?    
     1b. Critical limb ischemia, gangrene, ulcer due to ischemia?     
     1c. Lower extremity wound or ulcer?    
     1d. IF YES, Was this diagnosed as a diabetic ulcer?    
     1e. Diabetes?    
     1f. Peripheral neuropathy?    
     1g. Edema?    
     1h. Diminished pulses?    
     1i. Peripheral arterial disease?    
          If YES, was PAD only documented as due to:    
                   1j. Carotid/cerebrovascular    
                   1k. Abdominal Aortic Aneurysm (AAA)    
                   1l. Renal artery disease    
 
Diagnostic Tests 
   
2a. Was an exercise test performed?     
      2b. If YES, was test positive for claudication?    
3a. Was an ankle brachial index (ABI) performed?    
      3b. If YES, was ABI < 0.90?    
4a. Was LE angiography/CT angiography performed?    
4b. If YES, did angiography show a blockage or plaque?    
 
Procedures 
   
5. Ever had LE angioplasty or stent?    
6. Ever had LE surgical revascularization?    
7. Ever had LE amputation?    
 
 
Reviewer Classification Definite Probable PAD 
unlikely 
Unclassifiable 
8a. Does the patient have PAD?     
8b. If definite or probable, is it CLI?      
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Question-by-Question Instructions for Peripheral Artery Disease Final Diagnosis Form 
A Peripheral Artery Disease Diagnosis Form (PADX) is completed for each ARIC PAD 
hospitalization. The goal of this review is to be specific rather than too sensitive. Events are 
hospitalized events only. Your materials for each case will include: the PADX form, medical 
record documents such as a discharge summary, history and physical exam, and consults. PAD 
diagnosis refers to atherosclerotic disease in the iliac arteries or below; PAD includes a variety of 
diagnoses including (but not limited to) intermittent claudication, ischemic ulcers, gangrene and 
treatments including angioplasty, surgery, or amputation. 
Complete only one PADX for each event. 
Items: Review of PAD Diagnosis 
Review information provided to determine if this event meets criteria for PAD event. PAD will 
be classified as definite PAD, probable PAD, no PAD, or unclassifiable based on the following 
criteria: 
Based on your review of the medical record documents provided, indicate either Yes or 
No/Unknown for this criteria.  
SECTION I: DIAGNOSES/SYMPTOMS 
This section includes symptoms/physical exam findings or diagnoses associated with 
peripheral artery disease that may be present in the admission history and physical or the 
physician consult notes.  
1. Did the patient ever have any of the following diagnoses or symptoms/findings? 
1a. Claudication 
Review the medical record for statements regarding claudication when walking any distance. 
Alternative wordings that are sufficient to record ‘YES’ include: tired legs after walking, 
complains of leg weakness after walking, exertional leg pain relieved at rest, lower extremity 
cramping. Record ‘YES, current’ if this is an active problem. Record ‘Yes, history’ if this is a 
historical problem. Record ‘No/NR’ if only weak legs are described or if the claudication is 
neurogenic or if a spinal stenosis is mentioned. 
1b. Critical limb ischemia, gangrene, ulcer due to ischemia 
Review the medical record for statements regarding critical limb ischemia. Synonyms include: 
limb threatening ischemia. Other diagnoses that are relevant to record ‘YES’ include: rest pain, 
pain at rest, tingling in the foot/toes relieved with dangling the extremity, tissue loss of the lower 
extremities, ulceration of the toe/foot/leg/calf/shin/thigh/heel, diabetic foot ulcer, open leg 
wound, lower extremity necrosis, gangrene. Record ‘YES, current’ if this is an active problem. 
 132 
Record ‘Yes, history’ if this is a historical problem.  Record ‘No/NR’ if upper extremity 
mentioned or if there is no mention of the above terms. 
1c. Lower extremity wound or ulcer 
Review the medical record for statements regarding lower extremity wounds or lower extremity 
ulcers. Record ‘YES, current’ if this is an active problem.  Record ‘Yes, history’ if this is a 
historical problem. Record ‘No/NR’ if there is no mention of LE wounds or ulcers.  Record no if 
wound is due to trauma. 
1d. If ‘YES’, was this diagnosed as a diabetic foot ulcer? 
Review the medical record for statements regarding diabetic foot ulcers Record ‘YES, current’ if 
this is an active problem.  Record ‘Yes, history’ if this is a historical problem. Record ‘No/NR’ if 
there is no mention of diabetic foot ulcer.  
1e. Diabetes 
A history of diabetes includes a history of previous hospitalizations for ketoacidosis, 
hyperosmolar coma, or out of control glucose levels and those with juvenile onset diabetes, 
brittle diabetes, or diabetes treated with insulin or oral hypoglycemic drugs, a history of type I 
diabetes, a history of type II diabetes and current treatment with an oral hypoglycemic or insulin. 
If newly diagnosed during this hospitalization, consider this as a current problem and record 
‘Yes, current’. Record ‘YES, current’ if this is an active problem.  Record ‘Yes, history’ if this is 
a historical problem. Record ‘No/NR’ if there is no mention of diabetes.  
Synonyms: insulin dependent diabetes (IDDM), non-insulin dependent diabetes (NIDDM), 
diabetes mellitus (DM). 
1f. Peripheral neuropathy 
Review the medical record for statements regarding peripheral neuropathy. Synonyms include 
lower extremity neuropathy, diabetic neuropathy, and neuropathy.  Record ‘YES, current’ if this 
is an active problem.  Record ‘Yes, history’ if this is a historical problem. Record ‘No/NR’ if 
there is no mention of neuropathy.  
1g. Lower extremity edema 
Review the medical record for statements regarding lower extremity edema. Synonyms include: 
LE edema, peripheral edema, swollen ankles, 1+, 2+, 3+, 4+ pitting, nonpitting edema, trace, 
brawny edema. Record ‘YES, current’ if this is an active problem.  Record ‘Yes, history’ if this 
is a historical problem. Record ‘No/NR’ if there is no mention of edema.  
1h. Does the patient have diminished or absent pulses? 
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Review the “EXTREMITIES” section of the review of symptoms within the H&P for statements 
regarding diminished or absent pulses in the lower extremity arteries including: femoral, 
popliteal, tibial (posterior, anterior), peroneal, and dorsalis pedis. If pulses noted as 1+, 2+, 3+ 
pulses then they are not diminished and you should record ‘No/NR’. Record ‘YES, current’ if 
this is an active problem.  Record ‘Yes, history’ if this is a historical problem. Record ‘No/NR’ if 
there is no mention of diminished pulses.  
1i. Peripheral arterial disease 
Record ‘YES’ if the patient has a history of peripheral artery disease (PAD). This condition may 
also be referred to as peripheral vascular disease (PVD), which includes atherosclerotic disease 
of the arteries in the legs and arms. Synonyms include intermittent claudication, lower extremity 
arterial disease (LEAD). PVD does NOT include carotid or renal disease, however sometimes 
people refer to such disease as PAD. If stated to have PAD due to carotid, renal, or AAA then 
answer YES, then answer questions below.  Record ‘YES, current’ if this is an active problem.  
Record ‘Yes, history’ if this is a historical problem. Record ‘No/NR’ if there is no mention of 
PAD.  
If ‘YES’, was PAD only documented due to: 
1j. Carotid/cerebrovascular disease? 
Only answer YES here if the person does not have PAD in a peripheral location, but only the 
carotids or cerebrovascular area that is likely the source of the PAD diagnosis.  Record ‘YES, 
current’ if this is an active problem.  Record ‘Yes, history’ if this is a historical problem. Record 
‘No/NR’ if there is no mention of this.  
1k. Abdominal Aortic Aneurysm (AAA)? 
Only answer YES here if the person does not have PAD in a peripheral location, but only has an 
AAA that is likely the source of the PAD diagnosis.  Looking for PAD mentioned with an AAA 
manifestation. Record ‘YES, current’ if this is an active problem.  Record ‘Yes, history’ if this is 
a historical problem. Record ‘No/NR’ if there is no mention of AAA.  
1l. Renal artery disease? 
Only answer YES here if the person does not have PAD in a peripheral location, but only in 
renal vasculature that is likely the source of the PAD diagnosis.  Record ‘YES, current’ if this is 
an active problem.  Record ‘Yes, history’ if this is a historical problem. Record ‘No/NR’ if there 
is no mention of renal artery disease or if this manifestation is only end-stage renal disease 
(ESRD). 
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SECTION II: DIAGNOSTIC TESTS 
The purpose of this section is to determine if any diagnostic tests were completed relating 
to the lower extremity arteries.  
2a. Was an exercise test performed? 
Record ‘YES, current’ if there is evidence that an exercise test was performed during this 
admission/hospitalization. Record ‘Yes, history’ if there is evidence that an exercise test was 
performed from a prior office visit/hospitalization. 
2b. If ‘YES’, was the test positive for claudication? 
Record ‘YES’ if the test results indicate claudication.  
3a. Was an ankle brachial index test performed? 
Record ‘YES, current’ if there is evidence that an ankle brachial index test was performed during 
this admission/hospitalization. Record ‘YES, history’ if there is evidence that an ABI was 
performed during a prior office visit/hospitalization. 
3b. If ‘YES’, was the ankle-brachial systolic blood pressure ratio < 0.90? 
Record ‘YES’ if the test revealed an ABI of < 0.90 in either leg. 
4a. Was angiography of the lower extremity performed? 
A lower extremity angiogram is a test of the lower extremity arteries where a catheter is inserted 
into an artery and advance to the lower extremity arteries to assess for blockages. Synonyms 
include: lower extremity catheterization, arteriography. Record ‘YES, current’ if there is 
evidence that angiography of the lower extremity was performed during this 
admission/hospitalization. If a person had a percutaneous transluminal angioplasty (PTA) record 
‘YES’. If a person had CT angiography of the lower extremities, record ‘YES’. Record ‘Yes, 
history’ if there is evidence of lower extremity angiography performed in a prior 
admission/hospitalization. Record ‘No/NR’ if there is no mention of this procedure. 
4b. If ‘YES’, did the angiography demonstrate a plaque > 50% diameter or > 75% of cross-
section of artery) 
Record ‘YES’ if the angiography demonstrates a plaque > 50% diameter or > 75% of cross-
section of artery). 
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SECTION III: THERAPEUTIC PROCEDURES 
5. Has the patient ever had a percutaneous transluminal angioplasty/stent procedure performed 
on a lower extremity artery? 
Angioplasty is a procedure used to dilate (widen) narrowed arteries. A catheter with a deflated 
balloon angioplasty on its tip is passed into the narrow artery segment, the balloon inflated, and 
the narrow segment widened. Angioplasties can now also be done by laser. To keep arteries from 
collapsing, stents (stainless steel supports) can be inserted into the artery during angioplasty. 
This interventional procedure is often performed electively when the presence of severe 
blockages that needs to be treated. PTA may also include thrombolysis which involves injecting 
clot-busting medicine directly into the artery. An unsuccessful PTA or stent procedure in the past 
should be recorded as ‘YES‘ for history of PTA. Synonyms include percutaneous angioplasty, 
balloon dilation, balloon test.  
Lower extremity arteries include the abdominal aorta, iliac (common, external, internal), femoral 
(superficial, deep, profunda), popliteal (above knee, below knee), tibial (anterior, posterior), 
tibioperoneal trunk, or the dorsalis pedis. Record ‘YES’ if there is evidence that this treatment 
was performed. 
Record ‘YES, current’ if this is procedure occurred during this admission/hospitalization.  
Record ‘Yes, history’ if this is a historical procedure. Record ‘No/NR’ if there is no mention of a 
procedure.  
6. Has the patient ever had a surgical revascularization performed on a lower extremity artery? 
Surgical revascularization includes lower extremity bypass or endarterectomy.  Endarterectomy 
is surgery to take out plaque from an artery.  Locations include: Aortic/Iliac endarterectomy, 
Femoral endarterectomy, Popliteal/Tibial endarterectomy. Bypass is a procedure where 
additional blood flow is brought to an artery via a bypass from a location elsewhere in the body. 
Bypass possibilities include: Aorto-iliac, Aorto-femoral, Femoral to popliteal, Femoral-tibial, 
Popliteal-tibial, and Tibial to tibial). Record ‘YES, current’ if there is evidence that this 
treatment was performed during this admission/hospitalization. Record ‘YES, history’ if there is 
evidence that this treatment was performed during a prior admission/hospitalization. Record 
‘No/NR’ if there is no mention of a procedure.  
7. Has the patient ever had an amputation? 
Amputation is a procedure in which part of the extremity is removed. Options include: toe(s), 
transmetatarsal, forefoot, chopart, below-knee (BKA), through-knee (TKA), above-knee (AKA), 
or hip disarticulation. Record ‘YES, current’ if there is evidence that this treatment was 
performed. Record ‘YES, history’ if there is evidence that this treatment was performed during a 
prior admission/hospitalization. Record ‘No/NR’ if there is no mention of a procedure.  
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SECTION IV: REVIEWER CLASSIFICATION 
8a. Does the patient have PAD? 
Classification is: DEFINITE, PROBABLE, PAD UNLIKELY, or UNCLASSIFIABLE. 
If recorded ‘Yes, current’ or ‘Yes, history’ for any of the following: 1a, 1b, 1c, 2b, 3a, 4a 
classification is DEFINITE.  If recorded ‘Yes, current’ or ‘Yes, history’ for 5, 6, or 7 AND any 
of the following: 1a, 1b, 1c, 2b, 3a, 4a classification is DEFINITE. If recorded ‘Yes, current’ or 
‘Yes, history’ for 1i AND ‘No/NR’ for 1j, 1k, 1l, classification is DEFINITE. 
If recorded ‘Yes, current’ or ‘Yes, history’ for 1g or 1h, classification is PROBABLE. If 
recorded ‘Yes, current’ or ‘Yes, history’ for 5, 6, or 7 and ‘No/NR’ for all of the following: 1a, 
1b, 1c, 2b, 3a, 4a, classification is PROBABLE. 
If recorded ‘No/NR’ for 1a, 1b, 1c, 1i, 2b, 3a, 4a, 5, 6, AND 7, classification is PAD 
UNLIKELY. If recorded ‘Yes, current’ or ‘Yes, history’ for 1j, 1k, 1l then classification is PAD 
UNLIKELY. 
Otherwise classification is UNCLASSIFIABLE. 
8b. If definite or probable, is it CLI? 
Classification is: DEFINITE, PROBABLE, CLI UNLIKELY, or UNCLASSIFIABLE. 
If recorded ‘Yes, current’ or ‘Yes, history’ for 1b OR “1c or 1d AND 1i” OR “5, 6, or 7 AND 
1b, 1c, or 1d”, classification is DEFINITE. 
If recorded ‘No/NR’ for 1b, 1c then CLI UNLIKELY. 
Otherwise classification is UNCLASSIFIABLE 
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APPENDIX 2: DEFINITIONS OF PAD CODES 
CD-9-CM Diagnosis Codes for PAD: Definitions 
Description Code 
Atherosclerosis: 
of native arteries of the extremities  
of bypass graft of the extremities  
of other specified arteries  
 
440.2x 
440.3x 
440.8x 
Generalized and unspecified atherosclerosis:  
arteriosclerotic vascular disease NOS 
Peripheral vascular disease, unspecified  
 
440.9× 
443.9x 
 
ICD-9-CM Surgical/Intervention Procedure Codes for PAD: Definitions 
Description Code 
Amputation of lower limb  
Amputation not otherwise specified  
Aorta-iliac-femoral bypass  
Other (peripheral) vascular shunt or bypass  
Incision of lower limb arteries  
Endarterectomy, lower limb arteries  
Resection of vessel with anastomosis, lower limb arteries   
Resection of vessel with replacement, lower limb arteries  
Other excision of vessels, lower limb arteries  
Other revision of vascular procedure  
Angioplasty or atherectomy of other non-coronary vessel(s) Insertion of non-drug-
eluting peripheral vessel stent(s)  
Repair of blood vessel with tissue patch graft  
Repair of blood vessel with synthetic patch graft  
Repair of blood vessel with unspecified type of patch graft 
84.1x 
84.91  
39.25 
39.29 
38.08 
38.18 
38.38 
38.48 
38.68 
39.49 
39.50 
39.90 
39.56 
39.57 
39.58 
 
ICD-9-CM Diagnostic Procedure Codes for PAD: Definitions 
Description Code 
Other diagnostic procedures on blood vessels  
Aortography 
Arteriography of femoral and other lower extremity arteries Diagnostic ultrasound 
of peripheral vascular system  
38.29 
88.42 
88.48 
88.77 
 
CPT-4 codes for PAD-related surgical or intervention procedures: Definitions 
Description Code 
Repair blood vessel lower extremity; 
direct  
with vein graft  
with graft other than vein  
 
35226 
35256 
35286 
Thromboendarterectomy, including patch graft, if performed; superficial femoral artery  
popliteal artery  
tibioperoneal trunk artery  
tibial or peroneal artery, initial vessel  
each additional tibial or peroneal artery  
 
35302 
35303 
35304 
35305 
35306 
Thromboendarterectomy, with or without patch graft;   
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abdominal aorta (35331); 
 iliac (35351);  
iliofemoral (35355);  
combined aortoiliac (35361);  
combined aortoiliofemoral (35363);  
common femoral (35371);  
deep (profunda) femoral (35372);  
femoral and/or popliteal, and/or tibioperoneal (35381) 
35331 
35351 
35355 
35361 
35363 
35371 
35372 
35381 
In-situ vein bypass;  
aortofemoral-popliteal (only femoral-popliteal portion in-situ)  
femoral-popliteal  
femoral-anterior tibial, posterior tibial, or peroneal artery  
popliteal-tibial, peroneal  
 
 
35582 
35583 
35585 
35587 
Bypass graft, with vein;  
axillary-femoral  
axillary-femoral-femoral  
aortoiliac  
aortobi-iliac  
aortofemoral  
aortobifemoral  
aortoiliac or bi-iliac  
aortofemoral or bifemoral  
aortoiliofemoral, unilateral  
aortoiliofemoral, bilateral  
aortofemoral-popliteal  
femoral-popliteal  
femoral-femoral 
 ilioiliac  
 iliofemoral  
femoral-anterior tibial, posterior tibial, peroneal artery or other distal vessels  
popliteal-tibial,-peroneal artery or other distal vessels  
 
35521 
35533 
35537 
35538 
35539 
35540 
35541 
35546 
35548 
35549 
35551 
35556 
35558 
35563 
35565 
35566 
35571 
Percutaneous:  
aortic  
iliac  
femoral-popliteal  
tibioperoneal trunk and branches 
 
35491 
35492 
35493 
35495 
Transluminal peripheral atherectomy, Open:  
aortic  
iliac  
femoral-popliteal  
tibioperoneal trunk and branches 
 
35481 
35482 
35483 
35485 
Transluminal balloon angioplasty, percutaneous;  
tibioperoneal trunk and branches, each vessel  
aortic  
iliac  
femoral-popliteal  
 
35470 
35472 
35473 
35474 
Transluminal balloon angioplasty, open;  
aortic (35452);  
iliac (35454);  
femoral-popliteal (35456);  
 
35452 
35454 
35456 
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tibioperoneal trunk and branches (35459);  35459 
Bypass graft, with other than vein;  
axillary-femoral  
axillary-popliteal or –tibial  
aortoiliac  
aortobi-iliac  
aortoiliac or bi-iliac  
aortofemoral or bifemoral 
aortofemoral  
aortofemoral-popliteal  
axillary-femoral-femoral  
femoral-popliteal  
femoral-femoral  
ilioiliac  
iliofemoral  
femoral-anterior tibial, posterior tibial, or peroneal artery  
popliteal-tibial or -peroneal artery  
 
35621 
35623 
35637 
35638 
35641 
35646 
35647 
35651 
35654 
35656 
35661 
35663 
35665 
35666 
35671 
Exploration, reoperation, femoral-popliteal or femoral (popliteal) -anterior tibial, 
posterior tibial, peroneal artery or other distal vessels, more than one month after original 
operation (List separately in addition to code for primary procedure)  
 
 
35700 
Exploration (not followed by surgical repair), with or without lysis of artery;  
femoral artery  
popliteal artery  
  
35721 
35741 
Thrombectomy of arterial or venous graft, with revision of arterial or venous graft 35876 
Revision, lower extremity arterial bypass, without thrombectomy, open;  
with vein patch angioplasty  
with segmental vein interposition 
 
35879 
35881 
Revision, femoral anastomosis of synthetic arterial bypass graft in groin, open;  
with non autogenous patch graft (e.g., Dacron, ePTFE, bovine pericardium)  
with autogenous vein patch graft  
 
35883 
35884 
Primary percutaneous transluminal mechanical thrombectomy, noncoronary, arterial or 
arterial bypass graft, including fluoroscopic guidance and intra procedural 
pharmacological thrombolytic injection(s);  
initial vessel  
second and all subsequent vessel(s) within the same vascular family (List separately in 
addition to code for primary mechanical thrombectomy procedure)  
 
 
 
37184 
 
37185 
Secondary percutaneous transluminal thrombectomy (e.g., non primary mechanical, 
snare basket, suction technique), noncoronary, arterial or arterial bypass graft, including 
fluoroscopic guidance and intra procedural pharmacological thrombolytic injections, 
provided in conjunction with another percutaneous intervention other than primary 
mechanical thrombectomy (List separately in addition to code for primary procedure)  
 
 
 
 
37186 
Transcatheter placement of an intravascular stent(s), (except coronary, carotid, and 
vertebral vessel), percutaneous; 
initial vessel (37205) 
each additional vessel (List separately in addition to code for primary procedure) 
 
 
37205 
37206 
Transcatheter placement of an intravascular stent(s), (except coronary, carotid, and 
vertebral vessel), open; 
each additional vessel (List separately in addition to code for primary procedure)  
 
 
37208 
Disarticulation;  
of hip   
 
27295 
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at knee  
of ankle   
27598 
27889 
Amputation, thigh, through femur, any level   
immediate fitting technique including first cast  
open, circular (guillotine)  
leg, through tibia and fibula  
with immediate fitting technique including application of first cast  
open, circular (guillotine)  
ankle, through malleoli of tibia and fibula (e.g., Syme, Pirogoff type procedures), with 
plastic closure and resection of nerves  
foot; midtarsal (e.g., Chopart type procedure)  
transmetatarsal  
27590 
27591 
27592 
27880 
27881 
27882 
 
27888 
28800 
28805 
 
CPT-4 codes for PAD-related diagnostic procedures: Definitions 
Description Code 
Aortography:  
abdominal plus bilateral iliofemoral lower extremity, catheter, by serialography, radiological  
complete procedure  
 
 
 
75630 
75631 
Angiography, extremity, unilateral, radiological supervision and interpretation  
complete procedure  
bilateral; by serialography, complete procedure  
radiological  
without serialography; complete procedure 
by serialography, complete procedure  
75710 
75711 
75712 
75716 
75717 
75718 
Arterial duplex of the lower extremities,  
unilateral  
bilateral  
aorta  
 
93925 
93926 
93978 
CT Angiogram Abdomen with & w/o contrast  
Pelvis  
Lower Extremity  
abdominal aorta and bilateral iliofemoral lower extremity runoff  
74175 
72191 
73706 
75635 
MRA abdomen images from the diaphragm to the umbilicus or iliac crest 
Pelvis  
 
74185 
72198 
Lower extremity w/ or w/o contrast  73725 
Non-invasive physiologic studies of lower extremity arteries, single level, bilateral  
at rest and following treadmill stress testing, complete bilateral study 
93922 
93924 
 
Other PAD-related codes not included in the Mayo algorithm: Definitions 
Description Code 
Atherosclerosis of aorta 440.0 
Chronic total occlusion of artery of the extremities 440.4 
Arterial embolism and thrombosis of lower extremity 444.22 
Embolism and thrombosis of iliac artery 444.81 
Atheroembolism of lower extremity 445.02 
Diabetes with peripheral circulatory disorders, Type II or unspecified type, not stated as 
uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), not stated as 
uncontrolled 
250.70 
 
 
250.71 
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Diabetes with peripheral circulatory disorders, Type II or unspecified type, uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), uncontrolled 
 
250.72 
250.73 
Unspecified ulcer of lower limb: 
of thigh 
of calf 
of ankle 
of heel and midfoot 
of other part of foot 
of other part of lower limb 
707.10 
707.11 
707.12 
707.13 
707.14 
707.15 
707.19 
Gangrene 785.4 
Endarterectomy, abdominal arteries 38.16 
Other surgical occlusion of vessels, lower limb arteries 38.88 
 
Exclusion codes for non-atherosclerotic vascular disease: Definitions  
Description Code 
Neurofibromatosis  
Buerger’s disease  
Polyarteritis nodosa  
Wegener's granulomatosis  
Giant cell arteritis  
Thrombotic microangiopathy  
Takayasu's disease  
Arteritis, unspecified  
Systemic sclerosis  
Coarctation of the aorta  
 Lower limb vessel anomaly  
Atresia and stenosis of aorta  
237.7 
443.1 
446.0 
446.4 
446.5 
446.6 
446.7 
447.6 
710.1 
747.1 
747.64 
747.22 
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Exclusion codes for lower extremity trauma/injury and others: Definitions  
Description Code 
Acquired deformities of hip  
Genu valgum or varum (acquired)  
Genu recurvatum (acquired)  
Other acquired deformities of knee  
Other acquired deformities of ankle and foot  
Acquired deformities of other parts of limbs  
Acquired deformity of limb, site unspecified  
Acquired deformities of toe  
Congenital dislocation of hip   
Congenital genu recurvatum and bowing of long bones of leg  
Varus deformities of feet  
Valgus deformities of feet  
Other deformities of feet  
Other congenital anomalies of toes  
Syndactyly of toes without fusion of bone   
Syndactyly of toes with fusion of bone   
Reduction deformities of lower limb   
Reduction deformities, unspecified limb  
Other anomalies of lower limb, including pelvic girdle  
Other specified anomalies of unspecified limb  
Multiple congenital anomalies, so described   
Other and unspecified congenital anomalies  
736.3x 
736.4x 
736.5 
736.6 
736.7x 
736.8x 
736.9 
735.x 
754.3x 
754.4x 
754.5x 
754.6x 
754.7x 
755.02 
755.13 
755.14 
755.3 
755.4 
755.6x 
755.8 
759.7 
759.89 
Fracture of lower limb  820.xx - 
829.xx  
Dislocation;  
of hip  
of knee  
of ankle  
of foot  
 
835.xx 
836.xx 
837.xx 
838.xx 
Traumatic amputation;  
of toe(s), complete/partial  
of foot, complete/partial  
of leg(s) complete/partial  
 
895.xx 
896.xx 
897.xx 
Injury to blood vessels of lower extremity and unspecified sites  904.xx 
Crushing injury;  
of lower limb  
of multiple and unspecified sites  
 
928.xx 
929.xx 
Injury, hip and thigh  
Injury, knee, leg, ankle, and foot   
959.6 
959.7 
Mechanical complication of internal orthopedic device, implant, and graft   996.4 
Complications peculiar to certain specified procedures due to internal joint prosthesis  
Complications due to other internal orthopedic device, implant and graft  
Other complications of internal (biological) (synthetic) prosthetic device, implant, and 
graft (due to internal joint prosthesis) 
Complications due to other internal orthopedic device, implant, and graft  
 
996.66 
996.67 
 
996.77 
996.78 
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Exclusion codes for non-PAD indication of amputation: Definitions  
Description Code 
Malignant neoplasm of pelvic bones, sacrum, and coccyx  170.6 
Malignant neoplasm of bone and articular cartilage;  
long bones of lower limb  
short bones of lower limb  
Malignant neoplasm of bone and articular cartilage  
 
170.7 
170.8 
170.9 
Malignant neoplasm of connective and other soft tissue (lower limb, including 
hip)  
Malignant melanoma of skin; lower limb, including hip  
Other malignant neoplasm of skin; skin of lower limb, including hip  
Secondary malignant neoplasm of other specified sites (bone and bone marrow)  
 
171.3 
172.7 
173.7 
198.5 
Paraplegia  
Pyogenic arthritis  
Necrotizing fasciitis  
Cyst of bone  
344.1 
711.0 
728.86 
733.2 
Acquired deformities of hip  
Genu valgum or varum (acquired)  
Genu recurvatum (acquired) 
Other acquired deformities of knee  
Other acquired deformities of ankle and foot  
Acquired deformities of other parts of limbs  
Acquired deformity of limb, site unspecified  
Acquired deformities of toe  
Congenital dislocation of hip  
Congenital genu recurvatum and bowing of long bones of leg  
Varus deformities of feet  
Valgus deformities of feet  
Other deformities of feet  
Other congenital anomalies of toes  
Syndactyly of toes without fusion of bone  
Syndactyly of toes with fusion of bone  
Reduction deformities of lower limb  
Reduction deformities, unspecified limb  
736.3x 
736.4x 
736.5 
736.6 
736.7 
736.8 
736.9 
735.x 
754.3x 
754.4x 
754.5 
754.6x 
754.7x 
755.02 
755.13 
755.14 
755.3 
755.4 
Other anomalies of lower limb, including pelvic girdle  
other specified anomalies of unspecified limb  
755.6x 
755.8 
Multiple congenital anomalies, so described  
Other and unspecified congenital anomalies  
Fracture of lower limb  
759.7 
759.89 
820.xx-829.xx 
Dislocation;  
of hip  
of knee  
of ankle  
of foot  
 
835.xx 
836.xx 
837.xx 
838.xx 
Open wound of hip and thigh  
Open wound of knee, leg (except thigh), and ankle  
890 
891 
Traumatic amputation; of toe(s), complete/partial  
of foot, complete/partial  
 of leg(s) complete/partial  
895.xx 
896.xx 
897.xx 
Injury to blood vessels of lower extremity and unspecified sites  904.xx 
 144 
Late effect of fracture of lower extremities  905.4 
Crushing injury; of lower limb  
of multiple and unspecified sites  
928.xx 
929.xx 
Injury, hip and thigh  
Injury, knee, leg, ankle, and foot  
Mechanical complication of internal orthopedic device, implant, and graft  
959.6 
959.7 
996.4x 
Complications peculiar to certain specified procedures due to internal joint 
prosthesis  
Complications due to other internal orthopedic device, implant and graft  
 
996.66 
996.67 
Other complications of internal (biological) (synthetic) prosthetic device, 
implant, and graft (due to internal joint prosthesis)  
Complications due to other internal orthopedic device, implant, and graft  
 
996.77 
996.78 
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APPENDIX 3: EPIDEMIOLOGY OF PAD FROM LITERATURE REVIEW  
Appendix Table 4. PAD prevalence from population-based studies with assessment based on ABI measurement 
Author, year 
Country 
N= 
Age range in 
years 
 
 
 
Study Population  
 
 
 
PAD Prevalence 
Estimates 
 
 
 
Limitations 
Selvin, 2004 
United States 
N=2,174 
Ages > 40 
National Health and Nutrition Examination 
Survey (NHANES); cross-sectional 
4.3% (95% CI: 3.1, 
5.5)  
 
McDermott, 2005 
United States 
N=6,570 
Ages 45-84 
Multi-Ethnic Study of Atherosclerosis 
(MESA); cross-sectional 
3.7%  
 
Those with clinically evident 
cardiovascular disease were 
excluded 
Fabsitz, 1999 
United States 
N=4,276 
Ages 45-74  
The Strong Heart Study; 13 tribes across 3 
diverse centers in the Dakotas, Oklahoma, 
and Arizona;   
5.3% 
 
 
Criqui, 2005 
United States 
N=2,343 
Ages 29-91 
The San Diego Population Study; randomly 
selected defined population of employees and 
retirees of UCSD in SoCal including 4 ethnic 
groups 
4.4% 
  
Women over-sampled 
Zheng, 1997 
United States 
N=15,106 
Ages 45-64 
Atherosclerosis Risk in Communities Study 
(1987-1989) in four US communities (NC, 
MD, MS MN) 
3.0% 
 
ABI in only one leg 
African Americans over-
sampled in two centers 
Newman, 1999 
United States 
N=5,714 
Ages > 65 
Cardiovascular Health Study in Medicare 
eligible participants   
13.4%  
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Appendix Table 5. PAD prevalence among clinic-based studies with assessment based on ABI measurement 
Author, year 
Country 
N= 
Age range in years 
 
 
 
Study Population  
 
 
 
PAD Prevalence 
Estimates 
 
 
 
Limitations 
Alzamora, 2010 
Spain 
N=3,786 
Ages >49 
PERART; Barcelona, Spain; randomly 
selected from 28 primary care centers, 
cross-sectional 
7.6% (95% CI: 6.7, 8.4) 
 
Women over-
sampled 
Diehm, 2004 
Germany 
N=6,880 
Ages > 65 
Observational German 
Epidemiological Trial on Ankle 
Brachial Index (getABI) Study; 344 
general practitioners throughout 
Germany  
18.0% 
 
 
Garofolo, 2007 
Brazil 
N=1,008 
Ages > 30 
Survey of first and second-generation 
Japanese-Brazilian participants from 
Baurau, Sao Paulo, Brazil 
20.4% 
 
Persons with chronic 
kidney disease were 
excluded 
Collins, 2005 
United States 
N=403 
Ages > 50 
Participants screened from DeBakey 
VA and 3 primary care clinics in 
Harris County (Houston, TX)  
16.7% 
 
Small sample size 
suggesting low power 
to detect differences 
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Appendix Table 6. PAD prevalence studies with assessment based on both ABI and Questionnaire 
Author, year 
Country 
N= 
Age range in 
years 
 
 
 
Study Population  
 
 
PAD Diagnostic 
Criteria 
 
 
 
PAD Burden Estimates 
 
 
 
Limitations 
Meijer, 1998 
Netherlands 
N=7,715 
Ages >55 
The Rotterdam Study; 
invited to participate 
ABI < 0.90 and Rose 
Questionnaire  
PAD prevalence = 
19.1%;  
IC prevalence = 1.6% 
overall 
 
Poor response rate in 
elderly; WHO/RQ has 
sensitivity of 60% 
Fowler, 2002 
Perth, Australia 
N= 4,470 
Ages 65-83 
Cross-sectional survey of 
randomly selected urban 
men from the Western 
Australia State Electoral 
Roll 
ABI <0.90 and/or 
positive Edinburgh 
Questionnaire 
Prevalence = 15.6% 
(14.5,16.6) 
 
 
Sigvant, 2007 
Sweden 
N=5,080 
Ages 60-90  
Population-based in four 
different regions of 
Sweden 
Any PAD (ABI<0.9; 
asymptomatic PAD, 
ABI <0.9 and 
negative 
questionnaire); IC, 
ABI <0.9 and 
positive 
questionnaire;  
Any PAD 
prevalence=18.0%,  
Asymptomatic PAD = 
11.1% 
IC = 6.8% 
 
Low response rate 
(64%) 
Underestimate severe 
limb ischemia because 
of particularly low 
response rate in most 
elderly (> 80) 
He, 2006 
China 
N=2,334 
Ages > 60 
Population-based study 
in Wanshoulu 
Community of Haidian 
District in Beijing, China 
ABI < 0.90 and/or 
symptoms of IC 
measured by the 
WHO/RQ 
ABI <0.90 prevalence = 
15.3%  
IC prevalence = 11.3%  
Both IC and ABI <0.90 = 
19.8%  
WHO/RQ has 
sensitivity of 60% 
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Appendix Table 7. PAD prevalence among clinic-based studies with assessment based on self-report with/out ABI or questionnaire 
Author, year 
Country 
N= 
Age range in years 
 
 
 
Study Population  
 
 
PAD Diagnostic 
Criteria 
 
 
 
PAD Prevalence 
Estimates 
 
 
 
Limitations 
Hirsch, 2001 
United States 
N=6,979 
Ages > 50 
The PAD Awareness, 
Risk, and Treatment: 
New Resources for 
Survival (PARTNERS) 
program, 27 sites and 
25 cities and 350 
primary care practices; 
aged >70 or 50-69 if 
had a history of DM or 
smoking 
ABI <0.90 or PAD 
documented in 
medical record, or 
history of limb 
revascularization 
 
29% Not a population-based 
study; inclusion criteria 
leads to higher prevalence 
Criqui, 1985 
United States 
N=613 
Ages 38-82 
Lipid Research Clinics, 
half of subjects from 
random sample, half 
from high-risk 
cholesterol groups 
IC measured by 
WHO/RQ; Self-
report surgery, NIVS, 
pulses 
27.7% (large or 
small vessel PAD)  
16% isolated 
small-vessel PAD 
Study in predominantly 
white, upper-middle class in 
S. Cal, higher risk 
population 
 
  
  
1
4
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Appendix Table 8. PAD prevalence among population-based studies with assessment based on self-report with/out ABI or 
questionnaire 
Author, year 
Country 
N= 
Age range in years 
 
 
 
Study Population  
 
 
PAD Diagnostic 
Criteria 
 
 
 
PAD Prevalence 
Estimates 
 
 
 
Limitations 
Kroger, 2009 
Germany 
N=4,738 
Ages 45-75 
Heinz Nixdorf Recall 
Study of individuals in 
Bochum, Essen, and 
Mulheim/Ruhr, 
industrialized urban 
regions of W. Germany 
ABI <0.90 and/or 
self-reported doctor-
diagnosed PAD 
6.8% 
 
Poor response rate 
(55.8%) 
Sritara, 2007 
Thailand 
N=2,305 
Ages 52-73 
Cross-sectional study at 
Electric Generating 
Authority of Thailand’s 
head plant (Nonthaburi) 
on all former and 
current employees who 
had participated in 
original survey to 
assess CVDs 
ABI < 0.90 or had 
amputation, surgery, 
angioplasty because 
of DM but no hx of 
trauma 
5.2% 
 
Survivor bias 
Study completed in 
middle-class, urban 
population 
Only considered PAD if 
procedures related to DM 
 
  
  
1
5
0
 
Appendix Table 9. PAD incidence studies with assessment based on various methodologies 
Author, year 
Country 
N= 
Age range in 
years 
 
 
 
Study Population  
 
 
PAD Diagnostic 
Criteria 
 
 
 
PAD Incidence Estimates 
 
 
 
Limitations 
Leng, 1996 
Scotland 
n=1592 
Ages 55-74 
Edinburgh Artery 
Study; 1592 men and 
women aged 55-74 
randomly selected from 
10 general practices in 
1987; cohort followed 
for five years 
WHO/RQ, ABI, 
reactive hyperemia 
test 
116 incident cases of 
claudication (cum inc=9%, 
IR=15.5 per 1000 person-
years), 4.5% baseline 
prevalence of claudication.  
Not true population-
based study because 
sampled from GPs, 
only looked at 
claudication,  
Self-report  
Hooi, 2001 
Netherlands 
n=2589 
Ages 40-78 
Limburg PAOD Study 
(1998-1997) with 
source population from 
18 general practice 
centers 
ABI <0.95 for at least 
one leg measured 
twice at weekly 
intervals; Defined 
symptomatic IC by 
questionnaire 
Overall incidence = 11.0 
per 1000 person-years  
 
Non-traditional cut-
point for ABI 
Unvalidated 
questionnaire 
Murabito, 2005 
United States 
n=5209 
Ages 29-62 
Framingham Study, 
general population 
study in Mass 1950-
1999 
Unequivocal 
symptoms of IC, 
cases were 
adjudicated by panel 
Incidence by decade (per 
100,00 person-years): 
1950-1969 (282), 1970-
1979 (345), 1980-1989 
(243), 1990-1999 (225) 
All white population 
 
Merino, 2010 
Spain 
n=699 
Ages 55-74 
Pubilla Casas Artery 
Study in Barcelona, 
Spain identified via 
Pubilla Casas Primary 
Care Centre 
 
 
 
ABI < 0.90 Baseline prevalence = 
13.4% 
Incidence = 23.8 per 1000 
person-years  
All male population 
  
1
5
1
 
Author, year 
Country 
N= 
Age range in 
years 
 
 
 
Study Population  
 
 
PAD Diagnostic 
Criteria 
 
 
 
PAD Incidence Estimates 
 
 
 
Limitations 
Hsia, 2003 
United States 
n=16,608 
Ages 50-79 
The Women’s Health 
Initiative Estrogen Plus 
Progestin trial 
Overnight 
hospitalization with 
either symptoms or 
intervention; 
confirmed by NIVS, 
revascularization, 
absence of pulses 
Baseline prevalence=0.5%; 
Overall incidence = 13 per 
1000 person-years among 
those with history of CHD 
or PAD; 1 per 1000 
woman-years among those 
with no history of CHD or 
PAD 
All female population 
 
  
  
1
5
2
 
Appendix Table 10. PAD validation studies using ICD-9-CM or CPT-4 codes 
Author, year 
N= 
 
Study Population  
 
Codes 
 
Outcome (95% CI) 
Heckbert, 
2004 
N=34,016 
Women’s Health Initiative; 
January 1994–November 
2000 
440.2 
443.9 
PPV = 31 (26,36) 
Sensitivity = 61 (54,68) 
Kappa = 0.40 (0.35,0.46) 
Fisher, 1992 
N=7,050 
The National Diagnosis 
Related Group (DRG) 
Validation Study; The 
Office of the Inspector 
General, US Department of 
Health and Human Services, 
randomly sampled hospitals 
from each of three bed-size 
strata, excluding specialty 
hospitals and those in states 
not using prospective 
payment during the study 
period (1985) 
 
38.18, 38.38, 38.48, 38.68, 
39.25, 39.29 
 
 
 
 
 
 
440-442.9, 433.9 
In any position (n=34): 
PPV = 0.97 (0.84,1.0) 
Sensitivity = 0.94 (0.80,0.99) 
 
In primary position (n=29): 
PPV = 0.92 (0.75,0.99) 
Sensitivity = 0.83 (0.64,0.94) 
 
In any position (n=217): 
PPV = 0.53 (0.47,0.60) 
Sensitivity = 0.58 (0.51,0.64) 
 
In primary position (n=38): 
PPV = 0.69 (0.53,0.82) 
Sensitivity = 0.76 (0.60,0.89) 
Kullo, 2010 
N=11,644 
Northwestern University, 
Mayo Clinic – Rochester, 
Marshfield Clinic Research 
Foundation 
Mayo clinic algorithm codes  Northwestern: 
PPV=95% 
Sensitivity = 100% 
 
Mayo Clinic – Rochester: 
PPV = 90.7% 
Sensitivity = 85.5% 
 
Marshfield Clinic Research Foundation: 
PPV = 87.5% 
Sensitivity = 97.2% 
  
1
5
3
 
 
Appendix Table 11. ICD-9-CM and CPT-4 codes used in administrative claims studies to identify PAD 
 
Author, year 
 
Study Population  
PAD Identification 
Methodology 
 
ICD-9 Codes 
 
CPT Codes 
Jaff, 2008 
 
5% random sample 
of Medicare 
beneficiaries from 
1999-2005 
PAD diagnosis and/or 
procedures using ICD-
9-CM and CPT coding 
440.2, 440.3, 440.9, 443.9, 444.2, 
444.22, 444.8, 444.81, 447.1, 
445.0, 445.02, 250.7, 707.1, 
00.40, 00.41-3, 00.44, 99.10, 
39.50, 39.29, 39.25, 38.18, 38.08, 
38.38, 38.48, 38.68, 00.45, 00.46-
8, 39.90, 86.22, 86.27, 86.28, 
77.65-77.68, 440.21, 440.22, 
440.23, 785.4, 440.24, 84.17, 
84.10, 84.13, 84.14, 84.16, 84.18, 
84.12 
35450, 35470, 37184-6, 
35470, 35473, 35474, 
35492, 35493, 35495, 
35482, 35483, 35485, 
35563, 35556, 35558, 
35566, 35571, 35903, 
35351, 35355, 35302, 
35371, 35303, 35304-6, 
37205-8, 97597-606, 
11040-4, 27590-2, 27880-
2, 27884, 27886, 27888-9, 
28820, 28825, 28800, 
28805, 28810 
 
Hirsch, 2008 
 
5% Medicare sample 
of the non-cancer 
SEER Registry, 2001 
PAD diagnosis in 
primary or secondary 
position, discharge 
categorized with PAD 
DRG 
440.0, 440.0-440.24, 440.31, 
440.9, 442.3, 443.9, 444.2, 444.81 
 
DRGs: 5, 110, 111, 113, 114, 
124, 130-133, 213, 271, 285, 287, 
478, 479 
Not specified 
Margolis, 2005 
 
Managed care 
database, 1999-2003 
PAD diagnosis in 
primary or secondary 
position, pharmacy 
claim for Cilostazol or 
Pentoxifylline 
440.xx, 443.9, 38.08, 38.13, 
38.18, 39.25, 39.26, 39.29, 39.50, 
39.90 
Not specified – 30 codes 
available upon request 
Tunis, 1991 
 
Maryland Health 
Services Cost 
Review Commission 
PAD-related diagnosis 
in first five positions, 
PAD-related procedure 
39.25, 39.29, 84.12, 84.15, 84.17, 
39.59 
Not utilized 
  
1
5
4
 
 
Author, year 
 
Study Population  
PAD Identification 
Methodology 
 
ICD-9 Codes 
 
CPT Codes 
database in first three positions 
Goodney, 2009 100% sample of Part 
B claims from all 
insurance carriers 
PAD-related CPT code Not utilized 35646, 35661, 35556, 
35583, 35656, 35566, 
35585, 35666, 27590-
27592, 27880-27882, 
35492, 35493, 35495, 
35473, 35474, 35470 
O’Brien-Irr, 
2012 
Statewide Planning 
and Research 
Cooperative System 
in New York State, 
2001-2008 
PAD-related code 440.21-440.24, 707.10, 707.13-
707.15, 785.4, 39.25, 39.29, 
38.38, 38.48, 39.50, 39.90, 0.48-
00.48, 84.15, 84.17 
Not utilized 
  
  
1
5
5
 
Appendix Table 12. PAD Prevalence studies based on administrative data assessment 
Author, year 
Country 
N= 
Age range in years 
Study Population  PAD Identification 
Methodology 
Burden Estimates Limitations 
Hirsch, 2008 
United States 
n=152,381 
Ages > 65 
5% Medicare sample of 
the non-cancer SEER 
Registry in 2001 
PAD-related 
diagnosis code in first 
or second position 
and for discharge to 
be categorized in 
PAD DRG 
Overall prevalence = 6.8%;  
Age 65-74, 4.5% 
Age 75-84, 7.5% 
Age > 85, 11.8% 
Sampling strategy 
using 5% of SEER 
registry is not 
common and is 
poorly generalizable 
Jaff, 2008 
United States 
n=43,000-57,000 
5% random sample of 
Medicare beneficiaries 
from 1999-2005 
PAD diagnosis and/or 
procedures using 
ICD-9-CM and CPT 
coding 
Overall prevalence in 1999 
and 2005: 
1999: 8.2% 
2005: 9.5% 
5% sample, no 
regional stratification 
Margolis, 2005 
United States 
n=30,561 
Ages > 18 
Managed care database 
with medical, hospital, 
outpatient, and 
pharmacy claims from 
Jan 1, 1999- August 31, 
2003;  
Primary of secondary 
ICD-9-CM listing, 
CPT codes, or 
pharmacy claim for 
Cilostazol or 
Pentoxifylline 
Overall prevalence = 1.2% Managed care only 
population 
Did not stratify 
results by gender, 
race, age 
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APPENDIX 4: CONSTRUCTING A COMORBIDITY SCORE USING ADMINISTRATIVE 
CLAIMS 
 Several summary scores have been identified and validated to overcome the challenges 
associated with accurately identifying comorbidity burden from claims data. Charlson et al 
(1987) identified 19 conditions that they included in a summary score that is commonly used in 
administrative claims data [179]. Klabunde et al (2000) adapted and validated the score for use 
with physician claims data as well as inpatient claims [180]. Klabunde assigned new weights to 
each comorbidity based on the strength of associated hazard ratios, concluding that a large 
comorbidity burden can be found in the outpatient setting that is not found through inpatient 
claims [179, 180]. Table 16 shows the adapted comorbidity score that will be used in the 
proposed research along with the codes for each comorbid condition and their associated 
weights.  
Appendix Table 13. ICD-9-CM codes to identify comorbidities with associated weights 
Comorbid condition ICD-9-CM  Assigned weights 
Myocardial infarction 410.xx, 412 3 
Congestive heart failure 402.01, 402.11, 402.91, 425.x, 428.x, 
429.3 
2 
Cerebrovascular disease 430-437.x 3 
Dementia 290.x 3 
Chronic pulmonary disease 490-496, 500-505, 506.4 2 
Rheumatologic disease 710.0-710.1, 710.4, 714.0-714.2, 714.81, 
725 
3 
Mild liver disease 571.2, 571.4, 571.5, 571.6x 3 
Diabetes 250.0x-250.3x, 250.7x 2 
Diabetes with end stage 
disease 
250.4x-250.6x 2 
Hemiplegia or paraplegia 342.x, 344.x 3 
Renal disease 582.x, 583.0-583.7, 585, 586, 588.x 4 
Any malignancy including 
lymphoma and leukemia 
140.x-172.x, 174.x-195.x, 200.xx-208.xx 2 
Moderate or severe liver 
disease 
572.2-582.8, 456.0-456.2x 4 
* Table adapted from Romano et al (1993)[201] 
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 The weights for each condition are summed to form a comorbidity score. For example, an 
individual with heart failure (2), dementia (3), and diabetes (2) would receive a score of 7. Mean 
comorbidity scores will be presented for each demographic stratum. A one year period prior to 
the PAD occurrence will be used to calculate comorbidities.   
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APPENDIX 5: FORMULAS 
Formula 1: Annual Prevalence =  
# PAD eventsyear i,age,gender,race,race−gender
population at riskyear i,age,gender,race,race−gender
 
 
Formula 2: Incidence proportion =  
# new PAD eventsyear i,age,gender,race,race−gender
population at riskyear i,age,gender,race,race−gender
 
 
Formula 3: Incidence rate =  
# new PAD events year i,age,gender,race,race−gender
person years at riskyear i,age,gender,race,race−gender
 
Formula 4: Sensitivity =
a
c1
  
Formula 5: Specificity =
d
c2
  
Formula 6: Positive predictive value =  
a
r1
        
Formula 7: Negative predictive value =  
d
r2
 
Formula 8: Kappa (K) =  
p0−pe 
1−pe
  Where: p0 = (a+d)/N 
 pe = ((a+c)(a+b) + (b+d)(c+d))/N
2 
 
Formula 9: Bias Adjusted Kappa (Y) =
√ad − √bc
√ad + √bc
 
Formula 10: Comparability RatioHospitalization,Outpatient => cPAD =
EPAD,ARIC
E PAD,Claims
 
 
Formula 11: Adjusted Annual Prevalence = cPAD ∗  
# PAD eventsyear i,age,gender,race,race−gender
population at riskyear i,age,gender,race,race−gender
  
Formula 12:  Poisson formula: λk = exp(α + βX + ɣZ) 
Formula 13:  Negative binomial formula: λk = exp(α + βX + ɣZ + ηεk) 
Formula 14: R = 1 − ∑ Ik ∗ ∆tk
k
k=1  
Formula 15: Cumulative Incidence(t) = ∑
ej
nj−1
KM12(tj)
s
j=1
 
where ej = the number of patients who fail from the event of interest at time tj 
where nj = the number of patients known to be at risk of failure beyond time tj 
where KM12 = the Kaplan-Meier estimate of survival 
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